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Summary
In living cells, reversible protein phosphorylation events propagate signals caused by ex-
ternal stimuli from the plasma membrane to their intracellular destinations. Aberrations
in these signaling cascades can lead to diseases such as cancer. To identify and quan-
tify phosphorylation events on a large scale, mass spectrometry (MS) has become the
predominant technology. The large amount of data generated by MS requires efficient,
tailor-made computational tools in order to draw meaningful biological conclusions.
In this work, four new methods for analyzing MS-based phosphoproteomic data are
presented. The first method, called SubExtractor, combines phosphoproteomic data with
protein network information to identify differentially regulated subnetworks. The method
is based on a Bayesian probabilistic model that accounts for information about both dif-
ferential regulation and network topology, combined with a genetic algorithm and rigorous
significance testing.
The second method, called MeanRank test, is a global one-sample location test, which
is based on the mean ranks across replicates, and internally estimates and controls the
false discovery rate. The test successfully deals with small numbers of replicates, missing
values without the need of imputation, non-normally distributed expression levels, and
non-identical distribution of up- and down-regulated features, while its statistical power
scales well with the number of replicates.
The third method is a biomarker discovery workflow that aims at identifying a multi-
variate response prediction biomarker for treatment of non-small cell lung cancer cell lines
with the kinase inhibitor dasatinib from phosphoproteomic data (referred to as NSCLC
biomarker). An elaborate biomarker workflow based on robust feature selection in com-
bination with a support vector machine (SVM) was designed in order to find a phospho-
rylation signature that accurately predicts the response to dasatanib.
xi
Summary
The fourth method, called Pareto biomarker, extends the previous NSCLC biomarker
workflow by optimizing not only one single objective (i.e. best possible separation of re-
sponders and non-responders), but also the objectives signature size and relevance (i.e.
association of signature proteins with dasatinib’s main target). This is achieved by employ-
ing a multiobjective optimization algorithm based on the principle of Pareto optimality,
which allows for a simultaneous optimization of all three objectives.
These novel data analysis methods were thoroughly validated using experimental data
and compared to existing methods. They can be used on their own, or they can be
combined into a joint workflow in order to efficiently answer complex biological questions
in the field of large-scale omics in general and phosphoproteomics in particular.
xii
Zusammenfassung
In lebenden Zellen sind reversible Proteinphosphorylierungen für die Weiterleitung von
Signalen externer Stimuli zu deren intrazellulären Bestimmungsorten verantwortlich. Ano-
malien in solchen Signaltransduktionswegen können zu Krankheiten wie beispielsweise
Krebs führen. Um Phosphorylierungsstellen in großem Maßstab zu identifizieren und zu
quantifizieren, hat sich die Massenspektrometrie (MS) zur vorherrschenden Technologie
entwickelt. Die große Menge an Daten, die von Massenspektrometern generiert wird, er-
fordert effiziente maßgeschneiderte Computerprogramme, um aussagekräftige biologische
Schlüsse ziehen zu können.
In dieser Arbeit werden vier neue Methoden zur Analyse von MS-basierten phospho-
proteomischen Daten präsentiert. Die erste Methode, genannt SubExtractor, kombiniert
phosphoproteomische Daten mit Proteinnetzwerkinformationen um differentiell regulierte
Subnetzwerke zu identifizieren. Die Methode basiert auf einem Bayesschen Wahrschein-
lichkeitsmodell, das sowohl Information über die differentielle Regulation der Einzelknoten
als auch die Netzwerktopologie berücksichtigt. Das Modell ist kombiniert mit einem
genetischen Algorithmus und stringenter Signifikanzanalyse.
Die zweite Methode, genannt MeanRank-Test, ist ein globaler Einstichproben-Lagetest,
der auf den mittleren Rängen der Replikate beruht, und die False Discovery Rate implizit
abschätzt und kontrolliert. Der Test eignet sich für die Anwendung auf Daten mit weni-
gen Replikate, fehlenden und nicht normalverteilten Werten, sowie nicht gleichverteilter
Hoch- und Runterregulation. Gleichzeitig skaliert die Teststärke gut mit der Anzahl an
Replikaten.
Die dritte Methode ist ein Arbeitsablauf zur Biomarkeridentifizierung und hat zum
Ziel, einen multivariaten Stratifikationsbiomarker aus phosphoproteomischen Daten zu ex-
trahieren, der das Ansprechen von nichtkleinzelligen Bronchialkarzinomzelllinien auf den
xiii
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Kinaseinhibitor Dasatinib vorhersagt (bezeichnet als NSCLC-Biomarker). Dazu wurde
ein ausführlicher Biomarkerarbeitsablauf basierend auf einer robusten Feature Selection
in Kombination mit Support Vector Machine-Klassifizierung erstellt, um eine Phosphory-
lierungssignatur zu finden, die das Ansprechen auf Dasatinib richtig vorhersagt.
Die vierte Methode, genannt Pareto-Biomarker, erweitert den vorherigen Biomarker-
arbeitsablauf, indem nicht nur eine Zielfunktion (d.h. die bestmögliche Trennung von Res-
pondern und Nichtrespondern) optimiert wird, sondern zusätzlich noch die Signaturgröße
und Relevanz (d.h. die Verbindung der Signaturproteine mit dem Targetprotein von Dasa-
tinib). Dies wird durch die Verwendung eines multiobjektiven Optimierungsalgorithmus
erreicht, der auf dem Prinzip der Pareto-Optimalität beruht und die gleichzeitige Opti-
mierung aller drei Zielfunktionen ermöglicht.
Die hier präsentierten neuen Datenanalysemethoden wurden gründlich mittels exper-
imenteller Daten validiert und mit bereits bestehenden Methoden verglichen. Sie können
einzeln verwendet werden, oder man kann sie zu einem gemeinsamen Arbeitsablauf zusam-
menfügen, um komplexe biologische Fragestellungen in Omik-Gebieten im Allgemeinen
und Phosphoproteomik im Speziellen zu beantworten.
xiv
Chapter 1
Introduction
1.1 Protein phosphorylation
Protein phosphorylation is one of the most important post-translational modifications in
a living cell. For uncovering its outstanding biological importance, Edmond H. Fisher and
Edwin G. Krebs were awarded the Nobel Prize in Physiology or Medicine “for their discov-
eries concerning reversible protein phosphorylation as a biological regulatory mechanism”
in 1992 1. In chemical terms, phosphorylation is the addition of a phosphate group (PO43-)
to a molecule. Added predominantly to specific serine, threonine or tyrosine residues, a
phosphorylation can change the protein’s conformation and/or subcellular localization
and thus alter its function and activity – either positively (activation) or negatively (in-
hibition). The class of enzymes catalyzing phosphorylations is called kinases, or more
specifically protein kinases, when phosphorylating proteins. Protein phosphorylations are
reversible; the process of dephosphorylation is catalyzed by phosphatases. Phosphory-
lations play a pivotal role in signal transduction, where an external stimulus causes the
activation of certain signaling pathways. Such pathways usually start with the stimulation
of receptors on the cell surface and communicate the signal along a cascade of kinases
to its destination (nucleus, ribosome, proteasome, etc.). Aberrations in these signaling
pathways are responsible for many types of diseases, most prominently, cancer.
One of the best studied signaling pathways in cancer is the MAPK (mitogen-activated
1http://www.nobelprize.org/nobel_prizes/medicine/laureates/1992
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Figure 1.1: MAPK pathway example displaying the RAS-RAF-MEK-ERK cascade. Blue
arrows indicate protein phosphorylation events (also displayed by red circles), green arrows
other physical protein interactions.
protein kinase) pathway. In healthy cells, the MAPK pathway is responsible for cell dif-
ferentiation, proliferation and apoptosis; however, mutations in this pathway can easily
lead to uncontrolled pathological cell proliferation, that is, cancer. The MAPK pathway
consists of different sub-cascades [1], one of them, the RAS-RAF-MEK-ERK cascade,
which is found mutated in more than 30% of all tumors [2], is displayed as an example in
Figure 1.1. Here, the epidermal growth factor receptor (EGFR; a receptor tyrosine kinase)
homodimer is stimulated by an extracellular ligand (the mitogen EGF), and subsequently
phosphorylates itself on its cytosolic domain [3] (a process called autophosphorylation).
2
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The docking protein GRB2 is then able to bind to this phosphorylated region, and in
turn recruits the guanine nuclear exchange factor SOS to the plasma membrane [4]. Sub-
sequently, SOS activates the membrane bound GTPase RAS by promoting the exchange
of the bound guanosinediphosphate (GDP) for guanosine triphosphate (GTP) [5]. Next,
RAS activates the protein kinase RAF (a MAP3K – MAP kinase kinase kinase) [6], which
phosphorylates and therefore activates MEK1/2 (MAP2K1/2 – MAP kinase kinase 1/2),
which in turn phosphorylate ERK1/2 (MAPK3/1 – MAP kinase 3/1) in an activating
manner [1]. Both ERK1 and ERK2 then translocate to the nucleus where they directly
phosphorylate and activate various transcription factors (e.g. the proto-oncogene protein
MYC [7]), or phosphorylate other kinases, such as ribosomal s6 kinases (RSKs), which in
turn phosphorylate transcription factors (e.g. the cyclic AMP-responsive element-binding
protein 1(CREB1) [8]). The pathway depicted in Figure 1.1 is an exemplified version of
the processes taking place in a living cell. In reality, there are various feedback mechanisms
and crosstalks between different pathways (e.g. between the MAPK and the mammalian
target of rapamycin (mTOR) pathway [9] – another very important pathway in cancer
signaling).
In many types of cancers, genetic mutations render protein kinases constitutively (per-
manently) active. Drugs that specifically target such dysregulated kinases have become
increasingly important in cancer therapy. Most of these drugs are either antibodies (e.g.
trastuzumab (Herceptin®), the first FDA approved kinase inhibitor targeting HER2/neu
[10], a protein of the EGFR family) or small molecules (e.g. dasatinib (Sprycel®), a multi-
kinase inhibitor targeting BCR-ABL, the Src-kinase family, c-Kit, ephrin receptors, and
PDGFRb [11, 12]. Such targeted drugs are less toxic than traditional chemotherapeu-
tic therapies, but they are not effective in all patients. Thus, to effectively apply these
targeted therapies, discrimination between the different patient populations is indispens-
able in order to determine the optimal treatment for each patient. These therapeutic
approaches are referred to as personalized medicine.
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1.2 Mass spectrometry-based proteomics
To identify and quantify proteins and their modifications (e.g. phosphorylation) on a large
scale, mass spectrometry (MS) has become the predominant technology. By applying
latest sample preparation workflows, mass spectrometric equipment and bioinformatics
tools, today up to 10,000 proteins [13] or more than 20,000 phosphorylation sites [14]
can be routinely identified, and their relative abundance can be compared across different
experimental conditions (e.g. drug treated versus untreated cell line samples).
The most widely used proteomics workflow is referred to as bottom-up or shot-gun
proteomics. This approach involves enzymatic digestion of complex protein mixtures into
peptides, followed by fractionation and MS analysis [15]. In the case of phosphoproteomics,
the workflow contains an additional phosphopeptide enrichment step, since phosphory-
lated peptides are underrepresented in the total cell lysate and therefore enrichment is
required to efficiently analyze phosphoproteomes with high coverage by MS-based work-
flows (see Figure 1.2 for a typical phosphoproteomics workflow).
Samples
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Figure 1.2: Phosphoproteomics workflow displaying the steps from sample to mass spec-
trometry analysis. Cells are lysed and their proteins are digested. The resulting peptide
mixture is fractionated and subjected to phosphopeptide enrichment, followed by LC-
MS/MS analysis.
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Samples to be analyzed by an MS-based proteomics experiment can be any kind of
protein source (e.g. cell lines, primary cells, tissues or body fluids). After cell lysis, the
pool of proteins is digested with a protease, usually trypsin. Trypsin has the advantage
to generate peptides with suitable lengths and molecular masses for detection in a mass
spectrometer. In addition, trypsin generates peptides with C-terminal arginine (Arg) and
lysine (Lys) residues (except for the C-terminal peptide, if the protein sequence does not
end with Arg/Lys), which can be easily protonated under acidic conditions and thereby
support mass spectrometric detection in the positive ion mode.
Next, the peptide pool is fractionated, which represents a first step of complexity
reduction. For phosphoproteomics, strong cation exchange (SCX) chromatography has
been the method of choice for many years [15]. SCX separates peptides according to
their charge states and implicitly performs a phosphopeptide pre-enrichment, as peptides
carrying a phosphate have a lower net charge than unmodified peptides. Each of the
generated fractions is then subjected to further phosphopeptide enrichment by employing
immobilized metal affinity chromatography (IMAC). IMAC is based on the high-affinity
binding of phosphates to certain trivalent metal ions (e.g. Fe3+; confer [15] and Figure
1.2) immobilized on solid support beads.
The highly enriched phosphopeptide sample is then subjected to liquid chromatogra-
phy (LC), which is usually directly coupled (on-line) to the mass spectrometer (LC-MS).
In the LC procedure, the sample mixture is forced by a liquid (mobile phase) through
a packed column (stationary phase) containing a hydrophobic surface (reverse-phased),
leading to adsorption of the peptides to the stationary phase under aqueous conditions.
By increasing the concentration of the hydrophobic buffer, a gradient is generated that
leads to a fractionated elution of the bound peptides, while hydrophilic peptides elute
earlier than hydrophobic ones. The eluting peptides are electrosprayed into the mass
spectrometer [16], where they are further analyzed.
Since the nominal masses of peptides are not sufficient for reliable sequence assignment
when comparing them to peptide databases, a two-step MS approach is necessary in order
to reliably identify peptides and the corresponding protein. In the first step, the mass
over charge ratios (m/z) and corresponding intensities of the eluting peptide analytes are
measured in a so-called survey scan (MS or MS1 spectrum). From this scan, the most-
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Figure 1.3: 3D spectra example illustrating the vast amount of data generated in an LC-
MS/MS experiment. The green line on the right represents the gradient of hydrophobic
elution buffer (referred to as buffer B) resulting in the chromatogram painted in red
on the left. Approximately once every second a survey scan (MS spectrum) followed by
10 fragment scans (MS/MS spectra) are performed, leading to the complex pattern of
measured intensities for tens of thousands of m/z over time. With kind permission of
Andreas Tebbe, creator of this picture.
intense peaks (typically 10) are selected, isolated and fragmented as described in detail
below and the resulting fragment spectra are recorded (MS/MS or MS2 spectrum). This
cycle is repeated over the entire length of the LC gradient to analyze and identify as many
peptides as possible. The vast amount of data generated by this procedure is illustrated
as 3D spectral image in Figure 1.3.
To draw meaningful biological conclusions from MS experiments, it is usually not suf-
ficient to only analyze and identify the protein repertoire of the given samples (qualitative
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Figure 1.4: SILAC labeling diagram illustrating a triple-SILAC experiment with three
different treatments. On the bottom, intensities for one peptide are displayed exemplarily.
analysis), but also to quantitatively compare different proteomes under different condi-
tions (quantitative analysis). However, signal intensities generated by a mass spectrometer
are per se not quantitative, that is, they depend on the environment of co-eluting pep-
tides and are thus not directly comparable across different MS runs. In order to accurately
quantify differences in protein expression or phosphorylation levels across different exper-
imental conditions, labeling strategies were developed and are now routinely applied. One
of the most widely used labeling approaches is Stable Isotope Labeling by Amino acids
in Cell culture (SILAC) [17], where growth media of dividing cell lines are supplemented
with either light, medium or heavy isotopes of the amino acids arginine and lysine. After
the labeling process, the three different cell populations can be treated differently and are
subsequently pooled and subjected to the proteomics workflow. Here, another advantage
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of using trypsin as proteolytic enzyme takes effect, i.e. cleaving after Arg/Lys ensures
the presence of at least one SILAC labeled amino acid needed for quantification (again,
with the exception of C-terminal peptides). As the differently labeled peptides from each
SILAC growth condition are physico-chemically identical, they co-elute simultaneously
into the MS. Nevertheless, they are distinguishable due to their defined mass differences
introduced by the metabolically incorporated isotopologues, allowing for a direct and ac-
curate relative quantification between the three treatment conditions. There are various
alternatives to SILAC labeling, which are applied if metabolical labeling is not applica-
ble (e.g. mass differential tags for relative and absolute quantification (mTRAQ) [18] for
tissue samples), or a higher level of multiplicity is desired (e.g. tandem mass tags (TMT)
[19] for time series experiments with up to 10 states). Recent advances in computer algo-
rithms also allow for label-free quantification (e.g. [20]); however quantifications based on
labeled peptides are usually more precise [21] and allow for a higher level of multiplexing
capacity in such experiments.
Depending on the application, different types of mass spectrometers are preferred. For
global proteomics experiments aiming at detecting as many proteins or phosphosites as
possible, Orbitrap instruments are well suited. They provide high resolution and high
accuracy [23], which are both vital for reliable peptide identification and quantification.
The design of a current Orbitrap instrument, the Q Exactive (Thermo Fisher Scientific),
is depicted in Figure 1.5. The Q Exactive is a hybrid mass spectrometer that combines
a quadrupole used for ion selection with an Orbitrap used for ion detection [22]. The
electrospray of ionized peptides from the nanospray source is guided through a set of ion
optics (s-lens, flatapole) to the machine’s quadrupole. A quadrupole consists of four hy-
perbolical rods that are set parallel to each other, enabling the filtering of ionized peptides
of a certain mass over charge ratio (m/z) based on the stability of their trajectories in
the oscillating electric fields that are applied to the rods [24]. In the survey scan (MS1
spectrum), no filtering is applied, thus the spectrum contains information about the entire
effluent of a given time. To perform a fragment spectrum (MS2 spectrum) of a certain
spectral peak, the quadrupole is configured such that only a small mass range around the
desired peak’s m/z has stable trajectories and can pass through. Once the desired ions
have passed the quadrupole, they are guided to the C-trap, where they are collected and
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Figure 1.5: Schematic overview of a Q Exactive mass spectrometer. Ions are guided
through ion optics (s-lens, flatapole) to the quadrupole, which can filter ions within a
specific m/z range. The succeeding C-trap collects ions and injects them to either the
HCD collision cell for fragmentation or the Orbitrap for high-resolution spectra generation.
Picture adapted from Michalski et al. [22].
subsequently injected into the Orbitrap and higher-energy collisional dissociation (HCD)
collision cell, respectively. In survey scan mode (MS1), the total ion population is injected
directly into the Orbitrap that consists of an electrostatic device, into which ions orbit
around a spindle-shaped electrode [22, 25]. The image current of the ions’ axial motion is
detected, and this signal is Fourier-transformed in order to yield high resolution mass spec-
tra. To analyze fragment spectra, the ions of interest are first filtered by the quadrupole
and subsequently injected into the HCD cell, where ions are accelerated by an electrical
potential and collide with neutral molecules such as nitrogen, resulting in a fragmentation
of the peptides [26]. The fragments are then returned to the C-trap, which injects them
into the Orbitrap to perform a fragment spectrum scan (MS2). This is usually repeated
for 10 peptides, until the next survey scan is performed.
To extract qualitative and quantitative information from the vast amount of MS spec-
tra, sophisticated software like MaxQuant [27] is used to process the raw spectral files.
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MaxQuant identifies peptides by comparing fragment spectra to theoretical fragment ion
masses from a sequence database with the peptide search engine Andromeda [28]. An-
dromeda employs a probabilistic score that is based on the probability that the observed
number of matches between the measured and the theoretical fragments occur by chance.
For an accurate quantification, MaxQuant integrates peptide ion peaks, isotope clusters
and labeled peptide tuples as three-dimensional objects in m/z, elution time and signal
intensity space.
1.3 Analysis of phosphoproteomic data
One major interest in the area of phosphoproteomics is to unravel a drug’s mode of action.
In many cases, pharmaceutical investigators observe phenotypic effects when treating their
model organisms with a certain drug; however, they do not know the exact cellular mech-
anism that governs this effect. Unraveling a drug’s mode of action is vital during drug
discovery and development, helping to identify new medical applications, suggesting its
use in combination therapy, and predicting the responsiveness of patients [29–31]. In the
case of phosphoproteomic mode of action analyses, such drugs are mostly small molecules
or antibodies targeting one or several kinases [14, 32, 33]. Once a drug interferes with the-
ses kinases and inhibits their activity, they are unable (or at least reduced in their ability)
to phosphorylate their downstream targets. As a consequence, entire signaling cascades
can be affected by the treatment, eventually resulting in a change of gene transcription,
translation, apoptosis or the like. In the biological reality, however, such direct effects are
often accompanied by secondary effects, like feedback mechanisms, or, if treatment lasts
for hours, even changes in protein expression, which in turn has an influence on phospho-
rylation changes. Moreover, if the downstream effects of a certain inhibition are off known
canonical signaling pathways, customized tools are needed to help uncover the mode of
action. In Chapter 2, a method based on protein-protein interaction networks that reports
significantly regulated subnetworks is presented. The algorithm, called SubExtractor, em-
ploys a Bayesian probabilistic model in combination with a genetic algorithm and rigorous
significance testing.
When conducting mass spectrometry-based phosphoproteomic mode of action anal-
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yses, the limiting factor regarding both time and cost is MS run time. To keep the ex-
periments affordable, the number of biological replicates is often limited to three, which
requires proper statistical methods that are able to deal with data that consist of only
few replicates but thousands of features (phosphosites) at the same time. Moreover, mass
spectrometers regularly produce - more or less randomly - missing data, i.e. even if the
experiments are replicated three times, there is no warranty that every phosphorylation
site is quantified three times. In Chapter 3, a global one-sample location test is presented,
which is based on the mean ranks of the respective features across biological replicates.
The hypothesis test, called MeanRank test, was specifically designed for experiments with
few replicates and thousands of features, implicitly handles missing data, and internally
controls the false discovery rate.
Another area of interest is the discovery of biomarkers in the field of personalized
medicine. In general, there are four different types of biomarkers:
• Response prediction (stratification) markers foretelling the effect of a certain drug
treatment on patients (e.g. HER2/neu over-expression for predicting response to
treatment with trastuzumab (Herceptin®) [34, 35]).
• Diagnostic markers detecting a disease that already exists (e.g. PSA level for diag-
nosis of prostate carcinoma [36]).
• Prognostic markers predicting how a disease may develop (e.g. MammaPrint, the
first omics marker for foretelling the risk that a breast tumor will metastasize [37]).
• Pharmacodynamic markers monitoring pharmacological response (e.g. FDG-PET
imaging for monitoring tumor size [38]).
Chapter 4 deals with the identification of a response prediction biomarker for treatment
of non-small cell lung cancer (NSCLC) with the kinase inhibitor dasatinib from phos-
phoproteomic data. This study was the first global and unbiased approach to develop a
biomarker based on the differences in the basal phosphorylation levels of cancer cell lines.
To this end, an elaborate biomarker workflow based on robust feature selection in combi-
nation with a support vector machine (SVM) was designed in order to find a multivariate
phosphorylation signature that accurately predicts drug response.
Undoubtedly, the primary aim of a stratification biomarker is to accurately predict
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drug response in patients. However, in many cases there are several limitations, for ex-
ample, an effective application of a predictive phosphorylation signature in the clinical
environment may require phosphorylation-specific antibodies, which are not available for
all phosphorylation sites. For similar reasons, multivariate markers should not contain
too many different features (i.e. phosphosites); and ideally, signature proteins should be
meaningful, e.g. by having a connection to the drug’s target or mechanism of action.
Furthermore, it might be desirable to detect more than one signature in parallel. These
requirements are fulfilled by the Pareto biomarker workflow in Chapter 5, where the stan-
dard workflow is extended to optimize not only one single objective (i.e. best possible
separation), but also the objectives size and relevance, simultaneously. This is achieved
by employing the multiobjective optimization algorithm NSGA-II [39] that is based on
the principle of Pareto optimality.
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SubExtractor
In this chapter, a new method for identifying differentially regulated subnetworks from
phosphoproteomic data is presented. The proposed algorithm, called SubExtractor, com-
bines phosphoproteomic data with protein network information from STRING to identify
significantly regulated subnetworks. The method is based on a Bayesian probabilistic
model combined with a genetic algorithm and rigorous significance testing.
The content of this chapter was published as:
M. Klammer, K. Godl, A. Tebbe, and C. Schaab. “Identifying differentially regulated
subnetworks from phosphoproteomic data.” In: BMC bioinformatics 11 (2010), p. 351
The author was a key contributor to designing and implementing the algorithm, as
well as writing the paper. The wet laboratory work (cell culture and mass spectrometry)
were performed by his colleagues at Evotec Munich under the supervision of A. Tebbe.
2.1 Background
Global quantification technologies such as microarray, MS-based proteomics and phos-
phoproteomics can measure the expression of thousands to tens of thousands of genes,
proteins and phopshorylation sites, respectively. Often, a few thousand of them are identi-
fied as being significantly differentially regulated, but interpreting these results at a single
gene or protein level is a tedious and frequently unsuccessful task. However, by integrating
these data with protein-protein interaction networks, it is possible to identify significantly
regulated subnetworks that can be interpreted directly in a biological context. Moreover,
13
2. SubExtractor
identifying regulated entities from often noisy high throughput data should be supported
by this kind of integration.
One simple approach for detecting regulated subnetworks could involve distinguish-
ing between significantly regulated and non-regulated phosphosites by applying standard
hypothesis testing procedures such as t-statistics or SAM [41] to each phosphosite (the
number of data points corresponds to the number of experimental replicates). To avoid
too many false positives, one must further apply concepts such as the family-wise error
rate (FWER [42]) or the false discovery rate (FDR [43]) for multiple hypothesis test-
ing correction. Subsequently, the resulting list of statistically significant entities can be
mapped on pathways or protein-protein interaction networks, and connected subnetworks
can be determined. While this procedure may point to regulated subnetworks, it is not
an integrated solution, since the significance of each protein solely depends on the data
of its own phosphosites, regardless of its interactions with other proteins.
More sophisticated approaches use statistic-based techniques to score subnetworks. In
these cases proteins are first mapped onto a protein interaction network, and subsequently
high-scoring subnetworks are extracted. Ideker et al. [44] use an aggregated z-score of the
form
𝑧𝐴 =
1√
𝑘
∑︁
𝑖∈𝑆
𝑧𝑖,
where 𝑘 is the number of nodes in the subnetwork and 𝑧𝑖 is the z-score of a single
protein in the subnetwork 𝑆. High-scoring subnetworks are then found with a simulated
annealing approach [45]. Chuang et al. [46] presented a method based on the same idea,
but with a greedy search algorithm that specifies a seed and adds the best nodes in the
neighbourhood until the aggregated score no longer improves. Subsequently, the signifi-
cance of the resulting subnetworks is assessed based on null distributions estimated from
permuted networks. However, neither method accounts for the network topology, i.e. the
degree of interconnections between nodes.
Subsequently, Sanguinetti et al. [47] introduced a Bayesian probabilistic model that
integrates a priori network topology information into the analysis of high throughput
data. The authors used Gibbs sampling [48] to obtain suitable posterior probabilities and
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thus derived subnetworks. A major drawback of this method, however, is the missing
significance assessment for the resulting subnetworks.
All methods described above used either only a subset of known protein-protein in-
teractions or KEGG pathways [49] for their assessment. To obtain the most information
from such investigations, and considering that canonical pathway databases like KEGG
are rather static and contain only a limited number of interactions, it seems natural to
use larger and frequently updated protein-protein interaction network databases such as
STRING [50] or FunCoup [51].
Here, we introduce a Bayesian probabilistic model that combines local as well as topo-
logical information, i.e. information about regulation of a certain node and information
about the connectivity with its neighbours. Identification of subnetworks is carried out
using a genetic algorithm (GA [52]), followed by performing a significance analysis based
on a global rank test [53]. As a special feature, the significance test not only considers
subnetworks, but also single nodes that are not part of any larger subnetwork. This makes
the proposed method a powerful tool to uncover both differentially regulated subnetworks
and differentially regulated single proteins. The performance was assessed on an artificial
data set as well as on a comprehensive phosphoproteomics data set.
2.2 Methods
2.2.1 Data pre-processing and z-score calculation
The input of the proposed method is formed by a table with 𝑛 rows and 𝑚 columns; 𝑛
being the number of detected phosphosites and 𝑚 the number of biological replicates (i.e.
MS measurements of experiments using identical settings but conducted independently).
Several replicates (at least 3–5) are necessary to reliably identify differential phosphory-
lations. Each value in this table represents a ratio between the degree of phosphorylation
under two conditions (e.g. the extend of phosphorylation of a specific site in cells treated
with a drug versus its degree in untreated cells).
Log-transformation is preferred before calculating the z-score, since the distribution of
the transformed ratios is closer to normal. Subsequently, the log-ratios 𝑥𝑖𝑗 of phosphosites
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𝑖 = 1, ..., 𝑛 and replicates 𝑗 = 1, ...,𝑚 are further transformed to z-scores (referred to as
single z-scores) using the formula:
𝑧𝑖𝑗 =
𝑥𝑖𝑗 − 𝜇0
?^?
, (2.1)
where 𝜇0 = 0, since it is expected that the majority of phosphosites are not differentially
regulated and therefore their log-ratios are 0, and ?^? the standard deviation across repli-
cates estimated on the entire data set. Further, a combined z-score for each phosphosite
over all replicates is calculated as:
𝑧𝑖 =
1√
𝑚
𝑚∑︁
𝑗=1
𝑧𝑖𝑗. (2.2)
Not all phosphosites are detected in every experimental replicate. The resulting missing
values are simply ignored, so, for example, if three replicates have been conducted and a
given phosphosite was only detected in two of them, 𝑚 is set to 2 for this site and the
combined score is calculated based on the two available z-scores.
2.2.2 Protein network preparation
In this work STRING [50] was chosen as the source for protein-protein interactions.
STRING is a comprehensive resource that combines a vast number of databases derived
in different ways (e.g. experimentally determined interactions, gene neighbourhood data,
or data acquired via text mining) and is able to transfer homology information across
organisms. Obviously the method presented here is not limited to STRING and can also
be used in combination with other protein-protein-interaction databases. Depending on
the context of the study databases like HomoMINT [54], HPRD [55], or FunCoup [51]
may be preferable.
In STRING, all interactions are assigned with a confidence value ranging from 0 to
1. In order to retain only high confidence interactions, a very conservative cut-off value
of 0.995 is used. While this cut-off may seem too high, there is a valid reason for it:
some interactions reach very high confidence values (> 0.99), although the evidence is
only from text mining, which was considered too weak evidence. Furthermore, analysis of
canonical pathways showed that virtually all known interactions pass this high cut-off of
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0.995. Applying this cut-off, an interaction network of approximately 10,000 interactions
between 2,997 proteins is obtained (STRING version 8.1).
Subsequently, the phosphoproteomic data is mapped on the network (see upper part of
Fig. 1). Before doing so, the list of phosphosites has to be aggregated to a list of proteins,
with one z-score per protein and replicate. This is done by simply assigning the values of
the phosphosite with the highest combined z-score among all phosphosites of a protein to
this protein. Then each protein is mapped on the interaction network, where each node
has 𝑚 single z-scores and the combined z-score. Nodes that do not have a corresponding
entry in the phosphoproteomics data set are thought of being not regulated and thus
their z-scores are set to 0. On the other hand, proteins on the list that do not occur in
the network are added but without any connections in order to give them the chance of
being identified as regulated single proteins later on. In the genetic algorithm described
below, only nodes in the interaction network will be considered; the set of unconnected
nodes will be used again when it comes to significance assessment in the final step of the
method.
2.2.3 Bayesian probabilistic model
A probabilistic model that takes into account the above derived z-scores and the network
topology was developed. Let 𝑐𝑖 ∈ {0, 1} be the latent class variable, with 𝑐𝑖 = 1 if node 𝑖
belongs to a differentially regulated subnetwork and 𝑐𝑖 = 0 if not. Note that the approach
can easily be generalized to three classes, if up- and down-regulated subnetworks shall be
distinguished. Given the combined z-scores 𝑧1, . . . , 𝑧𝑛 derived from the observations, the
posterior probability of the subnetwork configuration (𝑐1, . . . , 𝑐𝑛) is
𝑝 (𝑐1, . . . , 𝑐𝑛|𝑧1, . . . , 𝑧𝑛) = 𝑝 (𝑧1, . . . , 𝑧𝑛|𝑐1, . . . , 𝑐𝑛) 𝑝 (𝑐1, . . . , 𝑐𝑛)
𝑝 (𝑧1, . . . , 𝑧𝑛)
. (2.3)
where the right-hand side is obtained by applying Bayes’ theorem. The denominator
𝑝 (𝑧1, . . . , 𝑧𝑛) does not depend on the 𝑐𝑖 and can be ignored when maximizing the posterior
probability. Since the observed data of node 𝑖 are mutually conditionally independent
(given the other nodes’ class variables) and depend only on the class variable of the node
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itself, the conditional probability can be written as
𝑝 (𝑧1, . . . , 𝑧𝑛|𝑐1, . . . , 𝑐𝑛) =
𝑛∏︁
𝑖=1
𝑝(𝑧𝑖|𝑐𝑖). (2.4)
Normal distributions 𝒩 (𝜇, 𝜎) with 𝜇 = 0 and 𝜎 = 1 or 𝜎 = 𝜎𝑧 are assumed:
𝑝(𝑧𝑖|𝑐𝑖 = 0) = 𝒩 (𝑧𝑖|0, 1)
𝑝(𝑧𝑖|𝑐𝑖 = 1) = 𝒩 (𝑧𝑖|0, 𝜎2𝑧).
(2.5)
The prior probability for the subnetwork configuration 𝑝 (𝑐1, . . . , 𝑐𝑛) is derived analogously
to the derivation of the joint probability distribution from conditional probabilities in
Bayesian networks. Let𝑁𝑖 be the set of parents of node 𝑖. If the protein interaction network
was a directed acyclic graph and the joint distribution fulfilled the Markov condition, the
following equality would hold [56]:
𝑝 (𝑐1, . . . , 𝑐𝑛) =
𝑛∏︁
𝑖=1
𝑝 (𝑐𝑖| (𝑐𝑗, 𝑗 ∈ 𝑁𝑖)). (2.6)
Clearly, protein-protein interaction networks are no directed acyclic graphs. Nevertheless,
the prior can be modelled by applying this theorem, if 𝑁𝑖 is now defined as the set of
neighbours of node 𝑖. The conditional probabilities are modelled similarly to [47]:
𝑝 (𝑐𝑖 = 1| (𝑐𝑗, 𝑗 ∈ 𝑁𝑖)) =
𝛼 + 1|𝑁𝑖|
∑︀
𝑗∈𝑁𝑖 𝑐𝑗
1 + 2𝛼 and
𝑝 (𝑐𝑖 = 0| (𝑐𝑗, 𝑗 ∈ 𝑁𝑖)) = 1− 𝑝 (𝑐𝑖 = 1| (𝑐𝑗, 𝑗 ∈ 𝑁𝑖)) or equivalently
𝑝 (𝑐𝑖| (𝑐𝑗, 𝑗 ∈ 𝑁𝑖)) =
𝛼 + 1− 1|𝑁𝑖|
∑︀
𝑗∈𝑁𝑖 (𝑐𝑗 − 𝑐𝑖)
2
1 + 2𝛼 ,
(2.7)
where the parameter 𝛼 determines the weight of the network structure, and |𝑁𝑖| is the
number of neighbours. For very large 𝛼 the posterior probability is not influenced by
the network structure. Taking the logarithm of Eq. (2.3), inserting above equations, and
ignoring the constant summands, the log posterior probability is:
ln 𝑝 (𝑐1, . . . , 𝑐𝑛|𝑧1, . . . , 𝑧𝑛) = const.
+
𝑛∑︁
𝑖=1
ln
(︀𝒩 (︀𝑧𝑖|0, (1− 𝑐𝑖) + 𝑐𝑖𝜎2𝑧)︀)︀+ ln
(︃
𝛼 + 1− 1|𝑁𝑖|
∑︁
𝑗∈𝑁𝑖
(𝑐𝑗 − 𝑐𝑖)2
)︃
.
(2.8)
The model parameters 𝛼 and 𝜎𝑧 are fixed. In principle, they could be handled as
unknown parameters in the Bayesian model, with the effect that the joint posterior prob-
ability would have to be maximized for (𝑐1, . . . , 𝑐𝑛), 𝛼 and 𝜎𝑧. Since the results turned
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out to be rather insensitive to variations in 𝛼 and 𝜎𝑧 (see Results and Discussion), the
model and the optimization were simplified by a priori fixing of these parameters.
2.2.4 Subnetwork extraction
To maximize the posterior probability, the optimal combination of the nodes’ class asso-
ciations (i.e. whether a protein is part of a regulated subnetwork to be extracted or not)
has to be found. Since this problem is NP-hard [44], a heuristic strategy has to be ap-
plied. Genetic algorithms (GAs) are particularly well-suited for this kind of binary-valued
combinatorical problem, since they are able to find close-to-optimum solutions even in
complex scoring landscapes with many local optima (see e.g. [52] for more details). An
overview of a standard GA workflow can be found in Supplementary Information A.
To apply a GA to the subnetwork extraction problem, the network has to be encoded
into a vector (i.e. an individual’s chromosome). Here each node in the network was assigned
a consecutive index value that represents the position of this node in the vector. The values
in the vector are binary: 1 meaning that the corresponding node is part of a regulated
subnetwork, and 0 that it is not (see also Figure 2.1). Initially, values of these binary
vectors are randomly generated, one for each of the 1000 individuals used. According to
the Bayesian scoring function described above, the fitness of each individual is evaluated
and 100 individuals are selected and used for breeding. Selection of these individuals
is performed using the tournament selector (cf. [57]), which randomly draws a subset
of individuals and then determines the fittest within this subset. By repeating these
steps 100 times, the 100 parent individuals are selected. Tournament selection ensures
that average-performing individuals also have some chance to reproduce, which reduces
the risk of premature convergence. Recombination of the selected individuals is carried
out with two-point crossover, that is, the chromosomes of two parents are cut at two
identical, random points 𝑐1 and 𝑐2, and the genes in the range [𝑐1, 𝑐2] are crossed (see
also Figure 2.1). Mutation, which is a simple bit flip, occurs with a probability of 0.05. The
newly created offspring’s fitness is assessed, and the fittest offspring replaces the weakest
individual in the parental generation. Then the algorithm continues with the selection of a
new set of parents. The algorithm is run for 5000 generations, an empirically determined
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Figure 2.1:Workflow of the subnetwork extraction. First, z-scores are calculated from the
phosphoproteomics data and mapped on an interaction network (orange nodes). Proteins
that do not occur in the network are stored in a separate list (violet node). For the genetic
algorithm (GA) procedure the network is encoded into a binary vector. The GA runs for a
defined number of generations and the strongest individual of the final generation encodes
for the globally best achievable solution. Finally, the global rank (GR) significance test is
performed on both extracted subnetworks and single nodes resulting in a set of significantly
regulated subnetworks.
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value, from where on no more appreciable improvement is observed. The best solution
(represented by the individual with the highest fitness value in the final generation) is
then used to extract all subnetworks from the entire network by starting at a given node,
checking all neighbours for their class association, and iteratively adding all neighbours
that belong to a regulated subnetwork. To avoid cycles, every node is flagged after it has
been checked, and if no more neighbours are to be added to the current subnetwork in
a certain iteration step, another as yet unchecked node is used as the starting point for
the next subnetwork. This is repeated until no unchecked nodes are left, and therefore all
subnetworks are detected. The z-score of a subnetwork is then defined as:
𝑧𝑠 =
1√︀|𝑆𝑠|
∑︁
𝑖∈𝑆𝑠
|𝑧𝑖| , (2.9)
where 𝑧𝑖 is the combined z-score of a protein as described in (2.2), 𝑆𝑠 is the set of proteins
in the subnetwork, and |𝑆𝑠| is its size. The absolute value of 𝑧𝑖 is taken, since it is not
know a priori whether the interaction between two proteins is activating or inhibiting,
and therefore this distinction is not made. Rather only the degree of regulation is taken
into account. When analysing gene or protein expression data, however, the direction of
regulation may be important and should not be ignored. In such cases the signed values
can be used. In some cases a subnetwork may contain only one node, which is not an
issue, since both, significant subnetworks and single nodes shall be determined anyway.
2.2.5 Significance evaluation
Once regulated subnetworks are extracted, one has to determine their statistical signif-
icance. Single nodes (those that could not be mapped on the network but had been
detected in the phosphoproteomics experiment) are regarded as subnetworks with only
one member and are thus added to the list of subnetworks. The significance test is based
on a modified version of the global rank test [53].
The main idea of this method is to identify differentially regulated entities (genes,
proteins or subnetworks) not based on hypothesis tests conducted for each entity inde-
pendently, but rather based on the entire set of entities at once. Under the null hypothesis
that entities are neither up- or down-regulated, the authors state the theorem of random
ordering, i.e. that no entity can rank consistently high or low across all replicates. On
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the contrary, those entities that do consistently rank top or bottom in all replicates are
identified as being significantly regulated. The number of identified significant entities will
then solely depend on the number that determines how many entities are considered top
or bottom ranked (here denoted as 𝑁), e.g. if 𝑁 is chosen to be a small number, only a
few entities or none at all will be among the top-N or bottom-N across all replicates.
Raising 𝑁 not only increases the number of identified significant entities, but also the
expected number of false positives. As described in [53], this number of false positives
can be estimated non-parametrically from the empirical null distribution. The idea for
this procedure is that a non-regulated entity has the same probability of ranking top-N
as ranking bottom-N. In other words, under the null hypothesis an entity has the same
probability of ranking top-N across all replicates (denoted as TTT for three replicates [𝑅 =
3]) as ranking bottom-N across all of them (BBB) or top-N in the first two and bottom-N
in the third (TTB). The same is true for all 2𝑅 = 8 classes of possible combinations of
high and low ranks. Entities in the TTT and BBB classes are differentially regulated,
and those in the remaining 2𝑅 − 2 = 6 classes are not. By dividing the average number
of entities in the 6 non-consistently regulated classes by the number of those in one of
the regulated classes, for each 𝑁 the FDR can be estimated (once for up- and once for
down-regulated entities). Different values of 𝑁 can now be tried until the desired FDR
level is reached (cf. algorithm in Table 1, line 10 – 19).
For the application to subnetworks the method estimating false positives has to be
modified, since the subnetworks’ z-scores have non-negative values only, which means
that bottom-N ranking subnetworks would be the ones with the weakest regulation. To
overcome this problem, one first has to introduce another way of counting entities that fall
under the non-consistently regulated classes, since the bottom ranked no longer represent
differentially regulated entities. In this new counting process, not simply the entities in
the non-regulated classes are counted but rather the signs of the replicates’ z-scores are
alternately changed (cf. algorithm in Table 1, line 5 – 8) and subsequently the number
of entities that consistently rank top across all replicates after this transformation are
counted (cf. algorithm in Table 1, line 14 – 16). In the case of the TTB class, for example,
rather than determining the number of entities ranking top-N in the first two replicates
and bottom-N in the third, the signs of the third replicate’s z-scores are flipped and one
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Algorithm 2.1 The algorithm for significance evaluation in pseudocode.
A = z-transformed phosphoproteomic data (n sites, m replicates)
STRING = STRING interaction data
origSN = list of extract subnetworks from STRING using A
flippedSNs = container for flipped subnetwork lists
for all 𝑠 ∈ Cartesian product {−1,+1}𝑚 without {(−1, . . . ,−1), (+1, . . . ,+1)} do
flippedA = multiply values in column (1, . . . , 𝑖, . . . ,𝑚) of A with the value at index i
in s
add list of extracted subnetworks from STRING using flippedA to flippedSNs
end for
FDR = 1.0
N = n
while FDR > desired FDR cutoff and N > 0 do
origCount = count subnetworks that are among the N most-regulated ones across all
replicates in origSN
flippedCount = 0
for all flipped lists of subnetworks in flippedSNs do
flippedCount = flippedCount + number of subnetworks from list of flipped subnet-
works that are among the N most-regulated ones across all replicates
end for
FDR = (flippedCount / number of lists in flippedSNs) / origCount
N = 𝑁 − 1
end while
if N > 0 then
return list of subnetworks that are among the 𝑁 +1 most-regulated ones across all
replicates in origSN
else
return empty list
end if
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determines the number of entities now ranking top-N across all three replicates (those
that are now in the TTT class). Note that both counting methods yield the same results,
since it makes no difference whether one counts the number of bottom-N entities of a
given replicate or the number of sign-flipped top-N ones.
The z-score of a subnetwork is as defined in (2.9), where 𝑧𝑖 is the combined score over
all replicates. To find subnetworks that are top ranked across all replicates z-scores have
to be calculated for each replicate separately:
𝑧𝑠𝑗 =
1√︀|𝑆𝑠|
∑︁
𝑖∈𝑆𝑠
𝑧𝑖𝑗, (2.10)
where 𝑧𝑖𝑗 is calculated with equation (2.1). The problem here is that two nodes within
a subnetwork – one with a highly positive and one with a highly negative score – would
mutually neutralize each other. This effect is undesirable, since the direction of regulation
does not matter for the application described here. On the other hand, if the absolute
value of 𝑧𝑖𝑗 was taken, the sign-flipping used to calculate the FDR would have no effect.
Thus, a trick is applied: if the sign of a given 𝑧𝑖𝑗 is in accordance with the z-scores of all
replicates (i.e. if it has the same sign as
∑︀
𝑗′ 𝑧𝑖𝑗′), 𝑧𝑖𝑗 will contribute positively to the score
𝑧𝑠𝑗, if not it will contribute negatively:
𝑧𝑠𝑗 =
1√︀|𝑆𝑠|
∑︁
𝑖∈𝑆𝑠
(︃
𝑧𝑖𝑗 · sgn
∑︁
𝑗′
𝑧𝑖𝑗′
)︃
, (2.11)
where sgn is the sign function. This equation is applied in line 12, 15 and 21 of the
algorithm in Table 1 to find consistently top ranked subnetworks.
Entities that lack data in one replicate are accepted as differentially regulated, if they
rank top in the remaining 𝑚− 1 replicates. This criterion compensates for missing data,
a particular problem in mass spectrometry experiments.
2.2.6 Implementation
Pre-processing, z-score calculation and generation of the artificial data set was performed
using Matlab. The SubExtractor algorithm is written in Java using the GA library
Jenes (http://jenes.ciselab.org; version 1.2.0) and made available for download online
at http://www.kinaxo.de/SubExtractor. Java version 5.0 or higher is required to run the
program. Network diagrams were created with Cytoscape [58].
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2.3 Results and Discussion
2.3.1 Artificial data
In order to benchmark and assess the proposed method, the algorithm was tested with
artificial data. For this purpose scale free networks based on the algorithm described in
[59] with 1000 nodes and an average connectivity of approximately 3.5 were generated.
Artificial z-scores were produced by sampling values for 969 nodes from a normal distribu-
tion with 𝜇 = 0 and 𝜎 = 1 representing non-regulated proteins (background distribution);
three times for each entity to simulate experimental replicates. The values for the 31 reg-
ulated nodes were determined in a two-step procedure. Firstly, the means 𝑥 were sampled
from a normal distribution with 𝜇 = 0 and 𝜎 = 5. Secondly, the actual replicate values
were generated by drawing three times from a normal distribution with 𝜇 = 𝑥 and 𝜎 = 1.
All 31 regulated nodes are connected with each other forming one regulated subnetwork,
which should be extracted by the algorithm as accurately as possible. This data generation
process was repeated ten times, resulting in ten artificial data sets.
Different 𝜎𝑧 and 𝛼 values were used to assess the subnetwork reconstruction. Values of
the 𝜎𝑧 parameter ranged from 2.0 to 8.0. The parameter 𝛼 that determines the weight of
the network structure on the entire Bayesian score was varied within a range of 0.01 to 10.
Figure 2.2 shows the mean prediction accuracies over all ten artificial data sets at an FDR
level of 0.05 (with 100 GA individuals and 3000 GA generations). Not surprisingly, a 𝜎𝑧
value of 5.0 delivers the best results (see Figures 2.2a and 2.2b), which is the same value
as used for sampling the regulated nodes. At the same time the graphs show a rather weak
dependence on its exact value. Only very small values (e.g. 𝜎𝑧 = 2.0) lead to a considerable
increase of false positive predictions (see Figure 2.2a), which was also expected since
such values are already very close to the 𝜎 value of the background distribution. For 𝛼
the best results could be obtained by setting its value between 0.5 and 2.5 (see Figures
2.2c and 2.2d). Lower values cause the model to put too much weight on the network
structure, which causes especially weakly regulated nodes that are only connected to
strongly regulated ones to be spuriously incorporate into the regulated subnetwork. Higher
values, on the other hand, result in under-weighting of the network structure, which in
turn causes an incorporation of moderately regulated nodes even if the majority of their
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Figure 2.2: SubExtracor’s performance on artificial data. Ten artificial data sets were
generated to assess the prediction quality of SubExtractor. The top figures (2a and 2b)
show the performance for varying 𝜎𝑧 values and a fixed 𝛼 of 1.0. The figures at the
bottom (2c and 2d) depict the mean accuracy for varying 𝛼 values ranging from 0.01 to
10 and a fixed 𝜎𝑧 of 5.0. Nodes sampled with the background distribution (𝜎 = 1) are the
negatives, those coming from the distribution with 𝜎 = 5 are the positives. The FN rate
is defined as false negativesactual positives , the FP rate as
false positives
actual negatives . The overall prediction accuracy
is 1 − false negatives+false positivesactual negatives+actual positives . Error bars display the standard error of the mean over
the ten generated data sets.
neighbours are not regulated at all. Furthermore, one can clearly see that the results are
not sensitive to the exact values of the parameters 𝛼 and 𝜎𝑧, which supports the decision
to fix them a priori. However, the overall prediction accuracy steeply increases between
𝛼-values of 0.25 and 0.5 (see Figure 2.2d). This is due to the effect that if a non-regulated
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node has only one connection to a well-regulated node (and no other connections) and 𝛼 is
smaller than a critical value 𝛼𝑐, it will be added to the differentially regulated subnetwork,
just because of this special connectivity property. To avoid this undesired effect, 𝛼 has to
be chosen
𝛼 > 𝛼𝑐 =
𝒩 (0|0, 𝜎2𝑧)
𝒩 (0|0, 1)−𝒩 (0|0, 𝜎2𝑧)
(2.12)
(the derivation of this formula and further explanation can be found in Supplementary
Information A). For 𝜎𝑧 = 5.0 this leads to valid 𝛼 values of 𝛼 > 0.25, which explains the
large number of false positives for values ≤ 0.25 (as depicted in Figure 2.2c).
A detailed graphical view of the 𝛼 parameter’s impact on the prediction results can
be seen in Figure 2.3, where the originally regulated network and three examples of
networks reconstructed by the method (for a fixed 𝜎𝑧 of 5.0 and alpha set to 0.3, 1
and 5) are depicted. A small value of 𝛼 just above 𝛼𝑐(Figure 2.3 top right) causes an
acquisition of some low regulated nodes (the bright ones within the green circles), since
the Bayesian score is mainly influenced by the network structure. On the other hand,
one node is lost since it has many connections to non-regulated nodes but only a few to
regulated ones (7 and 3, respectively) causing the network to break apart (upper right
empty circle). For 𝛼 = 0.3 the algorithm extracts 4 false positive nodes while missing 3
true positives. On the contrary, a high value of 𝛼 = 5 (Figure 2.3 bottom right) causes the
algorithm to almost entirely ignore topology information, and thus nodes are incorporated
mostly according to their level of regulation. This leads to false positive classification of
5 nodes, of which 4 are fairly well-regulated (i.e. although they were sampled from the
background distribution they received a high score by chance), and the fifth one–although
not regulated itself–acts as a link to one of the well-regulated false positives. Only one of
the true positives was missed. The results for 𝛼 = 1 (Figure 2.3 bottom left) form a good
compromise between the previous two settings, as neither of the two score components is
over-weighted. This reconstructed network has a lower number of false predictions (3 false
positives and 1 false negative), which is a very satisfying result given that many nodes
classified as regulated show very moderate regulation (weaker than some nodes from the
background distribution).
To demonstrate the advantage of SubExtractor over a method that does not take
network information into account, the original global rank test [53] was applied to the
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original α=0.3
α=1.0 α=5.0
Figure 2.3: Example of subnetwork extraction for one artificial data set. The top left area
shows the network of 31 nodes that have been sampled from the normal distribution with
𝜇 = 0 and 𝜎 = 5, thus being the regulated ones in the artificial data set containing 1000
nodes in total. The remaining three areas show networks reconstructed by the proposed
algorithm using different values of the parameter 𝛼. The colouring represents the level of
regulation, where down-regulated nodes are coloured blue, up-regulated ones red and non-
regulated nodes white (the darker the colour the stronger the regulation). The differences
between the original and the reconstructed subnetworks are highlighted by green ellipses.
artificial data sets. The average false negative rate of this method at an FDR level of
0.05 was 29.0%, the average false positive rate was 0.2% (the best results of SubExtractor
with 𝛼 = 1.0 and 𝜎𝑧 = 5.0 were 11.3% and 0.7%, respectively). Although SubExtractor
28
2. SubExtractor
produces slightly more false positives, the superior capability to detect true positives even
if they are only moderately regulated is obvious.
2.3.2 Sorafenib mode of action study
Subsequently the algorithm was applied to a real phosphoproteomics experiment, in
which triply SILAC-labeled PC3 cells were incubated with the small molecule kinase
inhibitor sorafenib (Nexavar®, Bayer HealthCare) for 30 and 90 minutes, including a
control. Proteins were extracted and digested, and phosphopeptides were enriched using
SCX-IMAC/TiO2. High resolution LC-MS/MS data of three biological replicates were
processed using MaxQuant [27].
A total of 15, 800 class-1 sites (i.e. highly confident phosphosites) on 3, 900 unique
proteins were detected. Since two time points are not sufficient to perform any sensible
time-course analysis, the more time point with the more extreme absolute value of its
average log ratios (either log 30minctrl or log
90min
ctrl ) over the three replicates is taken for each
phosphosite. Phosphorylation sites were then pre-processed as described in the Methods
section. Interaction data was taken from STRING version 8.1 [50] and pre-processed
as described in Methods. The 𝛼 parameter was set to 1.0, based on the observations
made from artificial data. 𝜎𝑧 was estimated by applying the original global rank method
[53] to the list of phosphosites and calculating the standard deviation of the resulting
differentially regulated sites’ combined z-scores, which led to a value of 𝜎𝑧 = 5.5. Other
parameter values were also tested, resulting in very similar networks (data not shown).
This supported the findings from the artificial data study, where it has been shown that
results are rather insensitive to the exact parameter values.
At an FDR level of 0.05 the proposed algorithm was able to reconstruct 21 significantly
regulated subnetworks with 168 nodes in total. Additionally, 225 individual proteins were
identified as significantly regulated. A selection of the results are depicted in Figure 2.4.
Besides parts of the MAPK pathway, which is known to be affected by sorafenib, the
largest network contains a substantial fraction of proteins from the mTOR pathway, which
was previously not known to be affected. Subsequent enrichment analyses of the mTOR
KEGG pathway confirmed the results of SubExtractor (p-value < 0.005 using Fisher’s
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exact test; data not shown). In particular, a substantial number of translation initiation
factors (eIF’s) show regulation of phosphorylation upon sorafenib treatment.
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Figure 2.4: Subnetwork extraction for sorafenib mode of action study. The largest two
resulting subnetworks are shown (blue nodes are down-regulated, red ones up-regulated).
Proteins in the orange circles belong to the MAPK pathway, which is known to be affected
by sorafenib. The green rectangle depicts the part of the largest subnetwork that belongs
to the mTOR pathway, which has not previously been reported to be affected by sorafenib.
The network on the right hand side shows an important strength of the algorithm, i.e.
that subnetworks are also reconstructed if the centre node (i.e. the hub) is not detected
to be regulated.
Another example in Figure 2.4 depicts a subnetwork centring the tumour suppressor
p53. This example shows the strength of the method to reconstruct networks, even if
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the hub of the subnetwork is not phosphorylated, not detected, or not regulated. Greedy
search methods that grow subnetworks by selecting a seed and iteratively expand it by
adding regulated neighbours cannot identify such subnetworks.
The complete result in Cytoscape session file format is provided as Additional File 2,
and in Excel format as Additional File 3.
2.3.3 Normal distribution assumption
Both regulated and non-regulated phosphosites were assumed to be normally distributed
with different variances (1 and 𝜎𝑧, respectively). Hence, a mixture model of these two
distributions should well describe the experimental data. To further investigate this as-
sumption we created a probability plot, which is used to assess whether data comes from
a given distribution. However, the plot (see Supplementary Figure A.2) indicates that a
mixture model of standard normal and t location scale distribution (essentially a normal
distribution with heavier tails) fits the data better than the mixture of the two normals.
Next, the impact of the different distributions on the SubExtractor results was assessed
by modelling the regulated data (cf. Equation 2.5) with a t location scale distribution with
the mean parameter set to 0, a variance of 𝜎2𝑧 and 6 degrees of freedom (estimated based
on the fit above). However, the results of the t-normal mixture model were strikingly
similar to those of the normal-normal mixture, suggesting that the slightly better fit of
the former does not increase the prediction accuracy (compare Additional Files 2 and
4). Given the simplicity of normal distributions (i.e. in comparison to t distributions no
degrees of freedom have to be estimated) and the comparable results, the normal-normal
mixture model was considered preferable.
2.3.4 Alternative STRING network preparation
Instead of applying a very conservative cut-off of 0.995 to the combined STRING interac-
tion score, an alternative version was created where the score was re-computed omitting
text mining evidence. The computation was performed according to [60], and should avoid
very high confidence values that are only due to sometimes doubtable text mining evi-
dences. For the re-computed score the cut-off was set to 0.95, which is still conservative
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but increases the number of interactions by 80% and the number of involved proteins by
20%. SubExtractor was then run with this version of network information and the so-
rafenib data (all parameters were left unchanged). While the general tendency of affected
pathways and groups of proteins is very similar, the nodes of the largest network have
roughly doubled making it rather complex (see Additional File 5). The decision on which
network data file to use is left to the user, as it may depend on the application whether he
prefers rather complex but comprehensive networks or smaller networks that are easier to
interpret. Both files are available for download at http://www.kinaxo.de/SubExtractor.
2.4 Conclusion
Here, we propose a novel method, SubExtractor, for extracting differentially regulated
subnetworks from protein-protein interaction networks based on data from global quan-
tification technologies. The core of the method is formed by a Bayesian probabilistic model
that accounts for the regulation of proteins as well as for the network structure. A genetic
algorithm was implemented to find the subnetworks that maximize the Bayesian score.
Furthermore, a global rank significance test was used to distinguish between significantly
regulated subnetworks and those formed by chance.
Although some parts of the method have already been presented elsewhere (cf. In-
troduction), the main advantage of the proposed method is the combination of the three
main parts: Bayesian probabilistic model, powerful heuristics in the form of GA and
rigorous significance testing. To our knowledge none of the existing methods offer this
combination. Additionally, the significances of single nodes (i.e. either proteins that could
not be mapped on the interaction network or extracted single-node networks) are also as-
sessed, which makes separate statistics on a protein scope redundant. Using data from the
comprehensive STRING database guarantees high reliability of the detected interaction
subnetworks.
The method was tested with artificial data sets and showed a high level of recon-
struction accuracy. Knowledge from this study was transferred to a mode of action study,
where SubExtractor revealed differentially regulated subnetworks from known and novel
sorafenib-affected pathways, e.g. the MAPK- and mTOR-pathway, respectively. These reg-
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ulated subnetworks led to creating new hypotheses about the mode of action of sorafenib
in prostate cancer PC3 cells. Furthermore, the subnetworks may also play an important
role in discovering biomarkers. It has been shown [46] that identified markers for class pre-
diction are more reproducible if their identification is based on subnetworks rather than
single genes. Generalization of the proposed method for identifying subnetwork markers
used for class prediction will be the focus of future work.
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Chapter 3
MeanRank test
In this chapter, a new hypothesis test specifically designed for experiments with few repli-
cates and thousands of features is presented. The proposed test, called MeanRank test,
is a global one-sample location test, which is based on the mean ranks across replicates.
The MeanRank test internally estimates and controls the false discovery rate, and handles
missing data without the need of imputation.
The content of this chapter was published as:
M. Klammer, J.N. Dybowski, D. Hoffmann, and C. Schaab. “Identification of significant
features by the Global Mean Rank test.” In: PloS one 9.8 (2014), e104504
The author was a key contributor to designing and implementing the algorithm, as
well as writing the paper. The figures in this chapter were created by J.N. Dybowski, the
co-first author of this publication.
3.1 Background
Today, omics-technologies are capable of generating vast amounts of data. Typical mi-
croarray experiments measure the abundance of thousands of features. With recent ad-
vances in the field of mass spectrometry (MS), over 10,000 proteins can currently be
measured in cell systems [62], while recent studies identified even more phosphorylation
sites through quantitative phosphoproteomics [63–65].
Many of these microarray and proteomics studies include the detection of differentially
regulated features as core step in the data analysis. For data with thousands of features,
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the false discovery rate (FDR), defined as the expected number of false positive features
among those reported as significant, has to be controlled [66]. However, strong control
of the FDR reduces the rate of true positive features (TPR) discovered. The problem is
often aggravated by experimental designs with small numbers of replicates. Further com-
plications arise from missing data, especially common in MS-based shot-gun proteomics
experiments. Microarray technologies often produce non-normally distributed expression
levels and non-identical distributions between genes [67].
In principle, single-feature hypothesis tests like Student’s 𝑡-test or the Wilcoxon rank-
sum test can be applied to assess the significance of each feature, if results are corrected
for multiple testing, e.g. by Benjamini-Hochberg (BH) [43] or the family-wise error rate
(FWER) [68] procedures. However, when applied to data with only few replicates, these
approaches are lacking statistical power, due to difficulties in estimating variance. Tusher
et al. developed the Significance Analysis of Microarrays (SAM) [41], a more sophisti-
cated method based on a modification of the 𝑡-statistic. The FDR is controlled by a
permutation-based approach and adjusted using an estimate of the fraction of truly un-
regulated features. Moreover, SAM employs k-nearest-neighbor (k-NN) imputation to
replace missing data. A similar approach is taken by empirical Bayes methods. Linear
Models of Microarrays (LIMMA), for example, uses a moderated 𝑡-statistics, in which the
estimated sample variance is shrunk towards a pooled estimate across all features [67].
Recently, methods applying a global approach, rather than determining significance
on a feature-by-feature basis, were proposed. These methods take into account the entire
dataset at once and thus avoid the difficult task of estimating the variance of each feature.
Zhou et al. proposed a rank-based, global one-sample location test, which performs very
well for small numbers of replicates and internally controls the FDR [53]. However, this
global rank test requires features to consistently rank high or low across all replicates. The
RankProducts test [69] is based on a similar global approach, but the ranks of each feature
are multiplied. The FDR is then estimated numerically using random rank matrices.
The MeanRank test presented here borrows concepts of the GlobalRank and RankProd-
ucts tests, but uses a different test statistics and a different method for estimating the
null-distribution. In the following, we describe the concept of MeanRank, including its
handling of missing data. While we focus on the one-sample case in the main text, exten-
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sions to the two-sample case are discussed in Appendix B. The one-sample location test
problem is equivalent to the paired-difference test problem for dependent samples. Paired
samples are very common in proteomics experiments, which often apply labeling methods
such as SILAC or iTRAQ, but also in transcriptomics (e.g. two-color microarray). We then
present an extensive simulation study, in which the performance of MeanRank is compared
to the previously mentioned tests, the t-test, and the Wilcoxon signed-rank test. In order
to demonstrate the value of MeanRank, it is compared to SAM and LIMMA on the ’Ag-
Spike’ two-color microarray spike-in data set recently published by Zhu et al. [70]. Finally,
MeanRank and SAM are applied to datasets of two published phosphoproteomics-studies.
3.2 Methods
3.2.1 MeanRank test
Given a matrix 𝑀 of 𝑅 columns (replicates) and 𝑁 rows (features, e.g. genes, proteins,
phosphorylation sites). Let 𝑀𝑖𝑓 be the value of feature 𝑓 (with 𝑓 = 1, ..., 𝑁) in replicate
i (with 𝑖 = 1, ..., 𝑅). Based on this matrix 𝑀 , for each replicate 𝑖 the ranks 𝑟𝑖𝑓 of each
feature 𝑓 within this replicate and across all features can be determined by sorting the
values in each replicate. This is in contrast to the Wilcoxon signed-rank test, for which
the ranks are calculated across the replicates. Then the mean rank is calculated for each
feature across all replicates. Similar to the approach of Zhou et al., [53], the mean rank
statistic is motivated by the random ordering theorem, i.e. under the null hypothesis 𝐻0
that no feature is either up- or down-regulated, it is very unlikely that a feature ranks
consistently high or low across all replicates. Therefore no extreme (very large or very
small) mean rank values can be expected. In contrast to Zhou et al., who require features
to rank top or bottom consistently across all replicates, the mean rank statistic may
tolerate some moderate outliers.
For simplicity, we will focus on the detection of significantly down-regulated features
in the following, but the same approach is applicable for up-regulated features by simply
switching the signs of all values. The mean rank test proceeds in these steps:
1. Sort features ascendingly by their values within each replicate
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2. Calculate mean rank as
𝑟𝑓 =
∑︀𝑅
𝑖=1 𝑟𝑖𝑓
𝑅
(3.1)
3. Sort values 𝑟𝑓 ascendingly (𝑟*𝑓 ) and identify the top 𝑛 as significantly down-regulated
In case of tied ranks, the values are left in the original order, receiving ascending ranks.
The list of significantly regulated features depends on the value of 𝑛, which has to be
chosen to meet the specified FDR. The FDR is defined as the expected fraction of false
positives among the reported positives. Following the approach of Zhou et al. [53], we
denote 𝛼0(𝑛) the expected number of false positives among the top 𝑛 features. The FDR
is thus
FDR(𝑛) = 𝛼
0(𝑛)
𝑛
. (3.2)
As the true form of the null distribution is not known, we have to estimate a null distri-
bution either parametrically or non-parametrically. For a parametric estimate, we assume
that the mean ranks of the null distribution follow a Bates distribution, i.e. the distribu-
tion of the mean of statistically independent uniformly distributed random variables. The
cumulative distribution function is defined as:
FBates(𝑚,𝑥) =
1
2𝑚!
𝑚∑︁
𝑘=0
(−1)𝑘
(︂
𝑚
𝑘
)︂
(𝑚𝑥− 𝑘)𝑚sgn(𝑚𝑥− 𝑘) (3.3)
where 𝑚 is the number of random variables and 𝑥 is the mean of the random variables
scaled to the interval (0, 1), and sgn(𝑎) is −1 for 𝑎 < 0, 0 for 𝑎 = 0, and 1 for 𝑎 > 0. The
expected number of false positives is then calculated as:
𝛼0(𝑛) = FBates
(︂
𝑅,
𝑟*𝑛
𝑁
)︂
·𝑁 (3.4)
Non-parametric estimation of 𝛼0(𝑛) follows Zhou et al., assuming a non-regulated
feature has the same probability of ranking top or bottom [53]. Thus, the null distribution
is independent of whether the features are sorted in ascending or descending order, or –
analogously – whether the features values have a positive or negative sign. Consequently,
𝛼0(𝑛) can be estimated by alternately flipping the signs of the ratios of the replicates,
calculating the flipped mean ranks 𝑟𝑓𝑙𝑖𝑝𝑝𝑒𝑑 on this flipped data, and counting the number
of values in 𝑟𝑓𝑙𝑖𝑝𝑝𝑒𝑑 < 𝑟*𝑛 (see pseudo-code in Appendix B).
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Missing data
To account for missing data values, which are especially common in MS-based proteomics
experiments, the equation in step (3.2) of the algorithm has to be modified to
𝑟𝑓 =
∑︀𝑅
𝑖=1 𝑟𝑖𝑓
?^?𝑓
, (3.5)
where ?^?𝑓 is the number of present data values of the respective feature and 𝑟𝑖𝑓 = 0
if the value is missing. It has to be ensured that missing values are not considered in the
ranking process and consequently do not receive a rank (they are ignored completely).
The FDR estimation has to be modified as well, as there are now features with different
numbers of data values in the dataset. Thus, the parametric estimation of false positives
has to be modified to
𝛼0(𝑛) =
𝑅∑︁
𝑖=1
FBates
(︂
𝑖,
𝑟*𝑛
𝑁
)︂
·𝑁𝑖 (3.6)
where 𝑁𝑖 is the number of features with 𝑖 data values present. The non-parametric
estimation of 𝛼0(𝑛) remains largely unchanged, however, one has to ensure that features
unaffected by sign-flipping are excluded. This occurs when sign-flipping is by chance
applied only to values that are missing. The resulting feature would be unchanged and
receive the same ranks and subsequently mean rank, after flipping.
3.2.2 Simulations
Artificial data was generated by sampling from various distributions. The background
distribution (unregulated data) containing 3600 features was drawn from a normal dis-
tribution with zero mean (𝜇 = 0) and standard deviation 𝜎 = 0.1; 400 regulated features
(80 up- and 320 down-regulated) were sampled from normal distributions with shifted
means (shift Δ = 0.2). We investigated the performance with an increasing number of
replicates (3 to 15). The described settings were then altered to simulate variable variance
by drawing 𝜎 from a uniform distribution 𝜎 ∼ 𝒰(0.05, 0.25))in combination with constant
regulation strength between features (Δ = 0.3) and variable regulation Δ ∼ 𝒰(0.2, 0.4).
Missing data were introduced by randomly discarding 20% of data points while ensuring
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that at least two thirds of the data points were present for each feature. In simulations of
non-normal data we sampled features from a 𝑡-distribution with two degrees of freedom.
Whenever imputation of missing values was applied, the k-nearest neighbor (𝑘 = 10)
method was used.
Significance analyses by RankProducts, SAM and LIMMA were performed using the
RankProd [71], samr, and limma packages of Bionconductor [72] for R [73], respectively.
The global rank method by Zhou et al [53] was implemented by the authors. 𝑡-test and
Wilcoxon signed-rank test 𝑝-values were BH corrected for multiple hypothesis testing [43].
3.3 Results and Discussion
3.3.1 Simulated data
In order to evaluate the performance of the MeanRank test and to compared it with
various other tests, we performed an extensive simulation study extending the range of
scenarios found in comparable publications [53, 74, 75] by including more parameters and
wider ranges of replicates and methods. The advantage of simulations is that underlying
statistical properties are known and, thus, the performance of different hypothesis tests
can be compared under various conditions. In the first set of simulations we assessed
the performance of the one-sample location tests for different sampling distribution pa-
rameters. Simulation parameters were strength of regulation (Δ), within-feature variance
(𝜎2) – both of which were either held constant or chosen to be variable – and the pres-
ence of missing values. These parameters were combined to generate different simulation
scenarios. We calculated the performance for an increasing number of replicates for the
respective scenarios. The parameters were deliberately chosen to simulate experiments
with hard-to-identify regulated features to investigate the added power over a wide range
of additional replicates. With the chosen settings, a true positive rate (TPR) of 1.0 should
not be achieved easily.
The simplest simulation setting assumes a constant variance and strength of regula-
tion. Figure 3.1A shows TPR and FDR achieved by the tests when 3,600 unregulated
features were sampled with constant 𝜎2 = 0.01 and 400 regulated features were sampled
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Figure 3.1: Performance on simulated data. Performance plot of one-sample significance
tests under different simulation settings. Traces show the true positive rate (TPR) of the
respective tests for a given number of replicates. Bars at bottom denote the false discovery
rate (FDR). TPR and FDR are averaged over ten independent simulations. All tests were
set to control the FDR at 0.05.
with a constant shift Δ = 0.2. The leading method in this setting is LIMMA, followed
closely by SAM, and then the non-parametric MeanRank (MR). This top-group clearly
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outperforms the other methods. The parametric MeanRank test (MR.par) has a some-
what lower power for data with less than five replicates in this specific simulation setting.
The power of the GlobalRank tests (GR and GR.par) does not scale with the number
of replicates, but reaches its maximum performance at nine replicates. Additional repli-
cates will even lead to a loss in power. This behavior is expected, because with a growing
number of replicates it becomes less likely for a regulated feature to consistently rank top
or bottom. Similar to the parametric MeankRank (MR.par), the parametric GlobalRank
(GR.par) is less powerful than its non-parametric counterpart for less than five replicates.
In contrast to the GlobalRank, the power of the RankProducts (RP) scales well with the
number of replicates, but it is less powerful for experiments with small number of repli-
cates. The TPR curves of GlobalRank and RankProducts underline the initial motivation
of developing the MeanRank test, i.e. combining the strengths of both tests without in-
heriting their shortcomings. The 𝑡-test shows significant lower TPR, most likely due to
variance estimation issues, especially evident at very small number of replicates. As an
example of a non-parametric, rank-based test that does not belong to the class of global
approaches, we included the Wilcoxon signed-rank test. Because of the discreteness of the
test statistics, it is not surprising that a minimum of nine replicates is required to identify
any significantly regulated feature after multiple hypothesis testing correction. For eleven
or more replicates the TPR approaches the TPR of the other tests beside the GlobalRank
tests. All tests correctly control the FDR at the pre-specified level of 0.05.
Next, we investigated the scenario with feature dependent variable variance, which is
frequently observed in omics data due to the dependence of the variance on the signal
intensity [76]. Overall the tests display a similar behavior as in simulations with constant
variance (Figure 3.1B). However, while the overall TPR is slightly lower for most tests
with variable 𝜎2, the parametric MeanRank and GlobalRank tests seem to be largely
unaffected. Thus, the discrepancy between the parametric and non-parametric versions,
which was observed for small number of replicates, disappears. Furthermore, MeanRank
has a slightly higher overall TPR than SAM or LIMMA under these simulation conditions.
The small gain in power for the 𝑡-test results from features with small variance caused by
the variable 𝜎2 setting.
We then combined the variable variance 𝜎2 with a variable regulation strength Δ,
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reflecting the complex response of systems to perturbations, e.g. of cells to drug treatment.
There is a further loss in power across all tests, since some of the regulated features are
hidden in the background noise (Figure 3.1C). The parametric MeanRank performs best
across all replicate numbers. The non-parametric MeanRank, SAM and LIMMA, exhibit
comparable but slightly reduced power. In general, the behavior of all tests is similar to
the previous simulation (Figure 3.1B).
When using heavy-tailed distributions, such as a 𝑡-distribution, SAM and MeanRank
exhibit similar power until up to seven replicates. However, while MeanRank progresses
to a TPR of 1.0 for 15 replicates, SAM has by then just reached TPR 0.8 and almost
levels off. (Figure 3.1D). The power of LIMMA is considerably reduced compared to the
previous scenarios and is comparable to the power of the 𝑡-test. The GlobalRank shows
particular problems with this setting, achieving a TPR of merely 0.4, before starting to
drop. The RankProducts even falls behind the 𝑡-test for less than nine replicates.
Missing data are common in technologies such as MS-based shotgun proteomics, thus in
the next set of simulations we introduced missing values combined with variable variance
𝜎2 (Figure 3.1E). It should be noted, that SAM is the only method used that does not
handle missing data intrinsically. Instead, it employs a k-NN imputation prior to the
actual significance analysis. In terms of power, parametric and non-parametric MeanRank
together with SAM and LIMMA delivered the best results. For small numbers of replicates,
the power of GlobalRank was comparable to that of MeanRank and SAM. However, SAM
and the parametric GlobalRank systematically underestimated the FDR.
We additionally simulated the effect of missing values on data with both variable vari-
ance 𝜎2 and shift Δ (Figure 3.1F). Here, the parametric and non-parametric MeanRank,
SAM and LIMMA perform best with respect to the TPR. As in the previous scenario,
SAM always underestimated the FDR considerably. In order to investigate whether the
violations of FDR threshold observed for SAM were due to imputation, we also applied
the other tests to the imputed data (see Supplementary Figure B.2). This resulted in sim-
ilar behavior: a general violation of the FDR threshold, accompanied by a slightly higher
TPR. Although it can be argued, that this is not a problem of SAM per se, the inability
of handling missing data makes imputation inevitable.
Zhou et al. [53] stated that, in contrast to single-feature analysis methods, large num-
42
3. MeanRank test
bers of features are advantageous for global methods and will lead to increased statistical
power. We tested whether this applies to MeanRank, by altering the proportion of regu-
lated and background features for a constant number of six replicates (see Supplementary
Figure B.3). The hypothesis was confirmed, revealing that the rank-based tests (Mean-
Rank, GlobalRank, and RankProducts) possess more power when the proportion of reg-
ulated to background features is small. The opposite is true for the single-feature-based
tests, such as 𝑡-test, SAM and LIMMA. Despite experiencing a loss of power over an in-
creasing fraction of regulated features, MeanRank always met the desired FDR threshold,
while GlobalRank increasingly violated this threshold.
The simulations show that the parametric MeanRank generally had a higher power
than the non-parametric version. Thus, we only used the parametric test in the follow-
ing real data experiments. In the following, we applied parametric MeanRank, SAM and
LIMMA, i.e. the tests showing the best performance in the above simulations, to mi-
croarray spike-in data and finally to real experimental datasets, for which, of course, the
identity of truly regulated features is not known. However, since we showed that all tests
with exception of SAM meet the pre-specified FDR in a series of different simulation sce-
narios, we can judge the performance of the test by evaluating the number of regulated
features identified.
3.3.2 Microarray spike-in data
Spike-in datasets are well-suited for the comparison of significance analysis methods,
since the identity of truly regulated features is known before-hand. Here, we used the
Agilent two-color microarray spike-in dataset (’Ag-Spike’) consisting of 1300 differentially
expressed and 2500 background cRNAs across 12 replicates [70]. In their study the authors
explored different combinations of preprocessing methods (background correction, within-
, between-array normalization) in order to identify optimal preprocessing routes for the
detection of differentially expressed genes using LIMMA.
We used the published preprocessed data to compare performance of the parametric
MeanRank test with that of SAM and LIMMA. Figure 3.2 shows the true positive and
false discovery rates of the three methods on the differently preprocessed spike-in data.
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Figure 3.2: Performance on spike-in data. Performance comparison of MeanRank (red),
SAM (brown), and LIMMA (cyan) on the ’Ag-Spike’ microarray dataset [70]. TPR and
FDR shown by lines and bars, respectively. Different combinations of preprocessing inves-
tigated by the authors of the original study are shown on the x-axis.
Most notably, the rank-based approach of MeanRank is very robust against changes in
preprocessing: 𝐶𝑉TPR = 0.04% and 𝐶𝑉FDR = 0.75% compared to SAM (𝐶𝑉TPR = 0.21%,
𝐶𝑉FDR = 5.02%) or LIMMA (𝐶𝑉TPR = 0.54% and 𝐶𝑉FDR = 6.02%). Slight variation is
still introduced by methods applying local corrections, thus causing rank alterations (e.g.
normalization loess). MeanRank on average identifies 2691 positives, 2354 (87%) of which
are identified in all twelve preprocessing scenarios. The number of positives identified
by SAM (4119) and LIMMA (3246) are higher on average, but clearly more dependent
on the preprocessing protocol, with the number of constantly identified features being
2413 (59%) and 1989 (61%), respectively. This behavior is in line with the observations
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of Zhu et al., who in a prior study found that the preprocessing protocol has a great
impact on the performance of methods for detection of differentially expressed features
[77]. The power of MeanRank is comparable to that of SAM and LIMMA, when none or
only minimal efforts of normalization are made. Additional preprocessing steps result in
greater power for SAM and LIMMA, however at the cost of an under estimated FDR. Zhu
et al. found that a combination of background correction by normexp and within-array
normalization using loess yields the best result. This measure looks at the true positive
and corresponding false positive rates given the absolute value of the test statistic. Hence,
the correct estimation of the FDR is not taken into account. Figure 3.3 shows volcano plots
of the normexp-corrected and loess-normalized spike-in data and highlights differentially
expressed features as identified by the different tests. The column-like structure of data
points on the x-axis reflects the levels of spike-in (see Supplementary Figure B.4). The
largest column centered at zero contains features not regulated. SAM and LIMMA, in
contrast to the MeanRank test, tend to produce more false positives as the feature variance
decreases.
3.3.3 Phosphoproteomics data of erlotinib-treated AML cells
We applied MeanRank, SAM and LIMMA to phosphoproteomics data published by We-
ber et al. [78]. The authors of that study performed SILAC-based, large-scale, quantitative
mass spectrometry analyses of KG1 acute myeloid leukemia cells treated with the small
molecule tyrosine-kinase inhibitor erlotinib, which mainly targets the epidermal growth
factor receptor (EGFR). In their subsequent significance analysis of ratios of erlotinib
versus control treatment the authors applied the RankProducts test to identify 33 signif-
icantly (FDR 0.05) regulated class-I sites (i.e. phosphorylation sites identified with high
confidence). Prior to testing, ratios of class-I sites were log10-transformed and subjected
to sample-wise median normalization (cf. [32]).
The MeanRank test yielded 57 significantly regulated phosphorylation sites at FDR
0.05, including 24 of the 33 sites published by Weber et al (Figure 3.4, Additional File
2). Of the remaining 9 sites, 8 had a local FDR smaller than 0.07, thus missing the sig-
nificance criterion only marginally. 27 of the additional 33 sites identified by MeanRank
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Figure 3.3: Volcano plot of spike-in data. Volcano plot of the ’Ag-Spike’ data, background
corrected by normexp and normalized with loess. This combination of preprocessing steps
was found to deliver the best performance by the authors of the original study [70]. Genes
are represented as points. Non-differentially expressed genes are scattered around Mean=0
on the x-axis. Differentially expressed genes, as identified by the respective methods are
colored.
had a missing ratio, emphasizing the tolerance of the test towards incomplete data. SAM
identified only 5 sites as significantly regulated, while LIMMA did not identify any signifi-
cantly regulated phosphorylation sites at all. The sites newly identified by MeanRank are
located on 29 different proteins. Most of these proteins are annotated as being involved in
the cell surface receptor signaling pathway (GO:0007166). Weber et al. further found that
most site-specific repression of phosphoserines by erlotinib occurred on proteins involved
in mRNA translation control. Supporting this finding, the MeanRank test also identified
several transcription factors (GTF2B, GTF2F1, GTF3C1, DEAF1, and TCF12) to be
significantly regulated upon treatment. In addition, we identified 6 additional phospho-
tyrosines sites. As the primary targets of erlotinib are tyrosine kinases, this significant
relative enrichment (Fisher’s exact test 𝑝 < 9.5 · 10−6) compared to the proportion of
phosphotyrosins in the full dataset supports the findings of MeanRank. One of the sites
that has not been identified as significantly regulated in the original paper is Tyr427 on
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Figure 3.4: Volcano plot of AML data. Volcano plot of the phosphoproteomic data pub-
lished by Weber et al. [78]. Significantly regulated phosphorylation sites are shown by
colored circles as identified by SAM (left), the MeanRank test (right center), and in the
original study (right).
the SHC-transforming protein 1 (Shc1). Tyr427 is phosphorylated in-vitro by Src kinase
and in-vivo in EGF-stimulated cells [79]. Phosphorylated Shc1 forms a complex with Grb2
which in turn activates Ras signaling [80]. By down-regulation of Tyr427 on Shc1, erlotinib
treatment inhibits the transmission of growth signals to the Ras signaling cascade.
3.3.4 Phosphoproteomics data upon reactivation of Plk1
We investigated the behavior of MeanRank and SAM on data from a second phospho-
proteomics study. Here, telomerase-expressing human retinal pigment epithelial (hTERT-
RPE) cells expressing an analog-sensitive Plk1 mutant (Plk1as) were treated with the
bulky kinase inhibitor 3-MB-PP1 [81]. 3-MB-PP1 inhibits the mutant kinase Plk1as har-
boring an enlarged catalytic pocket, but not wild-type Plk1. This allowed the investigation
of downstream effects upon Plk1 reactivation by inhibitor wash-out. The dataset contained
four biological replicates with a total of around 20,000 identified phosphorylation sites. In
this analysis, we considered only sites with values present in all four replicates in order
to avoid having to impute data for SAM analysis. This left around 5,200 phosphosites to
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be tested for significant regulation upon inhibitor wash-out. Since SAM requires proper
pre-processing, the data were log10-transformed and median normalized (cf. [32]).
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Figure 3.5: Volcano plot of Plk1-kinase-inhibited cells data. Volcano plot of the phos-
phoproteomic data of cells treated with an Plk1 tyrosine kinase inhibitor versus control
[81]. Significantly regulated phosphorylation sites shown in colored circles as identified by
MeanRank test, SAM, LIMMA (from left). The two rightmost volcano plots shows differ-
ences in detected phosphorylation sites by MeanRank/SAM and MeanRank/LIMMA.
While MeanRank identified 313 significantly regulated phosphorylation sites (FDR
0.05), SAM reported a slightly higher number of 359 significant sites for the same FDR
level (Additional File 3). The overlap of the reported significant features was 249. SAM
identified more significantly up-regulated features than MeanRank, most of which exhibit
low variance and low mean regulation (Figure 3.5). SAM found 152 sites that were less
than 1.5-fold up-regulated on a linear scale; MeanRank only 45. In contrast, SAM found
only 8 sites that were less than 1.5-fold down-regulated (linear scale), while MeanRank
reported 61. MeanRank draws a more consistent threshold between significantly up-, and
down-regulated features than SAM.
LIMMA reports 229 significantly regulated phosphorylation sites, 225 are also identi-
fied by MeanRank. Similar to MeanRank, LIMMA mainly reports sites with mean reg-
ulation stronger than ±1.5-fold on a linear scale. Only 23 sites with down-regulation of
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less than 1.5-fold and 18 with an up-regulation of larger than 1.5-fold are reported.
Generally, it appears that SAM puts more emphasis on variance and MeanRank more
emphasis on the level of regulation. This is reflected in the shape of the region within
the volcanoplot, in which the significant features are located (Figure 3.5): While the
significantly regulated features identified by MeanRank can be separated from the back-
ground features almost by a straight line, those identified by SAM exhibit a rather curved
threshold line. LIMMA behaved similar to MeanRank, however identifying slightly less
significantly regulated sites. Since the simulation study suggests that both tests comply
with the pre-specified FDR level when applied to four-replicate experiments, it can be
argued that at least 95% of the phosphosites reported as being significantly regulated by
either test are in fact true positives. While all three tests perform well and have a high
overlap, either might be more suitable depending on the application.
3.3.5 Two-sample test
Established methods such as SAM and LIMMA support two-sample comparison exper-
iments. The MeanRank test can be extended to accommodate two-sample comparisons
by basically transforming the two-sample into a one-sample problem. To do so, we create
a difference matrix by calculating the difference of each possible pair from both groups.
Here we assume that the data is log-transformed. The calculations of the mean ranks
is then performed on the difference matrix in the same way as for the one-sample test.
Since the columns of the difference matrix are not independent anymore, the dependency
structure has to be taken into account when estimating the null distribution. We found
that although the test generally performs well in terms of power compared to SAM for
most cases in our simulations and spike-in microarray data [77] while reliably controlling
the FDR, it is very conservative when applied to data with missing values. This can be
explained by the way the difference matrix approach exaggerates the relative amount of
missing values. The method and simulation setup is described in detail in Appendix B
(see also Supplementary Figure B.1).
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3.4 Conclusion
The simulations showed that borrowing traits from both the GlobalRank and RankProd-
ucts methods strongly improved the power over either of the two tests in all simulated sce-
narios, while reliably estimating the FDR. All three tests are rank-based and use a global
approach rather than testing feature-by-feature. The main differences of the MeankRank
test compared to the other two tests are the test statistics and the methods for estimating
the distribution under the null-hypothesis. We showed that this improves the power of
the test with respect to the RankProducts test for low number of replicates and avoids a
drop in power with increasing number of replicates in the case of the GlobalRank test.
While single-feature-based non-parametric tests, such as the Wilcoxon rank-sum or
signed-rank tests, require nine or more replicates in order to identify any significant reg-
ulated feature at all, this is not the case for global rank-based tests. The fixed 𝜎2 simu-
lations showed, that the non-parametric MeanRank test identifies more than 60% of the
true positives for three replicates.
The parametric and non-parametric MeanRank tests performed comparably to SAM
and LIMMA in most simulation scenarios. While SAM and LIMMA performed slightly
better in the case of fixed 𝜎2 simulations, MeanRank had a slightly higher power in the
cases with variable 𝜎2 and both variable 𝜎2 and Δ.
When introducing missing data, our simulations suggest that SAM tends to underes-
timate the FDR, since missing values have to be imputed. This naturally raises concerns
when applying SAM – and thus imputation – to data resulting from technologies like
MS-based shotgun proteomics, regularly producing missing values. The matter is further
complicated by the fact that different imputation methods (k-nearest-neighbor, singular
value decomposition, multiple imputation, etc.) can deliver deviating results [82]. These
aspects have to be considered, when applying SAM to data with missing values, while the
MeanRank test offers a convenient way to entirely avoid imputation. However if, under
certain conditions, imputation delivered results close to the ground truth, the power of
any test would increase. A distinct advantage of the MeanRank test lies in the decoupling
of significance testing and imputation procedures, leaving the freedom of choice with the
researcher. If the data were not normally distributed but followed a heavy-tailed distri-
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bution such as the 𝑡-distribution with few degrees of freedom, the one-sample MeanRank
test showed a better performance than SAM and in particular LIMMA, especially for
experiments with many replicates.
The global nature of the MeanRank test leads to a loss in power when a very large
fraction of features is truly regulated. However, several studies suggest that the fraction
of differentially regulated features is often lower than 10% [78, 81]. In fact, given such
experiments, our simulations show that the MeanRank test has an advantage over single-
feature-based tests like SAM and LIMMA. A notable practical advantage of MeanRank
over other methods such as SAM is that normalization of samples is not necessary due to
its rank-based nature. This is advantageous because normalization can have a direct influ-
ence on the results, as was demonstrated by our comparison based in the ’Ag-Spike’ data.
Here, MeanRank, in contrast to SAM or LIMMA, produced very stable results, indepen-
dent of the preprocessing steps applied. SAM attempts to determine the proportion 𝜋0 of
true null hypotheses in the dataset in order to adjust the false discovery rate [66]. This
usually leads to more positive calls; however, the estimation of 𝜋0 is not robust against
small variations in the data and depends strongly on the preprocessing applied. Since
the FDR estimation of the MeanRank test is rather conservative, an implementation of a
similar estimation could help to further improve the test with respect to statistical power.
However, we deliberately omitted 𝜋0 estimation because of the described inconsistent
behavior also seen in other studies [83].
In summary, the key advantages of the MeanRank test compared to other tests are: a
comparable or even superior power in detecting regulated features without underestima-
tion of the FDR, the possibility to analyze data with missing values without the necessity
for imputation; the robustness with respect to preprocessing. Although we focused on
the one-sample test in the main text, a two-sample version of the test is also available
and described in Appendix B. One-sample location tests are particular important for the
analysis of proteomics data which often uses labeling methods such as SILAC or iTRAQ,
but also for the analysis of two-color microarrays. Furthermore, they can be applied to
paired two-sample test problems emerging, for example, if matched tumor and normal
tissues are measured across many patients. The MeanRank test is not limited to testing
the significance of gene- or protein regulation. As no strong assumptions about the un-
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derlying distributions are made for the non-parametric test, inference about statistically
significant differences between groups could, in principle, be made for any kind of ordinal
features. Furthermore, MeanRank is freely available and can be used by anyone without
any restrictions, whereas SAM is patented and requires proper licensing. For most ex-
periments, running the MeanRank test is a matter of seconds, and can be performed on
standard computers (see Supplementary Table B.1).
Finally, we would like to emphasize the intuitiveness of our test. MeanRank is easy to
understand, easy to implement, does not require any parameter optimization and yields
results that are easy to interpret.
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Chapter 4
NSCLC biomarker
In this chapter, a phosphorylation signature that predicts the response to treatment with
the kinase inhibitor dasatinib in non-small cell lung cancer (NSCLC) cell lines is presented.
Quantitative mass spectrometry was used to globally profile the basal phosphoproteome of
NSCLC cell lines; the effect of dasatinib on cellular growth was tested against the same cell
line panel. An elaborate cross-validation workflow including robust feature selection and
support vector classification was developed in order to detect a phosphorylation signature
that accurately predicts sensitivity to dasatinib.
The content of this chapter was published as:
M. Klammer, M. Kaminski, A. Zedler, F.S. Oppermann, S. Blencke, S. Marx, S. Müller,
A. Tebbe, K. Godl, and C. Schaab. “Phosphosignature Predicts Dasatinib Response in
Non-small Cell Lung Cancer.” In: Mol Cell Proteomics 11.9 (2012), pp. 651–668
The author was a key contributor to designing and implementing the algorithms, as
well as writing the paper. The wet laboratory work were performed by his colleagues
at Evotec Munich: A. Zedler, S. Blencke and S. Marx performed the cell culture work
under the supervision of S. Müller; M. Kaminsky and F.S. Oppermann performed the MS
analyses under the supervision of A. Tebbe.
4.1 Background
The introduction of targeted drugs for treating cancer is a major biomedical achievement
of the past decade [84, 85] . Since these drugs selectively block molecular pathways that
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are typically over-activated in tumor cells, they are more precise and less toxic than tra-
ditional chemotherapeutics. However, while many cancer patients benefit from a specific
targeted therapy, many others do not. Therefore, predictive molecular markers are needed
to confidently predict the patient’s response to a specific therapy. Such markers would
facilitate therapy personalization, where the selected therapy is based on the molecular
profile of the patient.
Predictive tests currently used in the clinic are frequently based on one particular
marker that is often linked to the drug’s target. A well-known example for a predictive test
is assessing HER2/neu overexpression using immunohistochemistry or fluorescent in situ
hybridization to predict the response to therapy with trastuzumab (Herceptin®, Roche)
(see [34, 35] ). However, in some cases the expression or mutational status of the target or
other singleton markers might not be sufficient to predict a therapeutic response. Recently,
several studies tried to identify molecular signatures comprising multiple markers for
response predictions, usually based on gene expression profiling (e.g. [86, 87]. To our
knowledge, no study successfully identified a signature from global phosphoproteomic
profiles so far.
Recent advances in mass spectrometry, methods for enriching phosphorylated proteins
or peptides, and computer algorithms for analysing proteomics data have enabled the
application of mass spectrometry-based proteomics to monitor phosphorylation events
in a global and unbiased manner. These methods have become sufficiently sensitive and
robust to localize and quantify the phosphorylation sites within a peptide sequence [15,
32, 63]. Phosphorylation events are important in signal transduction, where signals caused
by external stimuli are transmitted from the cell membrane to the nucleus. Aberrations
in these signal transduction pathways are particularly important for understanding the
mechanisms of certain diseases, such as cancer, inflammation and diabetes [88, 89].
Approximately 391,000 incidences and 342,000 deaths from lung cancer were estimated
in Europe in 2008 [90], accounting for nearly 20% of all cancer deaths in Europe. Approx-
imately 85% of all lung cancer incidences are non-small cell lung cancer (NSCLC) [91].
Dasatinib (Sprycel®, Bristol-Myers Squibb) is a multi-kinase inhibitor targeting BCR-
ABL, the Src-kinase family, c-Kit, ephrin receptors, and PDGFRb [11, 12]. It is currently
approved for chronic myelogenous leukaemia and Philadelphia chromosome-positive acute
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lymphoblastic leukaemia. Recently, dasatinib was clinically evaluated in patients with ad-
vanced NSCLC. Dasatinib had modest clinical activity, with only one partial response
and twelve stable diseases among thirty patients. Neither Src family kinase activation nor
EGFR and Kras mutations could predict the response to dasatinib [92].
In this study we wanted to identify a signature of protein phosphorylation that pre-
dicts the response to dasatinib in NSCLC cell lines. In total, 26 NSCLC cell lines were
tested for their response to dasatinib. The identical cell lines were profiled in a global,
unbiased, phosphoproteomics study and the obtained phosphoproteome profiles were used
to assemble a biomarker signature of 12 phosphorylation sites. We evaluated the perfor-
mance of this signature in a cross-validation set-up and investigated the robustness of the
selected predictive features. Finally, we confirmed the predictive power of the signature
in an independent set of breast cancer cell lines.
In a recent study, Andersen et al. identified phosphorylation sites predicting response
to phosphatidy-linositol 3-kinase (PI3K) inhibitors [93]. Their study differs in two aspects
from the study presented here. First, the authors focused on the PI3K and MAPK path-
ways by immunoprecipitating phosphorylated peptides with antibodies directed against
corresponding phospho-motifs. In contrast, we followed an unbiased approach, where no
hypothesis about the involved signalling pathways has to be made. Second, the authors
first investigated the regulation of phosphorylation sites upon drug treatment in one sen-
sitive cell line, and subsequently confirmed the applicability of one site to response pre-
diction by evaluating its basal phosphorylation in a panel of cell lines. Here, we started
directly by investigating the basal phosphoproteome of a panel of sensitive and resistant
cell lines.
4.2 Methods
4.2.1 Cell culture
Based on the half-maximum growth inhibitory concentrations (GI50) of dasatinib on a
panel of 84 NSCLC cell lines reported in Supplemental Table 5 of Sos et al.[94], 13
cell lines with low and 13 with high GI50 values were selected (cf. Supplementary Table
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C.1). These 26 cell lines were obtained from the LGC Standards (Wesel, Germany), from
the DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig,
Germany), and Roman Thomas’ group at the Max Planck Institute for Neurological
Research (Cologne, Germany). The six breast cancer cell lines were obtained from the
LGC Standards (see Supplementary Table C.1).
All cell lines were cultivated in RPMI1640, 10% foetal bovine serum, 2 mM glu-
tamine, 1 mM sodium pyruvate and penicillin/streptomycin (PAA, Cölbe, Germany).
Cells were routinely monitored for mycoplasma infection using the MycoAlert reagents
(Lonza, Cologne, Germany). Metabolic labelling of the cell lines was performed using
SILAC (stable isotope labelling with amino acids in cell culture [17]). Cells were culti-
vated in media containing SILAC-RPMI (PAA) and dialysed FBS (Invitrogen, Darm-
stadt, Germany). L-lysine and L-arginine were replaced by normal L-lysine (Lys-0) and
L-arginine (Arg-0), or medium isotope- labelled L-D414N2-lysine (Lys-4) and L-13C614N4-
arginine (Arg-6), or heavy isotope-labelled L-13C615N2-lysine (Lys-8) and L-13C615N4-
arginine (Arg-10). Isotope-labelled amino acids were purchased from Cambridge Isotope
Laboratories (Andover, MA, USA). Cells were cultivated for a minimum of six doubling
times to obtain an incorporation efficiency for the labelled amino acids of at least 95%.
16 NSCLC cell lines were selected as a reference pool: A549, Calu6, H1395, H1437,
H1755, H2030, H2052, H2172, H28, H460, HCC827 (obtained from LGC Standards),
LCLC103H, LouNH91 (obtained from DSMZ), H322M, HCC2279, HCC2429 (obtained
from MPI for Neurological Research). The selected cell lines were grown in SILAC media
supplemented with the natural ’light’ forms of arginine and lysine. The labelled cells of
each cell line were lysed, pooled, aliquoted, and stored at -80°C. In total, 40 aliquots with
12 mg of protein each were generated.
4.2.2 Determination of cellular growth inhibition
Sensitivity of the cell lines for dasatinib was determined by measuring the cellular ATP
content after 96 hours of treatment using the CellTiter Glo chemiluminescent viability
assay (Promega, Mannheim, Germany). Cells were cultivated in 96-well plates (Greiner,
Frickenhausen, Germany) in the presence of dasatinib (LC Laboratories, Woburn, MA,
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USA) within a concentration range between 3 nM and 30 µM.
The raw data from the chemiluminometer (FLUOstar OPTIMA, BMG Labtech, Of-
fenburg, Germany) was used to determine the GI50 value. First, the background was
determined by calculating the median value of the plate’s border wells, which contained
only growth media. This value was then subtracted from each inner well. Since two ex-
periments were conducted on one 96-well plate with 10 compound concentrations each
(0(DMSO), 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1µM, 3 µM, 10 µM, 30 µM), three
data points per concentration and experiment were available. Ratios representing the per-
centage of growth inhibition were calculated by dividing each data point coming from a
concentration >0 by the median of the DMSO values. A logistic regression was performed
to fit a curve to those ratios and compute the GI50 value.
4.2.3 Classification into sensitive/resistant
The calculated GI50 values of the 26 selected cell lines were compared with the values
reported in [94]. Although the correlation between the two sets was strong (Pearson cor-
relation = 0.50, p = 0.009 on logged GI50s), a few cell lines showed inconsistent behaviour.
By setting the threshold to discriminate between sensitive and resistant cells to a GI50
value of 1 µM, seven cell lines were classified inconsistently (5 were resistant in the refer-
ence paper, but sensitive in this study, 2 vice versa). Consequently, these cell lines were
excluded from the workflow that aims at finding a predictive phospho-signature.
4.2.4 Phosphoproteomics workflow
Responsive and non-responsive cell lines were grown in medium or heavy SILAC media
and after washing twice with ice-cold PBS the cells were lysed directly on the plates by
the addition of ice-cold lysis buffer (8 M urea, 50 mM Tris pH 8.2, 5 mM EDTA, 5 mM
EGTA, SIGMA HALT Phosphatase Inhibitor Mix, ROCHE Complete Protease Inhibitor
Mix). After sonication cell debris was sedimented by centrifugation and the protein con-
centration was determined by Bradford assays. Equal protein amounts of the reference
cell culture mix and a medium and heavy labelled cell line (7 mg protein each) were
mixed as depicted in Supplementary Figure C.2 and subsequently subjected to reduction
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(20 mM DTT, 30 min 37°C) and alkylation (50 mM iodoacetamide, 30 min RT) prior to
proteolytic cleavage. Then 80 µg of LysC (Wako) was added for 4 h followed by a 4-times
dilution with 50 mM Tris pH 8.2. Proteolytic cleavage was continued by the addition of
120 µg of trypsin (Promega) overnight. The peptide mixtures were acidified by addition
of TFA to a final concentration of 0.5% and subsequently desalted via C18 SephPack
columns (Waters). Peptides were eluted with 50% ACN and dried under vacuum. For a
first separation of phosphorylated and non-phosphorylated peptides, the dried peptide
powder was reconstituted in 1 ml SCX buffer A (5 mM K2HPO4, pH 2.7, 30% ACN) and
loaded onto a polysulphoethyl column (9.4 x 250 mm, PolyLC) using an ÄKTA Purifier
chromatography system equipped with a fraction collector. The peptides were separated
by a linear gradient to 25% SCX buffer B (buffer A supplemented with 500 mM KCl)
over 40 min at flow rate of 3 ml/min. Twenty fractions (12 ml each) were collected across
the gradient.
Prior to IMAC enrichment the solvent of the SCX-fractions was removed by lyophili-
sation. Dried peptides were reconstituted in 1 ml of 0.1% TFA and desalted by using C18
reversed phase cartridges (Waters). The bound peptides were eluted with 50% ACN, 0.5%
HOAc and the peptides were lyophilized again. Dried peptides were reconstituted in 40%
ACN, 25 mM formic acid and phosphopeptides were captured using PhosSelect (Sigma)
according to the manufacturer’s instructions. Eluted phosphopeptides were subjected to
mass spectrometric analysis.
4.2.5 LC-MS/MS Analysis
Mass spectrometric analysis was carried out by on-line nanoLC-MS/MS. The sample
was loaded directly by an Agilent 1200 nanoflow system (Agilent Technologies) on a 15
cm fused silica emitter (New Objective) packed in-house with reversed phase material
(Reprusil-Pur C18-AQ, 3 µm, Dr. Maisch GmbH) at a flow of 500 nl/min. The bound
peptides were eluted by a gradient from 2% to 40% of solvent B (80% ACN, 0.5% HOAc)
at a flow of 200 nl/min and sprayed directly into a LTQ-Orbitrap XL or LTQ-Orbitrap
Discovery mass spectrometer (Thermo Fischer Scientific) at a spray voltage of 2 kV ap-
plying a nanoelectrospray ion source (ProxeonBiosystems). The mass spectrometer was
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operated in the positive ion mode and a data dependent switch between MS and MS/MS
acquisition. To improve mass accuracy in the MS mode, the lock-mass option was en-
abled. Full scans were acquired in the orbitrap at a resolution R = 60,000 (Orbitrap XL)
or 30,000 (Orbitrap Discovery) and a target value of 1,000,000 ions. The five most intense
ions detected in the MS were selected for collision induced dissociation in the LTQ at a
target value of 5000. The resulting fragmentation spectra were also recorded in the linear
ion trap. To improve complete dissociation of phophopeptides, the multi-stage activation
option was enabled applying additional dissociation energy on potential neutral loss frag-
ments (precursor minus 98, 49 and 32.7 Thompson). Ions that were once selected for data
dependent acquisition were 90 sec dynamically excluded for further fragmentation.
4.2.6 MaxQuant analysis
The raw mass spectral data was processed using the MaxQuant software (version 1.1.1.25)
[27] applying the Andromeda search engine for peptide and protein identification. The hu-
man UNIPROT database (version: 57.12) was used comprising 110,595 database entries
including the UNIPROT splice variants database. The minimal peptide length was set to 6
amino acids, trypsin was selected as proteolytic enzyme and maximally 3 missed cleavage
sites were allowed. Carbamidomethylation of cysteines was selected as fixed modifica-
tion, whereas methionine oxidation, N-terminal protein acetylation and phosphorylation
of serine, threonine and tyrosine residues were considered as variable modifications. As
MaxQuant automatically extracts isotopic SILAC peptide triplets, the corresponding iso-
topic forms of lysine and arginine were automatically selected. The maximal mass devi-
ation of precursor and fragment masses was set to 20 ppm and 0.5 Da before internal
mass recalibration by MaxQuant. A false discovery rate (FDR) of 0.01 was selected for
proteins and peptides and a posterior error probability (PEP) below or equal to 0.1 for
each MS/MS spectrum was required. The MaxQuant results were uploaded to the MaxQB
database [95] for further analysis.
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4.2.7 Data pre-processing
Data from MaxQuant’s PhosphoSTY table were the data source for identifying a predic-
tive phospho-signature. Each entry in this table describes one specific phosphosite along
with information about its localisation, confidence and regulation. The regulation of a
phosphosite is provided as ratio of the site’s abundance between each cell line and the
super-SILAC standard. MaxQuant already provides normalized ratios, which were used
in this study. There are two coefficients that account for the reliability of identification
and localization of a phosphosite, i.e. Localization Probability and Score Diff. Sites that
satisfy the constraints Localization Probability ≥ 0.75 and Score Diff ≥ 5 were consid-
ered to be sufficiently reliable (class-I sites). Furthermore, sites that are flagged as Reverse
or Contaminant hits were also excluded. All phosphosites that fulfill both requirements
(class-I, no contaminant/reverse) were subjected to further analysis. The identification
and quantification data on the class-I sites, as well as the fragment spectra of the best
localization evidence are accessible in Additional Files 2-5 (Appendix C).
4.2.8 Analysis of differential phosphorylation sites
Significance analysis
After preprocessing the data, a Wilcoxon rank-sum test was applied to find differentially
abundant phosphorylation sites between sensitive and resistant cell lines. For this analysis
only phosphosites with values in at least two thirds of the experiments in each group were
considered (i.e. at least 8 of 11 sensitive and 6 of 8 resistant data points had to be present).
Subsequently, the p-values reported by the Wilcoxon rank-sum test were corrected for
multiple hypotheses testing by applying Benjamini-Hochberg FDR correction [43].
Enrichment analysis
To analyze whether proteins harboring differentially abundant phosphorylation sites are
enriched in certain GO terms [96] or KEGG pathways [49], FatiScan enrichment analysis
[97] was applied. In brief, FatiScan performs a segmentation test, which checks for asym-
metrical distribution of biological labels (e.g. GO terms, KEGG pathways) associated with
proteins in a ranked list. For this purpose, the phosphorylation sites were sorted according
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to their q-values and the algorithm was set-up to search for a possible enrichment in the
low-q-value area of this ranked list. The analysis was performed via the Babelomics web
interface (http://babelomics.bioinfo.cipf.es/, version 4.2).
Detection of significantly different subnetworks
In order to visualize and interpret the data in a network context, the SubExtractor al-
gorithm was applied [40] (see also Chapter 2. In brief, SubExtractor combines phospho-
proteomic data with protein-protein interaction data via a Bayesian probabilistic model.
Regulated subnetworks are found with a genetic algorithm and subsequent significance
evaluation based on the global rank test [53]. The STRING database version 8.3 [50] was
used as source for protein-protein interactions. It was preprocessed to contain only hu-
man interactions with a confidence score larger than 0.9 without considering text mining
evidences. The algorithm’s parameters were set to 𝛼 = 0.5 and 𝜎 = 5.0, and subnetworks
with an FDR smaller than 0.1 were reported.
To calculate z-scores required as input for the algorithm, pair-wise phosphorylation
abundance differences between sensitive and resistant cell lines had to be computed first.
Since the number of experiments in the two groups are not balanced (11 and 8, respec-
tively), sampling with replacement was applied to the smaller group (i.e. it was sampled
11 times from the 8 experiments ensuring that each experiment was chosen at least once).
Subsequently, the pair-wise differences could be computed along with the estimated global
standard deviation as suggested in [40]; and finally the z-scores were calculated.
4.2.9 Identification and evaluation of phospho-signature
Cross validation
The data set containing 𝑁 = 19 objects was split into two parts, one containing data of
one cell line, and the other containing the data of the remaining 𝑁 − 1 cell lines. The
larger part was then used for training a predictor (training set) and the smaller one for
testing this predictor (test set). By alternating the cell lines that made up the training
set, each cell line was used once for testing. Each of the N cross validation steps included
missing data imputation, feature selection, predictor training and predictor testing (see
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also Supplementary Figure C.3). A phosphosite was only considered as a potential feature
if it had training data values in at least two thirds of the experiments in each class (e.g.
if the training set contained data from 10 sensitive and 8 insensitive cell lines, at least 7
and 6 training data points had to be present, respectively). Since this criterion uses the
class-labels, the features have to be filtered within the cv-loop. This further means, that
the filtered features may be different in each cv-step.
Data imputation
For each phosphosite and class the mean and standard deviation was computed and
the missing values were filled by sampling from the resulting normal distribution. This
procedure was only applied to the training data, since the test data should be handled
as if the class association was unknown. Nevertheless, test data can also contain missing
values. If so, the mean of the corresponding two group means was imputed, which is an
unbiased way of replacing the missing value that does not involve information about the
test sample’s class association. Geometrically speaking, the imputed test sample value is
located exactly halfway between the two class means, which should minimize its influence
on the prediction process.
Feature selection
In this study, a simple Wilcoxon rank-sum test in combination with the ensemble feature
selection method [98] was used. Since the Wilcoxon test often delivers identical p-values
due to its rank-based nature, ties were broken by preferring features that have a larger
difference in their two classes’ medians. The core idea of the ensemble method is that
robust features should still rank among the best if the dataset is slightly modified. For
this purpose, different samplings of the training data were generated by drawing (with
replacement) 50 different bootstrap samples (i.e. if the training set consists of 10 sensitive
and 8 resistant cell lines, one randomly draws 10 and 8 times with replacement from the
respective set to get one bootstrap sample). The Wilcoxon rank-sum test is applied to each
sample, and thus a diverse set of feature rankings is generated. The ranks of each feature
were then averaged across all bootstrap runs and sorted in descending order according
to this meta-ranking. Subsequently, the k best features were used to train and test the
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predictor. By varying 𝑘 = 1 . . . 200 and assessing the prediction accuracy and area under
the receiver operator curve (AUROC), one can find the optimal number of features.
Support Vector Machine training
Once a set of features has been selected, and the training and test data have been modified
to include only those features (i.e. ’reduced’ sets), a SVM with linear kernel (see e.g.
[99]) can be trained. Besides the kernel function, an SVM has a parameter C, which
controls the trade-off between margin maximization and training error minimization, if
the hyper plane cannot perfectly separate the two classes. The default value of C=1
was used throughout the analysis. First, the SVM was trained with the training data.
Subsequently, the class association of the test data was predicted with the trained SVM.
The result of this prediction is the probability of the test sample belonging to either of
the two classes (the closer the test data is to the decision boundary, the less confident
the prediction is). The class prediction with the larger probability was then taken and
compared to the actual class association. In this way, correct predictions were counted
across all cross validation steps.
Area under the receiver operating characteristic curve
To calculate the area under the receiver operating characteristic curve (AUROC), the
separating hyper-plane of a trained SVM was shifted by introducing cost matrices. For
example, by shifting the hyperplane towards the group of sensitive training samples, it
becomes more likely for a test sample to be classified as resistant. Ultimately, this shifting
leads to the extreme that every test sample is classified as resistant, which means that
all resistant test samples have been classified correctly (true negative rate = 1 and false
positive rate = 0, given that the resistant ones are the negatives) and all sensitive test
samples wrongly (true positive rate = 0). The exact opposite is true if the separating
hyperplane is shifted towards the resistant group. Thus, by applying different cost values,
one can control the degree of shifting, calculate the respective true positive rates and false
positive rates, and compute the resulting area under the curve by means of the trapezoidal
rule (see Appendix C for an example).
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Random seeds
For the imputation of missing values, a random number generator is needed to sample
values from a normal distribution. Different seeds of the random generator will produce
different imputation data. To avoid a bias of the data towards the seeding, the entire cross
validation procedure was repeated five times using different random number generator
seeds. The prediction accuracies, AUROC values and global feature rankings for different
numbers of selected features (k) were averaged over the five CV runs and used for the
final selection of the phospho-signature.
Data Normalization
Among the fraction of non-phosphorylated peptides, 15 peptides had values in at least two
thirds of the experiments and a standard deviation < 0.1 (log10 scale). Eight of them were
from ribosomal proteins, which are expected to be constantly expressed. Thus, for each
experiment the median of the corresponding eight ratios was computed and used as an
alternative normalization approach (by subtracting the median from each phosphosite’s
non-MaxQuant-normalized logarithmic ratio).
Final predictor construction
When selecting the final set of phosphosites (phospho-signature) to be used for the pre-
diction of future samples, the optimal number of features was determined in a CV loop.
This is essentially the same as the inner loop in the quality assessment process (see also
Supplementary Figure C.4 ). Therefore, after running the cross validation process five
times with different random number generator seeds, we obtained the following results: A
200x5 prediction result matrix (200 being the rows, 5 the columns) containing the num-
ber of correct CV predictions for 𝑘 = 1 . . . 200 selected features (i.e. k best ranking in
each CV step) across the 5 random seeds; a 200x5 AUROC matrix containing the corre-
sponding area under the ROC curve values; and a 25,020x19x5 rank matrix holding the
rank of each feature in each CV step across the 5 random seed runs (features that were
not subjected to imputation/feature selection due to too many missing values received
the rank maxRank+1, where maxRank is the number of features that were subjected to
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imputation/feature selection).
The primary criterion for selecting the best subset of features was the number of
correct predictions. For this purpose the values in the prediction matrix and AUROC
matrix were row-averaged, leading to a vector of 200 average correct predictions and area
under the curve values. Within this vector the indices (numbers of features) that lead to
the best number of correct predictions were determined. Among those the one index that
had the highest AUROC value was selected as best performing feature number, which
was twelve. Next, the final feature rank was determined by averaging first over the third
and subsequently over the second dimension of the rank matrix. The resulting vector of
length 25,020 containing the average rank of each feature was sorted in ascending order
and the 12 top-ranked were selected. These were the phosphosites described in Table 4.2.
The twelve selected final features were then used to train the final predictor. However,
since these features also contained missing values, imputation had to be performed first.
The original sampling should reflect the variance within each feature and class, which
is crucial for the quality of a feature. Since the best features had already been selected
at this stage, sampling can influence the feature weights in the final predictor only. We
used the mean of each feature and class for replacing missing values in the dataset for
the final predictor. Alternatively, we could use the same sampling approach as above, and
then aggregate the resulting predictors by, for example, averaging the classification score.
The differences in these two alternatives are only marginal (Supplementary Figure C.9
). Finally, a SVM based on the predictive 12-site phospho-signature (again with linear
kernel and C=1) was trained and can now be applied to the classification of new samples.
4.2.10 Quantitative Western-Blot Analysis
For protein detection in human lung cancer cell lines, exponentially growing cells from 15
cm dishes were used. After cell lysis 80 µg of total protein was separated on 4−12% Bis-Tris
NuPAGE gels (Invitrogen) for the detection of integrin β4 or on 7.5% Tris-Glycine gels
(Biorad Mini PROTEAN) for the detection of tankyrase 1-binding protein (TNKS1BP1).
Proteins were transferred overnight to 0.2 µm nitrocellulose membranes and probed with
the appropriate antibodies in LI-COR Odyssey blocking buffer. All primary antibod-
65
4. NSCLC biomarker
ies were used in 1:1000 dilutions: anti-integrin β4 antibody [M126] (ab29042, Abcam);
anti-TNKS1BP1 (SAB4503414; Sigma Aldrich); anti-actin (I-19) (sc-1616-R, Santa Cruz
Biotech). Actin served as a loading control. Following primary antibody incubation, mem-
branes were probed with IRDye 800CW conjugated goat anti-mouse IgG (H+L9 (LI-COR
#926-32210), dilution 1:15000 for the detection of integrin β4; or IRDye 800 conjugated
affinity purified anti-rabbit IgG, (611-732-127; Rockland), dilution 1:20000, for the detec-
tion of TNKS1BP1 and actin; or DyLight 800 conjugated affinity purified anti-rabbit IgG
(H+L) (611-145-122; Rockland), dilution 1:50000 for the detection of actin. Signals were
detected at 800 nm using the LI-COR Odyssey infrared system.
4.3 Results and Discussion
4.3.1 Confirmation of dasatinib sensitivity
Based on the half-maximum growth inhibitory concentration (GI50) of dasatinib reported
previously [94], 13 sensitive and 13 resistant NSCLC cell lines were pre-selected. For these
26 cell lines we repeated viability assays to verify the reported GI50 values. We chose
the median GI50 as classification threshold, so that depending on the GI50 the cell lines
were assigned to sensitive (GI50 <1 µM) and resistant (GI50 >1 µM) classes. For 19 out
of 26 cell lines the assignment was consistent. For 7 cell lines the assignment based on
the sensitivity determined here differed from that reported previously [94]. By using only
the cell lines, for which the sensitivity could be reproduced in two different labs, we
maximize the reproducibility of the cell line assignment and therewith the robustness of
the predictive signature. The other cell lines were therefore excluded from the training set
(see Supplementary Table C.1 for GI50 values). The remaining 19 cell lines (11 sensitive
and 8 resistant) were used to identify a predictive phospho-signature. The peak dasatinib
plasma concentration (Cmax) obtained in a phase II trial in patients with advanced NSCLC
is 124± 59 ng/mL [92]. The corresponding molarity is below the classification threshold
chosen above. However, only the GI50 values of two cell lines, HCC4006 and H322M, are
marginally higher than the average peak plasma concentration.
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4.3.2 Identification of differentially phosphorylated proteins
To quantitatively compare the cell lines to be analyzed, we isotopically labelled sensitive
and resistant NSCLC cell lines using stable isotope labelling by amino acid in cell culture
(SILAC; [17]). The sensitive cell lines were grown in SILAC media supplemented with the
medium forms of arginine and lysine (Arg6/Lys4), whereas the resistant cell lines were
grown in heavy media (Arg10/Lys8, see Supplementary Table C.2 for experimental pair-
ing scheme). A Super-SILAC reference [100] was generated by mixing protein lysates of
16 randomly selected cell lines in unlabelled (light, Arg0/Lys0) media. The Super-SILAC
reference serves as a spike-in standard, enabling accurate cross-sample comparison (see
Supplementary Figure C.2 ). Equal protein amounts of the Super-SILAC reference, a
sensitive, and a resistant cell line were mixed and subsequently subjected to a global,
quantitative phosphoproteomics workflow using strong cation exchange chromatography
(SCX) and immobilised metal ion affinity chromatography (IMAC) followed by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) analysis (see Methods for de-
tails). In total, 37,747 phosphosites were identified in the 26 profiled cell lines. 88% of
all quantified phosphorylation sites had a cell line to Super-SILAC ratio <4-fold, which
allowed for accurate quantification of phosphorylation changes between the analyzed cell
lines. From the 37,747 identified phosphorylation sites, 25,020 were rated as class-I sites,
i.e. sites that could be identified with high localization confidence [63]. Only these sites
were used in the following analyses. The frequency distribution of the phosphorylated
residues (serine: 83.2%, threonine: 15.3%, tyrosine: 1.5%) is similar to the frequency dis-
tribution observed by Olsen et al. [63].
We first tried to identify proteins that are differentially phosphorylated between the
sensitive and resistant cell lines. To this end, the Wilcoxon rank sum-test was applied to
the set of phosphosites with data values in at least two thirds of the experiments (leading
to 4457 valid sites with approximately 11% missing values on average). Indeed, 58 phos-
phosites were significantly regulated between the group of 11 sensitive and 8 resistant cell
lines at a false discovery rate (FDR) of 10% (see Table 4.1). The regulated sites reside on
41 unique proteins. Most of the regulated sites (53 or 91%) are stronger phosphorylated
in sensitive cell lines. Only 5 (9%) sites are stronger phosphorylated in resistant cell lines.
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Table 4.1: Significantly different phosphorylation sites. Median diff: median difference
of log10 ratios between sensitive and resistant classes; q-value: FDR-corrected Wilxocon
rank-sum p-value.
Accession Gene Name Site Median diff q-value
A8K556 GPCR5A S345 0.872 0.047
Q6ZSZ5 ARHGEF18 S1101 0.419 0.047
Q13177 PAK2 S141 0.315 0.047
Q15149-2 PLEC1 S42 0.334 0.047
Q9C0C2 TNKS1BP1 S429 0.968 0.047
P16144-2 ITGB4 S1424 1.406 0.055
P16144-2 ITGB4 S1387 0.992 0.055
Q6ZSZ5 ARHGEF18 S1103 0.345 0.055
Q3KQU3 MAP7D1 S116 0.514 0.055
Q86SQ0 LL5B S212 0.721 0.055
Q8IVF2 AHNAK2 S2657 0.909 0.055
Q92614 KIAA0216 S1970 0.657 0.055
Q9Y2U5 MAP3K2 S153 0.494 0.055
P49792 RGP3 T799 -0.261 0.055
B2R5W6 MAPRE3 T164 0.447 0.055
B8QGS6 PKP2 S151 0.742 0.079
B4DIK2 NUP153 S338 -0.317 0.079
Q13177 PAK2 S2 0.234 0.079
O15231-3 ZNF185 S469 1.662 0.080
O43399-2 TPD52L2 S141 0.563 0.080
Q14573 ITPR3 S916 0.782 0.080
Q676U5 APG16L S269 0.725 0.080
Q86SQ0 LL5B S513 0.606 0.080
B8QGS6 PKP2 S154 0.688 0.082
P16144-2 ITGB4 S1445 1.473 0.082
P16144-2 ITGB4 S1448 1.544 0.082
P16144-2 ITGB4 S1069 1.236 0.082
A6NDI6 FNBP1L S490 0.239 0.082
68
4. NSCLC biomarker
Table 4.1: Significantly different phosphorylation sites (continued).
Accession Gene Name Site Median diff q-value
A8K1D2 LASP1 S146 0.366 0.082
A8K7M3 SEPT10 S451 1.015 0.082
A9UF02 BCR/ABL S459 0.270 0.082
B3KSZ4 GATAD2B S129 -0.181 0.082
D6W4Y8 ASAP2 S701 0.430 0.082
O60303 KIAA0556 S691 0.618 0.082
Q52LW3 ARHGAP29 S1019 1.340 0.082
Q8WUF5 IASPP S102 0.528 0.082
Q9UQB8-5 BAIAP2 S509 1.197 0.082
P16144-2 ITGB4 T1385 0.937 0.082
B8QGS6 PKP2 S155 0.854 0.083
O15231-3 ZNF185 S466 1.560 0.083
P23528 CFL S156 0.445 0.083
Q13439 GOLGA4 S78 0.468 0.083
Q8N4C8 MINK S699 0.486 0.083
Q14573 ITPR3 S934 0.788 0.086
Q9BY89 KIAA1671 S1800 0.422 0.086
B8QGS6 PKP2 S251 0.655 0.096
B2RBM8 ADNP S769 0.793 0.096
Q8NEY8 HSPC206 S133 -0.213 0.096
D3DXE9 BAZ1B S1468 -0.217 0.096
P28066 PSMA5 S16 0.430 0.096
Q53EP0 FAD104 S208 0.391 0.096
Q6ZRV2 FAM83H S870 1.049 0.096
Q6ZRV2 FAM83H S936 1.026 0.096
Q6ZRV2 FAM83H S785 0.795 0.096
Q86SQ0 LL5B S415 0.631 0.096
Q86YV5 SGK223 S696 0.716 0.096
Q8TDM6 DLG5 S264 0.518 0.096
Q3KQU3 MAP7D1 T118 0.396 0.096
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For three known dasatinib targets, Bcr-Abl, EphA2, and Lyn [11, 12], we could detect
phosphosites that were quantified in at least two thirds of the experiments. The phos-
phorylations of EphA2 and Lyn cannot differentiate between the sensitive and resistant
groups (see Supplementary Figure C.6). Only the site S459 on the breakpoint cluster
region protein (Bcr) is differentially phosphorylated (see Table 4.1 and Supplementary
Figure C.6).
We next investigated whether any KEGG pathway or Gene Ontology term is en-
riched in the set of proteins with differential phosphosites. The list of proteins ordered
by the Wilcoxon rank sum-test statistic of their most significant phosphosite were anal-
ysed with FatiScan [97]. Only the KEGG pathway ’Regulation of actin cytoskeleton’
(hsa04810) is significantly enriched at an FDR of 5%. Many of the significantly regu-
lated phosphosites are located on proteins involved in this pathway. A similar analysis
revealed that 40 terms of the biological process and the molecular function gene ontolo-
gies are significantly enriched (see Supplementary Table C.6). Many of them relate to very
generic and not surprising terms, like ’kinase activity’ (GO:0016301) or ’signal transduc-
tion’ (GO:0007165). However, a few of them are more specific, like ’Ras protein signal
transduction’ (GO:0007265) and ’Rho protein signal transduction’ (GO:0007266) in the
biological process ontology, and ’cytoskeletal protein binding’ (GO:0008092) and ’actin
binding’ (GO:0003779) in the molecular function ontology.
As a next step, we applied the SubExtractor algorithm [40] to the phosphoproteomic
data. SubExtractor detects significantly regulated sub-networks in the STRING protein-
protein interaction network [50]. The tool combines local as well as topological informa-
tion, i.e. information about the regulation of a certain node (represented by the protein’s
strongest regulated phosphorylation site) and information about the connectivity with its
neighbours. The largest sub-network that has been identified by SubExtractor (Figure
4.1) clustered around the EGF receptor, with most of the proteins again being stronger
phosphorylated in the sensitive cells. The largest subnetwork comprises many proteins in-
volved in cell-adhesion and actin cytoskeleton organization, such as ajuba (JUB), catenin
α1 (CTNNA1) and δ1 (CTNND1), ephrin type-A receptor 2 (EPHA2), brain-specific an-
giogenesis inhibitor 1-associated protein 2 (BAIAP2), integrin β4 (ITGB4), and plectin
(PLEC1).
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Figure 4.1: Protein-protein interaction subnetwork showing differential phosphorylation
in sensitive and resistant cells. The subnetworks were identified using the SubExtractor
algorithm. Only the largest network is shown. Red (blue) nodes are stronger (weaker)
phosphorylated in sensitive than in resistant cells.
4.3.3 Identification of a predictive phospho-signature
Following the general workflow for detecting phospho-signatures (Figure 4.2), a predictive
phospho-signature was identified and its accuracy was estimated by cross validation (CV)
based on the cell line dataset (19 valid cell lines). Feature selection was applied within
each CV loop to reduce dimensionality of the data and thus avoid overfitting the resulting
predictor. We used a Wilcoxon rank-sum test combined with the ensemble method [98]
for selecting the phosphosites used for the signatures. The number of phosphosites is opti-
mized in an inner leave-one-out cross-validation loop. The phosphosites were used to train
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Figure 4.2: The general workflow of phospho-biomarker classification. First, a predictive
phospho-signature is identified based on phospho-profiles of sensitive and resistant cell lines
using the cross validation approach (described in detail in the text). Once this signature
has been identified, it can be applied to new samples to predict the response of the donor
to the respective drug.
a support-vector machine (SVM) with linear kernel, which was chosen as the predictor,
since it offers state-of-the-art prediction quality and has been successfully applied several
times to biological data (e.g. see [29, 101, 102]). SVMs separate two classes by a hyper
plane, such that the margin between the classes becomes as wide as possible (e.g. [99]).
The final phospho-signature comprises twelve phosphosites (Table 4.2) located on nine
different proteins. The phosphorylation degrees of the twelve identified sites strongly sep-
arate the class of sensitive and resistant cell lines (Figure 4.3). All of them are stronger
phosphorylated in the sensitive cell lines. The five highest ranked phosphosites show ap-
proximately 10-fold differences in their medians. The differences between the 25th and
75th percentiles are still approximately 5-fold. Interestingly four of the highest ranked
phosphosites are located on the same protein, integrin β4 (ITGB4 or CD104). The sec-
ond highest ranked phosphosite is located on the brain-specific angiogenesis inhibitor
1-associated protein 2 (BAIAP2). Further we identified phosphosites that are located
on the G-protein coupled receptor family C group 5 member A (GPCRC5A), the inosi-
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Table 4.2: Phosphorylation sites of the final phospho-signature. Avg rank: the average
rank of the feature across all cross validation steps; Median diff: median difference of log10
ratios between sensitive and resistant classes; #Rank ≤ 12: the number of times the feature
was among the 12 best across all CV steps; SV weight: the importance of the feature in
the SVM predictor (the larger the absolute weight, the more important).
Accession Gene name Site Avg rank Median diff #Rank SV≤12 weight
P16144-2 ITGB4 S1448 2.716 1.544 18 -0.386
Q9UQB8-5 BAIAP2 S509 3.611 1.197 18 -0.311
P16144-2 ITGB4 S1387 4.337 0.992 19 -0.155
P16144-2 ITGB4 T1385 5.716 0.937 18 -0.275
P16144-2 ITGB4 S1069 7.937 1.236 13 -0.076
A8K556 GPCR5A S345 9.632 0.872 16 -0.174
Q14573 ITPR3 S916 14.168 0.782 8 -0.205
Q9C0C2 TNKS1BP1 S429 15.032 0.968 1 -0.159
Q6ZSZ5 ARHGEF18 S1101 16.874 0.419 0 -0.188
Q8WUF5 IASPP S102 17.516 0.528 7 -0.145
Q676U5 APG16L S269 18.190 0.725 13 -0.240
O43399-2 TPD52L2 S141 18.274 0.563 8 -0.155
tol 1,4,5-triphosphate receptor type 3 (ITPR3), the 192kDa tankyrase-1-binding protein
(TNKS1BP1), the Rho guanine nucleotide exchange factor 18 (ARHGEF8), the RelA-
associated inhibitor (IASPP), the autophagy-related protein 16-1 (APG16L), and the
tumor protein D54 (TPD52L2).
4.3.4 Sensitivity and specificity of the phospho-signature
To determine the prediction performance, leave-one-out cross validation (LOOCV) was
applied. It has been shown that CV, including LOOCV, estimates the true prediction
performance accurately and shows a low bias [103]. Since not all phosphosites discriminate
well between sensitive and resistant cell lines, feature selection is applied in each CV step,
which selects a defined subset of predictive phosphosites. First the features are ranked
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Figure 4.3: Final phospho-signature consisting of 12 phosphosites. Each pair of boxes
corresponds to one phosphosite. The blue (red) box represents the sensitive (resistant)
cell lines. On each box, the central mark is the median, the edges of the box are the 25th
and 75th percentiles, the whiskers extend to the most extreme data points not considered
outliers, and outliers are marked individually with crosses.
according to their discriminative power, and then the optimal number of top-ranking
features is determined by an inner parameter optimization cross validation. In this inner
CV procedure, different numbers of top-ranking features (𝑘 = 1 . . . 200) are used, and
their respective performance is assessed. The smallest number of features leading to the
best prediction quality in the inner CV loop is then applied to the feature selection in the
outer cross validation loop (see also Supplementary Figure C.3). Subsequently, a SVM
predictor is trained on the reduced training data (reduced in the sense of containing only
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features that passed the feature selection criteria) and tested with the reduced test data.
It is important to note that the test sample is used neither for optimising the number
of features nor for selecting the features within cross validation. Furthermore, the pre-
processing steps and classification workflow were fixed before acquiring the NSCLC data.
Otherwise, the prediction accuracy would be overestimated.
Missing data are a common phenomenon in shotgun proteomics. Although the quan-
titative information (i.e. SILAC peaks) of a peptide may be present in the MS spectrum,
at least one of the SILAC peaks has to be selected for fragmentation. In this case, the
resulting fragment spectrum is used to identify the corresponding peptide. Since the se-
lection of peptides for fragmentation is data-dependent, a certain peptide may be selected
in some MS runs but not in others. Therefore, a missing value does not necessarily mean
that the corresponding phospho-peptide was not present. This is particularly true when
applying the Super-SILAC approach like in this study.
Since many machine learning techniques (SVMs among them) cannot handle missing
values, they were replaced by estimated values that were randomly sampled from the
respective empirical distribution. As a consequence, the entire assessment was carried out
five times with different seeds for the random number generator used for imputation,
leading to five distinct prediction results. The five results were strikingly similar, as can
be expected from a robust set of features, i.e. four times only one cell line was misclassified
(HCC78), and once two were falsely classified (HCC78 and HCC827), which leads to a
prediction accuracy of 94% and an area under the receiver operating characteristic curve
(AUROC) of 0.92 (Figure 4.4A). Each circle in Figure 4.4A shows the averaged predicted
outcome of this cell line when all other cell lines were used as training data. A sensitive
cell line is predicted correctly if the SVM predictor assigns a negative value; vice versa for
a resistant cell line. The larger the distance to the separating hyperplane (i.e. the distance
from 0 in the plot), the more confident the prediction is. It can be clearly seen that 18 of
19 cell lines were predicted correctly by cross validation.
For the final predictor, the workflow was carried out with only one CV loop, cor-
responding to the inner loop during the prediction quality assessment (see Supplemen-
tary Figure C.4 ). This resulted in identifying a predictive phospho-signature contain-
ing 12 phosphosites. Interestingly, the average number of selected features within the
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Figure 4.4: Classification results represented by distance to the respective SVM’s sepa-
rating hyperplane. The cell lines in A, B and C are: 1 LouNH91, 2 H1648, 3 HCC827, 4
H322M, 5 H2030, 6 HCC2279, 7 HCC366, 8 HCC4006, 9 H1666, 10 PC9, 11 H2009, 12
H460, 13 Calu6, 14 H2077, 15 H1395, 16 H2172, 17 HCC78, 18 H157, 19 H520; in D: 1
BT-20, 2 MDA-MB-231, 3 HCC1937, 4 MDA-MB-468, 5 BT-549, 6 MCF7. Sensitive cell
lines (blue) are predicted correctly if they get a negative value; resistant ones (red) if they
are positive. (A) The results of the prediction quality assessment. (B) Prediction results
of the final predictor when applied to the same date as used for training (circles) along
with the results for the label switch experiments (crosses). (C) Prediction results of the
final predictor when applied to the same data as used for training (circles), along with the
results for the same data when normalized by the selected set of ribosomal proteins (dots).
(D) Prediction results of the final predictor when applied to the breast cancer samples.
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Figure 4.5: Heat map of the final 12 selected phosphorylation sites. Rows are the 19
cell lines that were used to identify the phospho-signature (the upper 11 are sensitive, the
lower 8 resistant), columns are the phosphosites ordered by their importance ranks (left
is the best). Red indicates up-, blue down-regulation, grey no regulation. Missing values
are coloured white.
inner parameter optimization loop during the prediction quality assessment was also ap-
proximately 12, which further supported the robustness of the selected set of phosphosites.
The sites are listed in Table 4.2) sorted by their global feature ranks, and depicted as a
heat map in Figure 4.5 (see also Supplementary Table C.3 for more details and Sup-
plementary Table C.4 for observed ratios). With an increasing number of features the
prediction accuracy also increased, until it saturated at 12 features (see Supplementary
Figure C.5). Additional features did not improve the prediction accuracy.
These results show that a predictive phospho-signature can be identified from phos-
phoproteomics data. However the question remains, whether the identified signature is
specific to dasatinib or whether it also works for other substances not related to dasa-
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tinib. As a first step to answer this question, we applied the prediction quality assessment
workflow to randomized class labels. Strikingly, the prediction accuracy was only 51%
(AUROC=0.53), which is almost exactly what one would expect if predicting the classes
by chance. Thus, a predictive signature cannot be found for arbitrary class associations.
As a next step, we investigated whether the classification scores of the final predictor
correlate with the cell doubling times of untreated cell lines. The classification score cor-
responds to the distance from the SVM classification hyperplane and can be interpreted as
the confidence in correct classification. In particular, the score is negative (positive) if the
sample is predicted as being sensitive (resistant). The cell doubling times range from 25
to 55 hours (confer Supplementary Table C.1). A Pearson correlation coefficient of -0.08
(p-value 0.79) indicates that the doubling times are not associated with the classification.
In contrast, the correlation between classification scores and GI50 values of dasatinib is
significant (0.81, 𝑝 = 2.6e-6 ). Finally, we sought to show whether the dasatinib signature
is predictive for other substances. The small molecule sorafenib (Nexavar®, Bayer) is a
multi-kinase inhibitor targeting the Raf/Mek/Erk and the VEGFR pathway. The corre-
lation between the doubling times and GI50 values of sorafenib [94] is -0.05 (p-value 0.83).
Taking these results together, we could demonstrate that the identified phospho-signature
is specific for predicting response to treatment with dasatinib.
4.3.5 Robustness of the phospho-signature
A good feature and consequently a good set of features should be robust to small varia-
tions in the data. Only when slight changes in the data composition still lead to correct
predictions, is the biomarker reliably applicable to samples not used for training. There-
fore, robustness already plays a crucial role in the process of feature selection. First, a
robust feature is chosen frequently by the feature selection method across all cross vali-
dation steps. Second, within each cross validation step, slight variations in the training
data should also result in the constant selection of robust features.
To identify such robust phosphosites, we applied the Wilcoxon rank-sum test in com-
bination with the ensemble feature selection method [98] to get a feature ranking in each
CV step. The average of these ranks across all CV iterations for the signature’s 12 fea-
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tures along with the number of times each of them was ranked under the first 12 positions
are listed in Table 4.2). The best features turned out to be very stable, e.g. the top four
have an average rank smaller than 6 and were among the 12 best more than 90% of all
iterations. The importance of these features is also indicated by their high weight in the
SVM. Overall, 7 features are among the 12 best in more than two thirds of the iterations,
and only 2 in less than one third.
To ensure that the SILAC labelling procedure of cell lines has no effect on the results,
label switch experiments were performed, where originally medium-labelled cell lines were
now labelled with heavy amino acids and vice versa. The classification results of the final
predictor applied to these experiments are depicted in Figure 4.4B. For two of the three
label switched samples, the prediction is virtually identical to the original data (circles
and crosses on position 11 and 14; Figure 4.4B). In the case of the position 4 (H322M), the
difference is somewhat larger, but the corresponding label switch experiment still classifies
it correctly.
Since phosphosites in this study are detected in a global and unbiased way, we applied
global normalization strategy during the discovery phase. However, when the phospho-
signature is applied in the clinic, a method that specifically measures the phosphosites
of the signature in a robust and cheap way is more likely to be used (see Appendix C
for how SVM predictor can be adapted to use data from other methods). Such targeted
methods could be either based on phospho-specific antibodies (e.g. immunohistochem-
istry or ELISA based assays) or targeted mass spectrometry methods such as multiple
reaction monitoring (MRM [104, 105]). Since a global normalisation strategy is not ap-
plicable to targeted methods, it is necessary to develop an alternative. We focused on
non-phosphorylated peptides that showed a very low variance across all cell lines’ reg-
ulation data regardless of whether the cell line was sensitive or resistant. Although the
phosphoproteomic workflow is designed to specifically enrich for phosphorylated peptides,
a significant fraction of non-phosphorylated peptides is still present. In this study, a nor-
malization factor based on a set of non-phosphorylated ribosomal proteins exhibiting low
variance across all cell lines proved useful (see Supplementary Table C.5 for normalization
data). The classification results of the ribosomal protein normalized data are depicted in
Figure 4.4C, which shows that the prediction quality is essentially as good as for the
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globally normalized data the predictor was trained on.
4.3.6 Signature validation in breast cancer cells
To test whether the phospho-signature is also applicable to other cancer types, we se-
lected 3 sensitive and 3 resistant breast cancer cell lines. Again, GI50 values were also
determined in-house and compared to the previously reported values [86]. This time, all
data were consistent (confer Supplementary Table C.1) and the 6 breast cancer cell lines
were subjected to our global phosphoproteomics workflow (see Supplementary Table C.4
for data).
Subsequently, the cell lines were classified with the SVM predictor trained on the set of
NCSLC cell lines. Strikingly, 5 of the 6 breast cancer cell lines could be classified correctly
(Figure 4.4D); only one resistant sample was wrongly predicted to be sensitive (MDA-
MB-468). These findings indicate that the proposed phospho-signature is also predictive
for dasatinib sensitivity in other cancer types.
4.3.7 Integrin β4 expression as a surrogate marker
Four of the highest ranked predictive phosphosites reside on the protein Integrin β4
(ITGB4, see Table 4.2)). Since we did enrich for phosphorylated peptides and did not
measure the abundance of the non-phosphorylated peptides or the total protein, it is
principally impossible to distinguish between differences in the phosphorylation degree and
differences in the expression of the corresponding protein. However, in case of ITGB4 it is
likely that the differences in the phosphorylation of the four sites are caused by differences
in the abundance of the protein itself. To prove that the expression of this protein is
indeed different in the two classes of the NSCLC cell lines, we performed quantitative
western blots using antibodies against the total protein of ITGB4 and 182 kDa tankyrase-
1-binding protein (TNKS1BP1). We selected TNKS1BP1 as one of the eight proteins, for
which only one phosphosite was identified as predictive feature. Whereas TNKS1BP1 is
present in almost all cell lines and its expression shows no correlation with the sensitivity
of the cell line to dasatinib, ITGB4 can be detected in 8 sensitive cell lines, but only
in 2 resistant cell lines (see Figure 4.6A). This is confirmed by quantitative analysis of
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three replicate experiments (see Figure 4.6B and 4.6C). The background-corrected signals
of ITGB4 correlate with the phosphorylation degree measured by mass spectrometry
(Pearson correlation 0.88, 𝑝 = 2e-6). The signals of most resistant cell lines are low,
while strong signals can be determined in the sensitive cell lines. This clearly shows
that expression of ITGB4 is also predictive and that it can be used as surrogate marker
instead of its phosphorylation. Indeed, if choosing the average of the median signals in
each group as classification threshold, all resistant and 8 sensitive cell lines would be
correctly classified, whereas 3 sensitive cell lines would be falsely classified as resistant.
Nevertheless, the prediction accuracy of ITGB4 expression (84%) is not as high as the
accuracy of the full phospho-signature (94%). In contrast, the signals for total TNKS1BP1
do not correlate with sensitivity, although its phosphorylation is predictive.
4.3.8 Expression of integrin β4 in lung and breast cancer tissues
We demonstrated that the signature consisting of 12 phosphorylation sites and the expres-
sion of ITGB4 is predictive in NSCLC and breast cancer cell lines. To explore, whether
ITGB4 is also expressed in cancer tissues, we examined immunohistochemistry images of
several cancer tissue slices. The Human Protein Atlas [106] systematically analyses the
human proteome in cell lines, normal tissues and cancer tissues using antibodies. In par-
ticular, it contains a number of immunohistochemistry images of cancer tissues stained
with an antibody (CAB005258) against total protein of ITGB4. Five lung cancer samples
(42%) are negative, whereas seven samples show weak to strong expression of ITGB4
(see Supplementary Figure C.7). Similarly, six breast cancer samples (50%) are negative,
whereas six samples show weak expression (see Supplementary Figure C.8). In summary,
we could show that the expression of ITGB4 can be used as surrogate marker for its
phosphorylation. The marker is measurable by immunohistochemistry in clinical tissue
samples and it is present in a sub-population of approximately 50% of the investigated
cancer tissues.
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Figure 4.6: Western blots of ITGB 4 and TNKS1BP1 in NSCLC cell lines. A: Western
blot images for one replicate. The sensitivity to dasatinib treatment is indicated by +/-.
B: Quantitative readout for ITGB4 in resistant (red) and sensitive (blue) cell lines. The
error bars represent the standard error across three replicates; the green line is the average
of the class medians. C: Quantitative readout for TNKS1BP1.
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4.4 Conclusion
This study shows that the identification of response prediction markers from global and
unbiased quantitative phosphoproteomics experiments in a preclinical setting is possible.
Detection of a few ten thousands of phosphorylation sites across a panel of cancer cell
lines is feasible. The use of a pool of cell lines as a common reference enabled the accurate
quantification of the detected sites. The accuracy and reproducibility of the phosphopro-
teomic workflow was demonstrated in label switch experiments. Measuring protein phos-
phorylation levels allowed us to monitor over-activation and repression of disease-specific
signalling pathways. Since kinase inhibitors, such as small molecules and monoclonal an-
tibodies interfere with signal transduction pathways, we hypothesised that determining
the basal activity of these pathways will allow predicting a response to therapy with such
an inhibitor.
We identified 58 phosphosites that are differentially abundant between sensitive and
resistant cell lines. Enrichment analysis of gene ontology terms and KEGG pathways as
well as subnetwork analysis show that many of the differentially phosphorylated proteins
are involved in cell adhesion and cytoskeleton organization, where most phosphorylations
are higher in the sensitive group. Interestingly, it has been shown that dasatinib inhibits
migration and invasion of various solid tumors through inhibition of the Src-kinase [107–
109], which is one of the main targets of dasatinib [11, 12]. We thus hypothesize that
cells, in which pathways related to cell adhesion and cytoskeleton organization are over-
activated, respond to a treatment with dasatinib. Src is a non-receptor tyrosine-protein
kinase. That none of the differentially phosphorylated residues is a tyrosine, does not
contradict the hypothesis, since we studied the basal phosphoproteome of untreated cells.
Proteins that are causal for resistance to Src-inhibition may be located down- or up-stream
of the direct Src-kinase substrates in the signalling cascades.
We showed that a phospho-signature consisting of only 12 phosphorylation sites it
sufficient to predict the response from the basal phosphoproteome of a cultured cell. The
predictor model was based on a support vector machine with linear kernel. We validated
the accuracy of the prediction in a leave-one-out cross-validation procedure. 18 out of 19
cell lines could be classified correctly. The obtained prediction accuracy was 94%, the area
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under the curve was 92%.
10-times up
10-times down
unregulated  
PLEC
ASPP2
GPRC5A
ASPP
ITGB4
ITGA6
TP53
IASPP
ARHGDIA
RHOA
ARHGEF18
ARHGEF12
ARHGAP1
ARHGEF11
BAIAP2
WAVE2
ITPR3 CDC42
Figure 4.7: Protein-protein interaction network that shows the relationship between six of
nine predictive signature proteins (marked with green border). The network was obtained
using STRING.
The 12 phosphorylation sites were located on 9 different proteins (see Table 4.2) and
Figure 4.7). Four of the phosphorylation sites are located on Integrin β4 (ITGB4 or
CD104). In general, integrins mediate cell-matrix or cell-cell adhesion and are involved in
transducing signals to regulate transcription and cell growth. The subunit β4 associates
with α6 and the resulting integrin α6β4 is a receptor for the laminin family of extracellular
matrix proteins. Integrin β4 is linked to various signalling pathways such as the MAPK,
PI3K-Akt, and Src-Fak pathways [110–112]. Furthermore, expression of α6β4 is associated
with poor patient prognosis in various cancers [113–115]. According to the PhosphoSite
database [116] the sites S1457 and S1518 were detected in previous mass spectrometry
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based proteomics experiments, but to our knowledge the functions for none of the four
sites have been described so far. All four sites are stronger phosphorylated in sensitive
cells than in resistant cells.
Besides the integrin β4 phosphorylations, the signature comprised eight additional
phospho sites on eight other proteins. Like integrin β4, the brain-specific angiogenesis in-
hibitor 1-associated protein 2 (BAIAP2) and the Rho guanine nucleotide exchange factor
18 (ARHGEF18) are involved in regulating the actin cytoskeleton. BAIAP2 (also called
insulin receptor substrate p53, IRSp53) serves as an adaptor link-ing a Ras-related protein
Rac1 with a Wiskott-Aldrich syndrome protein family member 2 (WAVE2). The recruit-
ment of WAVE2 induces Cdc42 and the formation of filopodia [117, 118]. ARGHEF18
acts a guanine nucleotide exchange factor for the GTPases RhoA and Rac1 [119, 120].
Activation of RhoA induces actin stress fibres and cell rounding.
The RelA-associated inhibitor (PPP1R13L, also called inhibitor of ASPP protein,
IASPP) and the G-protein coupled receptor family C group 5 member A (GPRC5A,
also called retinoic acid-induced protein 3, RAI3) are functionally connected to the tumor
suppressor p53. PPP1R13L binds to p53 and inhibits its activation by ASPP1 and ASPP2
[121]. On the other hand, p53 was demonstrated to bind to the promoter of GPRC5A and
thereby negatively regulates its expression [122].
The tumor suppressor p53 is associated with at least two signature proteins. At the
same time, p53 is inactivated by mutations in a large proportion of tumor cell lines.
We therefore investigated whether the p53-status alone is predictive of a response to
dasatinib. According to the IARC TP53 database [123], 6 out of 7 sensitive and 3 out of 5
non-sensitive cell lines have a mutation in the p53 protein (7 cell lines were not listed, see
also Supplementary Table C.1). Since the functional effect is not known for all mutations,
we assumed that any mutation, apart from neutral or silent mutations, is functionally
relevant. The null-hypothesis that sensitivity to treatment with dasatinib does not differ
between p53-mutated and p53-wildtype cell lines cannot be rejected (Fisher’s exact test
p-value is 0.52). Therefore, the mutation status of p53 is not a good predictor of dasatinib
sensitivity.
Although, based on the current literature, a direct link cannot be made between
the other four proteins inositol 1,4,5-triphosphate receptor type 3 (ITPR3), 182 kDa
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tankyrase-1-binding protein (TNKS1BP1), autophagy-related protein 16-1 (APG16L),
tumor protein D54 (TPD52L2), and the main dasatinib targets, the fact that their phos-
phorylation correlates with the treatment response supports their use in the predictive
model.
From the discussion above it is clear, that many of the signature proteins are related
to each other. Indeed, when mapping the nine proteins to the STRING protein-protein
interaction network [50], we revealed one network involving six signature and few addi-
tional proteins (Figure 4.7). Phosphorylation sites for most of the proteins in this network
are less abundant in the resistant cell lines than in the sensitive cell lines.
The difference in phosphorylation of a specific site between two cell lines may be
due to a difference in either expression of the corresponding protein, or the degree of
phosphorylation of this site, or a combination of both. Since we did not investigate the
protein expression, we cannot distinguish between the three possibilities. However, as long
as the abundance of a certain phosphorylated peptide consistently differs between sensitive
and resistant cell lines, the cause for its difference is not important for its use as a predictive
biomarker. In case of ITGB4, we could indeed show that its protein expression is also
predictive. Contrary, the protein expression of TNKS1BP1 does not differentiate between
sensitive and resistant cell lines. The study also showed that the predictor identified from
a panel of NSCLC-cell lines can be used in other cancer cell lines. 5 out of 6 breast cancer
cell lines were correctly predicted (prediction accuracy 83%). Only one resistant cell line
(MDA-MB-468) was predicted to be sensitive.
A few markers for dasatinib have been suggested in the literature or are already applied
in the clinic. For example, Huang et al. [86] identified a predictive six-gene model from
gene expression profiles. Obviously, the phosphorylation grade may be largely independent
of the mRNA expression level. Nevertheless, we investigated whether the phosphorylation
sites on the corresponding proteins are also predictive. We detected phosphorylation sites
on five of the six proteins: EPHA2, CAV1, CAV2, ANXA1, and PTRF. Although, the
phosphorylation tends to be high in sensitive cell lines and low in resistant cell lines,
the relationship is not as sound as for the markers identified in this study. All sites
are not significantly different between the two classes. As an example, Supplementary
Figure C.6 shows three sites on the Ephrin type-A receptor (EPHA2). Additionally the
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tyrosin phosphorylations p-Src(Y418), p-BCR-ABL(Y412), p-Crkl(Y207), p-Pax(Y31),
p-Fak(Y576) have been described as pharmacodynamic markers for dasatinib in mouse
experiments and in clinical trials [124–126]. These markers are modulated after treatment
with dasatinib and their basal levels do not necessarily differentiate between sensitive and
resistant subjects. Nevertheless, we were interested in their behaviour across the untreated
cell lines. We could detect the phosphorylation site Y418 of Src in five cell lines, but could
not identify any relationship to the sensitivity of these cell lines. The site ABL(Y412) on
the fusion protein BCR-ABL was not detected. However, a different site BCR(S459) was
detected in almost all cell lines and is significantly modulated between the sensitive and
resistant group (see Table 4.1 and Supplementary Figure C.6).
We demonstrated our method for the identification of a predictive phospho-signature
in a set of NSCLC and breast cancer cell lines. The application to cultured cells has
a number of advantages: the cell population is very homogenous; sample amounts from
cell lines are not limited; experiments are easily reproducible; and the drug’s efficacy
can be experimentally determined. However, whether the signature or parts of the sig-
nature are also predictive in clinical samples has to be shown in future studies with
clinical samples. Instead of applying shotgun phosphoproteomics, it is possible to apply
targeted detection methods, such as immunological methods, or the mass-spectrometry-
based multiple-reaction-monitoring method [127]. These methods allow the quantification
of marker phosphosites of relatively low sample amounts and can be applied to large num-
ber of samples. Since fresh-frozen tissues are rare, the translation of our results to the
clinic requires the analysis of formalin-fixed and paraffin-embedded (FFPE) tissues. It has
been assumed, that the cross-linking of proteins prevents a proteomic analysis. Recently,
it could be shown that proteins can be effectively extracted from FFPE samples and that
the proteins and phosphorylations are quantitatively preserved compared to fresh-frozen
tissues [128–130].
As an alternative, we demonstrated that the expression of ITGB4 can be used as surro-
gate marker for its phosphorylation. The marker is measurable by immunohistochemistry
in clinical tissue samples and it is present in a sub-population of approximately 50% of
the investigated cancer tissues.
In this study, the phosphorylation data were globally normalized, assuming that the
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overall phosphoproteome is fairly well conserved between the different cell lines. However,
this strategy is no longer applicable to targeted detection of the selected phosphosites,
since all measured phosphosites will be regulated. We proposed an alternative normaliza-
tion strategy using the expression of eight non-regulated ribosomal proteins. It could be
demonstrated that the prediction of sensitivity using the phospho-signature is stable for
the application of the alternative normalization strategy.
In summary, the identified phospho-signature consisting of twelve phosphorylation
sites is highly predictive for the sensitivity to treatment with dasatinib in NSCLC cell lines
as well as breast cancer cell lines. The results suggest that the phosphorylations of integrin
β4 as well as eight further proteins are candidate biomarkers for predicting response in
solid tumors to dasatinib and potentially to other Src family kinase inhibitors. That many
of the signature proteins have related function and are connected in a protein-protein
interaction network, further supports the generalizability of the predictive signature.
In this study we proposed a general method for identifying response prediction biomark-
ers based on a phosphorylation signature. The method is hypothesis-free insofar as the
investigated phosphorylation sites do not have to be preselected, and no assumptions
about the mechanism of action of the therapeutic drug have to be made. The basis of the
method is the global quantitative phosphoproteomic analysis of baseline samples. While
we demonstrated that the method permits identifying a highly predictive phosphorylation
signature for response to dasatinib treatment in NSCLC cell lines, it can be assumed that
the method can also be applied to other drugs, particularly other kinase inhibitors, and
to other tumor types.
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Chapter 5
Pareto biomarker
In this chapter, the biomarker workflow presented in Chapter 4 is extended to optimize not
only one single objective (i.e. best possible separation of responder and non-responder),
but also the objectives signature size and relevance (i.e. association of signature proteins
with dasatinib’s main target). This is achieved by employing a multiobjective optimization
algorithm based on the principle of Pareto optimality, which allows for an optimization
of all three objectives in parallel.
The content of this chapter was submitted for publication as:
M. Klammer, J.N. Dybowski, D. Hoffmann, and C. Schaab. “Pareto Optimization Iden-
tifies Diverse Set of Phosphorylation Signatures Predicting Response to Treatment with
Dasatinib”. In: PLoS one 10.6 (2015), e0128542
The author was a key contributor to designing and implementing the algorithm, as
well as writing the paper.
5.1 Background
Targeted drugs, such as kinase inhibitors, are extensively studied as promising agents
either alone or in combination with other agents for treating cancer. Unfortunately, only
subsets of patients usually respond to targeted therapeutic interventions. Tests that can
predict whether patients will benefit from these therapies are therefore desired companions
of targeted drugs. Many, if not all response prediction tests currently used in clinical
practice are based on markers directly linked to the disease-relevant drug target. However,
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singleton markers measuring the expression or mutation status of a drug target may often
not be sufficient to predict response. For example, it has recently been shown that the
success of predicting how melanomas respond to targeted therapies by genotyping alone
may be limited [132].
Therefore, several studies have focussed on identifying molecular signatures comprising
multiple markers for response prediction. Predominantely, these signatures were identified
using transcriptomics data (for example [86, 87]). In recent years, advances in sample pro-
cessing, mass spectrometry, and computer algorithms for the analyses of proteomics data
have enabled the application of mass spectrometry-based proteomics in order to monitor
phosphorylation events in a global and unbiased manner [15, 32, 63]. These methods have
become sufficiently sensitive and robust to identify and quantify thousands of phospho-
rylation sites in a single experiment. Multivariate markers based on the phosphorylation
status of certain sets of proteins – here referred to as phospho-signature – can predict the
clinical response, as they link therapy outcome to the most predictive phosphorylation
events in the context of signal transduction therapy. This has been demonstrated in two
recent studies, where phosphoproteomics data was used to identify predictive multivariate
markers for the multi-kinase inhibitor dasatinib [65] and the FLT3 inhibitor quizartinib
[133].
Previous studies have focused on the identification of one single multivariate marker
signature that was optimized for prediction accuracy. Here, we investigate a method that
allows for the incorporation of additional objectives that are optimized simultaneously, and
enables the identification of several predictive markers. Such objectives can, for instance,
be related to the annotations of protein markers (e.g. localization, function), to technical
properties (e.g. size of the signature), or to network information (e.g. proximity of markers
to drug target). It has been shown recently that the inclusion of annotated biological
information, but not the method category (e.g. support vector machine, random forest,
etc.) or handling of missing data, significantly improved prediction accuracy in a study
analyzing 44 drug sensitivity prediction algorithms [134]. More specifically, it has also been
demonstrated that adding network information can improve prediction accuracy or at least
improve the robustness of feature selection (e.g. [135]). These methods have in common
that the network information is factored in by modifying the objective function (e.g.
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network-based support vector machines [136]) or the rank order for filter-based feature
selection (e.g. NetRank [137, 138]). However, instead of optimizing a combined objective
function, we choose to optimize multiple objectives in parallel using principles of multi-
objective or, specifically, Pareto optimization [139]. Multi-objective optimization methods
return a set of optima, the so-called Pareto front, instead of a single optimum solution.
In case of selection of predictive biomarkers, these solutions differ in their composition of
selected features and in the degree to which different objectives are optimized. If necessary
to limit the number of marker candidates, the researcher can apply post hoc weighting of
objectives.
In biomedical research, Pareto optimization has been mainly applied to design of small
molecules [140] and peptide sequences [141]. More recently however, it has also been
applied to selection of features. For example, Rajapakse and Mundra optimized features
for multi-class classification by decomposing the over-all objective to multiple objectives
for each pair of classes [142]. Xue et al. complemented the objective of classification
accuracy with minimizing the size of the signature [143]. In this study, we generalize
the idea of applying Pareto optimization to the problem of selecting predictive marker
signatures by optimizing not only the prediction accuracy and the size of the signature,
but also the biological relevance of the selected features. Here, the biological relevance
is defined by the proximity of features to the respective drug target as derived from
protein-protein interaction networks. In principle, all obtained solutions on the Pareto
front can be evaluated and tested in validation experiments. However, since in practice the
Pareto front consists of several dozens of solutions, we propose to cluster these solutions
in feature space and investigate a much smaller number of cluster centroids. We apply
the proposed method to the identification of multivariate phosphorylation signatures that
predict response to dasatinib in non-small cell lung cancer and breast cancer cell lines
using the phosphoproteomic data generated by Klammer et al. [65].
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5.2 Methods
5.2.1 Data
The training data comprising the class-I phoshorylation site ratios of 19 NSCLC cell lines
relative to a SuperSILAC spike-in were obtained from Supplemental Table 3 of Klammer
et al. [65]. The validation data for 6 breast cancer cell lines were taken from Supplemental
Table 4 of the same source. Detailed information about the generation of both datasets
is provided in the main article of Klammer et al. [65]. In brief, the dataset contains more
than 25,000 class-I phosphorylation sites (i.e. sites with high localization confidence),
contaminant and reverse database hits were removed, and the normalized ratios (cell line
versus SuperSILAC) were log10-transformed.
5.2.2 Pareto objective functions
Three objectives were considered: signature size, separation and relevance.
Signature size: This objective score is defined by the number of phosphosites in a given
signature. The score is to be minimized.
Separation: This objective focuses on the generalization of the marker. Not only should
a good marker separate the training data, but also unseen data. Thus, an inner leave-
one-out cross validation was performed by employing a support vector machine with
linear kernel and cost parameter 𝐶 = 1. For each test sample, its distance of to the
SVM hyperplane was computed and the posterior class probability was calculated from a
sigmoid model 𝑝𝑖 = 11+exp(𝐴𝑓𝑖+𝐵) , where 𝑝𝑖 is the probability of the sample being resistant
and 𝑓𝑖 the SVM output of the respective training data [144]. Parameter 𝐴 was determined
by optimizing a regularized maximum likelihood problem (see [144] for details); parameter
𝐵 was fixed to 0, so that points on the separating hyperplane are assigned a probability
of 0.5. The separation objective corresponds to minimization of the negative minimal
probability distance −min𝑖(𝑐𝑖(12 − 𝑝𝑖) + 12), where 𝑐𝑖 is the actual class of the cell line
(sensitive = 1, resistant = −1).
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Relevance: This objective deals with the relevance of a signature with respect to the
drug target. Here, the mean distance of the signature’s proteins to the target of the inves-
tigated drug in a protein-protein interaction network (STRING) was calculated. To this
end, we calculated an adjacency matrix using all interactions with a interaction confi-
dence larger than 0.9 (STRING version 9.05 [145]). The remaining edges with interaction
confidence scores 𝑠 ranging from 0.9 to 0.999 were transformed into a penalty score using
the equation 𝜌𝑖 = 1−log10(1−𝑠𝑖) , ranging from 0.33 to 1. The function was chosen to get
more pronounced differences between higher and lower confidence scores. Subsequently,
the shortest path between each protein in the signature and the drug target based on the
penalties 𝜌 was calculated with the Dijkstra algorithm [146] and the mean distance of all
signature proteins was used as objective score.
5.2.3 Pareto optimization
For the detection of the Pareto front, we applied the NSGA-II algorithm. NSGA-II is
a fast, elitist multi-objective genetic algorithm [39] that employs the principle of Pareto
optimality. In brief, the algorithm works as follows: First, a random parent population
𝑃0 was generated that consists of 𝑁 = 200 chromosomes. The representation of the
chromosome is binary, i.e. a feature that is part of the signature is represented by 1, a
feature that is not part of the signature by 0. The chromosomes were randomly initialized
with 10% of features set to 1. Next, a fitness value was assigned to each chromosome,
which represents the Pareto front the individual was located on. A fitness value of 1
stands for a solution on the first Pareto front, 2 for a solution on the second Parteo front,
and so forth.
Subsequently, 5-way-tournament selection, single-point crossover (𝑝 = 0.8) and bit
flip mutation (𝑝 = 0.02) were performed to generate the first offspring generation 𝑄0
(𝑁 = 200). To compile the next parent generation 𝑃1, the individuals of 𝑃0 and 𝑄0 were
combined and the individuals were sorted according to non-domination (Pareto front
1 . . . 𝐹 ) and within each front according to the crowding distance (favors individuals that
have a large distance to their neighbors, see [39] for details). Finally, the top N individuals
were chosen to become 𝑃1, which ensured elitism.
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This procedure was repeated for 𝐺 generations, where 𝐺 is a number determined at
runtime, at which the solutions on the first Pareto front do not change for 200 generations
in feature space.
5.2.4 Biomarker discovery workflow
In order to detect multiple signatures based on the 19 NSCLC samples, the phospho-
rylation sites were first pre-filtered for missing data, i.e. only class-I sites with at least
2/3 of ratios present in each group (responder and non-responder) were considered for
further analyses. Next, the 100 sites that discriminated best between responders and
non-responders according to the MeanRank [61] test were selected, while ensuring that
the mean difference of the features between the two groups was at least 4-fold and only
one phosphosite per protein was included. This pre-selection is necessary to reduce the
complexity of the subsequent Pareto optimization. The 100 top-ranking features were
subjected to the NSGA-II algorithm, which aims at detecting Pareto-optimal solutions
based on the three objective functions (size, separation, relevance).
After convergence, the results were filtered for solutions that were located on the first
Pareto front. Since many of them were very similar and only differ in very few features,
hierarchical clustering with Ward’s method was applied on the binary solution vectors
to detect clusters of similar features. Subsequently, the solutions that had the smallest
Euclidean distance to the cluster centroids were taken as final Pareto signatures. If more
than one solution had the smallest distance, the one with the better separation score was
preferred.
5.2.5 Biomarker validation
For each Pareto signature, a support vector machine with linear kernel and cost parameter
𝐶 = 1 was trained. These SVMs are the final predictors and can be used to predict new
samples. To validate the signatures, we used phosphorylation site data of the six breast
cancer samples. Prior to prediction, missing values were imputed by the mean of the
training data class means (for details see [65]). Subsequently, the responsiveness of the six
samples was predicted with each of the final predictors.
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5.3 Results and Discussion
The main goal of response prediction biomarker studies is the identification of molecular
signatures that separate the group of responders from the group of non-responders well
and thus enable an accurate prediction of drug response. However, there are further qual-
ities that characterize a successful biomarker. For example, a marker should consist of a
manageable number of features (i.e. genes or proteins) in order to allow testing through
methods applied in clinical routine such as quantitative PCR or ELISA. Furthermore, the
features should be biologically relevant, for instance, by being connected to the drug’s
target or mechanism of action. In the proposed Pareto biomarker workflow, these three
objectives - separation, signature size and relevance - are optimized in parallel (for defi-
nitions of objectives see section Pareto objective functions in Materials and Methods).
Generation (50 bins) 
Figure 5.1: Evolution of the number of individuals (solutions) on the Pareto front and
for the three objectives (separation, size and relevance), as generated by the NSGA-II
algorithm [39]. The objectives are averaged across the solutions on the Pareto front. The
number of generations is binned and the average of each bin is displayed on the y-axis.
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5.3.1 Pareto biomarker workflow
To this end, a multiobjective optimization algorithm (MOA) was incorporated into our
established biomarker discovery workflow [65], allowing the simultaneous optimization of
all three objectives. Most MOAs employ the principle of Pareto optimality, which aims at
detecting solutions that are not dominated by other solutions. At any given iteration, non-
dominated solutions are defined such that there exist no other solutions that have a better
or equal score in all objectives and a strictly better score in at least one objective. All
non-dominated solutions (Pareto points) together form the Pareto front (see also Figure
D.1), which is optimized during each iteration. Of the many MOA algorithms available
(e.g. PAES [147], PESA [148], SPEA2 [149], NSGA-II [39] or SMS-EMOA [150]), we found
the NSGA-II algorithm [39] most suitable for our Pareto biomarker workflow, as it shows
fast convergence, is efficient and well tested [151, 152].
In a previous study, we used quantitative mass-spectrometry to globally profile the
basal phosphoproteome of a panel of 19 non-small cell lung cancer (NSCLC) cell lines
[65]. The effect of the kinase inhibitor dasatinb on cellular growth was tested against the
same panel. Using the phosphoproteome data, we identified a phosphorylation signature
consisting of 12 phosphorylation sites on 9 different proteins (referred to as original sig-
nature). The signature accurately predicted response to treatment with dasatinib in the
NSCLC cell lines used for training and in an independent validation panel of breast cancer
cell lines.
Here, we investigated whether the Pareto biomarker workflow could confirm the orig-
inal signature and/or identify additional multivariate predictive phosphorylation signa-
tures when applied to the same data set. In particular, these signatures should not only
maximize class separation, but also the two additional objectives signature size and rel-
evance. We hypothesize that a marker protein is more relevant if it is closely related to
the drug target (e.g. through interaction). Although this might not always be the case,
we think that this is a good assumption on average. Since this is only one out of three
objectives to be optimized, signatures that are not connected to the drug’s target may
still be identified and are not discarded. More specifically, we define the relevance score
of a signature as the average distance of the signature’s proteins to dasatinib’s main tar-
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get in solid tumors, the Src kinase (SRC), as it has been shown that dasatinib inhibits
migration and invasion of various solid tumors through inhibition of SRC [107–109]. All
three scores are defined such that smaller values are better. Thus, all three objectives are
to be minimized (see Materials and Methods for details).
From the 4,457 phosphorylation sites quantified in at least 2/3 of the samples in
each class (responders and non-responders), we selected the 100 sites that discriminated
best between responders and non-responders according to the MeanRank test [61], while
ensuring that the mean difference between the two groups was at least 4-fold and only
one phosphosite per protein was taken. This pre-selection was performed to reduce the
complexity of the subsequent Pareto optimization. The algorithm terminated after 1353
generations, at which point the results on the first Pareto front had not changed for 200
generations (Figure 5.1). While the number of solutions on the Pareto front constantly
increased, the three objectives (i.e. separation, size and relevance) were minimized with
respect to Pareto optimality. As can be deduced from the graphs of the three objectives,
the size and relevance criteria are rather easy to optimize, as they exhibit a steep decline
at the beginning of the optimization process and reach the global minimum early on.
Optimization of the separation criterion took longer and its decrease in the later stages
was accompanied with an increase of the size objective, while the relevance criterion
remained stable. In essence, small signatures that have a short distance to the drug target
in the STRING protein-protein interaction (PPI) are readily discovered. It is, however,
harder to find those that additionally separate the groups well and, essentially, good
separation comes at the cost of larger signatures.
After termination, 77 solutions were located on the Pareto front. Solutions with a
separation score ≥ −0.6 were removed (𝑁 = 24), as the Pareto approach also found very
small and biologically relevant solutions with poor separation. This is an inherent feature
of Pareto optimization, and removing undesired solutions is common practice (see e.g.
[153]). The remaining 53 solutions contained 35 different phosphorylation sites. One site,
S1148 on integrin β4 (ITGB4), was part of all but three solutions.
Figure 5.2A shows a series of three-dimensional plots of the Pareto front. The front
has the shape of a stretched canvas attracted by the origin, which represents an ideal but
infeasible point. Figure 5.2B depicts 2D projections of the 53 Pareto front solutions in
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Figure 5.2: 3D plots of the Pareto front (A) and 2D projections (B). (A) The different
panels are views of the Pareto front when rotated around the relevance-axis (with two
different viewing angles in each column). Coloring indicates relevance score, from blue
(low) to red (high). Since better solutions are smaller in all three dimensions, the optimal
point is the origin in the lower background, i.e. the only hidden vertex in the plots. (B)
2D projections of the solutions on the Pareto front. Solutions are colored according to
their assignment to four clusters. Stars mark the solutions closest to the respective cluster
centroid that were selected as final Pareto signatures.
objective space. The top panel, relating size and separation, shows that smaller signatures
lead to less pronounced separation and illustrates our initial motivation for identifying
multivariate markers. Therefore, the lower left corner in the plot, where ideal solutions
for the two respective objectives are expected, is not populated. However, there are also
no large signatures in the area of the best-separating solutions (< −0.68). This is due
to the third objective, the relevance criterion, as it becomes harder to identify features
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Figure 5.3: Hierarchical clustering of the 53 accepted solutions on the Pareto front in
feature space. In each row, red areas represent features (phosphosites) that are part of the
corresponding solution. The solutions were subdivided into four clusters according to the
row dendogram on the left. Cluster numbers are indicated on the right.
that all interact directly or indirectly with the target. As mentioned before, the task
of finding small and biologically relevant solutions is achieved more easily, as can be
seen in the center panel of Figure 5.2B. Solutions are found in the lower left area, but
not in the lower right. The bottom panel of Figure 5.2B depicts the relationship between
separation and relevance. This projection of the Pareto front has a curved shape, revealing
the compromise between good separation and biologically meaningful features, as not all
well-discriminating phosphosites are also related to the drug target.
5.3.2 Pareto signatures
Each of the identified solutions on the Pareto front is optimal in the sense that none of
them are dominated by any other solution. Therefore, each solution could be evaluated
individually. Here we took another approach and investigated whether solutions can be
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reduced by clustering according to their similarity while retaining discriminatory power.
To this end, we hierarchically clustered the solution in features space using the Ward
method and obtained four major clusters (see Figure 5.3). For each of these clusters, the
feature with the smallest Euclidean distance to the respective cluster centroid was selected
as so-called Pareto signature for further analysis (see Figure 5.2B).
In order to compare the original 12-phosphosite signature with the Pareto signatures,
we calculated its objective values: 𝑠𝑖𝑧𝑒 = 12, separation = −0.60, relevance = 1.63
(see also Table 5.1). Note, that the original signature was optimized with respect to
prediction accuracy only, and the feature selection method did not explicitly optimize
the separation criterion as defined here (see Materials and Methods). Figure 5.4A shows
the PPI network of the original marker, where solid lines indicate the shortest path from
each signature phosphoprotein (blue) to SRC (red), which is dasatinib’s main target in
solid tumors. The phosphorylation sites of the signature are listed in Table 5.2. Some
of the signature proteins ITGB4, ARHGEF18 and BAIAP2 are closely related to SRC,
while others (e.g. ATG16L1 and TNK1SBP1) have larger distances in the PPI network.
TPD52L2 and GPRC5A have no connection to SRC at all. In the original publication
[65], the selected features were used to train a support vector machine (SVM) with linear
kernel. The signature and the corresponding predictor were then validated by application
to six independent breast cancer cell lines, which had not been used for feature selection or
SVM training. In the case of the original signature, five out of six cell lines were predicted
correctly with an average probability distance to the hyperplane of 0.13 (calculated as
1
𝑁
∑︀𝑁
𝑖=1(0.5−𝑝𝑖)𝑐𝑖, where 𝑁 is the number of tested cell lines, 𝑝𝑖 the prediction probability
for the cell line to be resistant, and 𝑐𝑖 the actual class of the cell line (sensitive = 1,
resistant = −1)).
The first Pareto signature (Pareto1, Figure 5.4B) contains only three phosphopro-
teins - ITGB4 (integrin β4) S1448, EGFR (epidermal growth factor receptor) S1064 and
KIAA0556 (uncharacterized protein KIAA0556) S691 – for details see Table 5.2. While
the separation and size objective scores are better than those of the original signature
(see Table 5.1), the relevance score is slightly worse, which is due to the uncharacterized
protein KIAA0556 that lacks functional annotation and therefore has no connection with
SRC. The prediction accuracy on the validation set is comparable to that of the original
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Figure 5.4: Network of the original (A) and the four Pareto signatures (B-E) are shown in
the left column along with the prediction results for the breast cancer validation set (right
column). Blue nodes in the network are signature proteins, solid lines represent the shortest
path to SRC, dashed lines indicate additional high-confidence interactions. Sensitive (1–3)
and resistant (4–6) breast cancer cell lines were considered to be predicted correctly if
they received a probability (y-axis) of less than 0.5 and more than 0.5, respectively.
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signature, however, the average probability distance to the SVM hyperplane is slightly
higher and thus better. Phosphorylation site S1448 on ITGB4 is one of the best separators
in the data set and is also part of the original signature. ITGB4 is linked to the Src-Fak
pathway [112] and is associated with poor patient prognosis [113–115]. The EGF receptor
can be phosphorylated by the Src kinase [154], and is therefore directly linked to SRC in
the protein-protein interaction network (STRING confidence score of 0.999).
The signature Pareto2 (Figure 5.4C), contains the same phosphosites on ITGB4 and
EGFR, and additionally TANK (TRAF family member-associated NF-kappa-B activator)
S225, TIAM1 (T-lymphoma invasion and metastasis-inducing protein 1) S231 and JUP
(Junction plakoglobin) S665 – see also Table 5.2. This signature has a particularly good
relevance score (cf. Table 5.1), which is also visible in the PPI network, where 4 out
of 5 proteins are closely connected to SRC. The performance on the validation data is
comparable to that of Pareto1.
The third Pareto signature (Pareto3, Figure 5.4D) is another small signature contain-
ing sites S1448 on ITGB4, S20 on PLEC1 (Plectin) and S429 on TNKS1BP1 (182 kDa
tankyrase-1-binding protein). S429 on TNKS1BP1 is also part of the original signature,
together with S1448 on ITGB4. TNKS1BP1 has a rather large distance to SRC, leading to
a mediocre relevance score. The other scores are identical to those of Pareto1, the second
3-phosphosite signature (cf. Table 5.1).
Finally, the largest Pareto signature (Pareto4, Figure 5.4E), contains ITGB4 S1448,
TNK1SBP1 S429, TJP2 (Tight junction protein ZO-2) S174, CGN (Cingulin) S137,
SEPT9 (Septin-9) S30, TIAM1 S231 and ITPR3 (Inositol 1,4,5-trisphosphate receptor
type 3) S934. Again, the sites on ITGB4 and TNKS1BP1 are those that are part of the
original signature. ITPR3 appears in the original signature with a different phopshosite
(S916).
Taken together, Pareto markers are consistently smaller than the original marker, while
three of four also have better separation and relevance scores. The prediction accuracy
on the validation set is identical for all investigated signatures, however, the average
probability distance to the separating SVM hyperplane is slightly higher for the Pareto
signatures, suggesting that the Pareto signatures are more robust when being applied to
other classes of related tumor cell lines.
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Table 5.1: Objective scores (smaller are better), prediction accuracy and average proba-
bility distance for the validation data (larger are better).
Signature Size Separation Relevance Validation Validation
accuracy distance
Original 12 -0.60 1.63 5/6 0.13
Pareto1 3 -0.65 1.88 5/6 0.19
Pareto2 5 -0.63 0.72 5/6 0.22
Pareto3 3 -0.65 1.55 5/6 0.19
Pareto4 7 -0.67 1.26 5/6 0.15
5.4 Conclusion
We and others have previously shown that the identification of response prediction mark-
ers from phosphoproteomics experiments in pre-clinical or clinical settings is possible [65,
93, 133]. These studies sought to identify single signatures of phosphorylation sites max-
imizing the separation on the data used for training. Here, we investigated the idea of
integrating additional objectives, such as the relevance with respect to the drug target or
the size of a signature, into the feature selection process. We applied the multi-objective
genetic algorithm NSGA-II [39] to the identification of Pareto-optimal solutions for the
prediction of response of NSCLC cell lines to treatment with dasatinib. Beside separabil-
ity, we used the proximity of markers to the main drug target – the Src kinase – and the
size of the signature as objectives for optimization.
In total, the algorithm identifies 77 Pareto-optimal solutions, i.e. solutions that are
not dominated by any other solution. Each solution corresponds to a phosphorylation
signature that can be used for response prediction. 53 of them had a sufficiently good
separation score and were considered in the following analysis. Clustering of these solutions
in feature-space revealed four groups of solutions with similar sets of phosphorylation sites.
We used the solution closest to the centroid of each cluster as representatives of the four
Pareto signatures. All four signatures predicted the response of six breast cancer cell lines
that were not used for training with good accuracy (83%). The same accuracy was also
reached by the original 12-marker signature identified in Klammer et al. [65].
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Table 5.2: Phosphorylation sites of the final signatures. Sites/proteins in bold are part
of the original signature [65].
Signature Accession Gene name Site
Original
P16144-2 ITGB4 S1448
Q9UQB8-5 BAIAP2 S509
P16144-2 TGB4 S1387
P16144-2 TGB4 T1385
P16144-2 TGB4 S1069
A8K556 GPCR5A S345
Q14573 ITPR3 S916
Q9C0C2 TNKS1BP1 S429
Q6ZSZ5 ARHGEF18 S1101
Q8WUF5 PPP1R13L S102
Q676U5 APG16L S269
O43399-2 TPD52L2 S141
Pareto1
P16144-2 ITGB4 S1448
A9CB80 EGFR S1064
O60303 KIAA0556 S691
Pareto2
B2R7S3 TANK S225
P16144-2 ITGB4 S1448
A9CB80 EGFR S1064
Q13009 TIAM1 S231
P14923 JUP S665
Pareto3
P16144-2 ITGB4 S1448
Q15149-4 PLEC1 S20
Q9C0C2 TNKS1BP1 S429
Pareto4
P16144-2 ITGB4 S1448
Q9C0C2 TNKS1BP1 S429
Q9UDY2 TJP2 S174
B9EK46 CGN S137
Q9UHD8 SEPT9 S30
Q13009 TIAM1 S231
Q14573 ITPR3 S934
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The phosphorylation site S1448 on ITGB4 (Uniprot accession: P16144-2; or, equiva-
lently, S1518 in the canonical sequence P16144-1) is the central feature in all four Pareto
signatures. This is in accordance with the results from Klammer et al. [65], where the
same site was ranked first in the robust feature selection approach. Furthermore, ITGB4
is closely linked to dasatinib’s main target SRC via the adapter protein GRB2. Thus, the
Pareto marker approach is consistent with the outstanding role of ITGB4 in predicting
dasatinib response in cancer cells.
The four Pareto signatures are characterized by properties that correspond to the
objectives used for optimization. Signature 1 and 3 are relatively small with only three
phosphorylation sites each. On the other hand, signature 4 is larger (7 sites), but has
the best separation. Finally, signature 2 shows the best relevance score, meaning that its
marker proteins are interacting with the drug target SRC either directly or through inter-
mediate proteins. Surprisingly, while its separation on the training data is the smallest of
all four signatures, it yields the highest separation on the breast cancer cell lines that were
used for validation. This hints at the importance of incorporating network information in
general and the relationship to the drug target in particular for the selection of predictive
features.
Here, we optimized the selected features with respect to the objectives separation,
size, and relevance. Naturally, the proposed method can be applied to other objectives.
For example, it may be sensible to include the detectability of marker phosphorylations
in immunoassays, the localization of the marker proteins (e.g. cell membrane, nucleus,
or cytosol), or the extend of knowledge about the proteins (e.g. number of PubMed ab-
stracts).
Aside from the possibility of incorporating multiple objectives into the selection of the
biomarker signatures, an even more important advantage of the approach presented here
is the identification of several independent signatures instead of only one. These signatures
can be evaluated post-hoc using additional criteria before a final signature or a set of a
few signatures is selected for further validation experiments.
In summary, we presented a general method for identifying a set of biomarker signa-
tures from high-dimensional data such as proteomics, phosphoproteomics, or transcrip-
tomics data. Besides optimizing the separation between two classes, the method allows
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the consideration of additional objectives. In particular, we showed that the relation of the
marker proteins to the drug target in a protein-protein interaction network can improve
the robustness of the prediction when applied to new samples.
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Conclusions and Outlook
In this thesis, four new methods for analyzing mass spectrometry-based phosphopro-
teomic data were presented. The first two methods (SubExtractor and MeanRank test)
were designed to help uncovering a drug’s mode of action, but are also applicable to target
identification or biomarker discovery projects. The SubExtractor algorithm (Chapter 2)
aims at discovering significantly regulated subnetworks from protein-protein interaction
databases by employing a Bayesian probabilistic model in combination with a genetic
algorithm and stringent significance evaluation. SubExtractor has been part of Evotec
Munich’s phosphoproteome analysis platform from the beginning, and has aided the inter-
pretation of numerous mode-of-action studies (e.g. [33], [14]) as well as biomarker projects
(e.g. [65], Chapter 4). Since the first development and publication of the algorithm, some
enhancements and modifications have been made. The hypothesis test to determine the
significance of the resulting subnetworks was changed from the global rank test [53] to the
MeanRank test, as the latter shows superior performance under virtually all conditions
(confer Chapter 3). Furthermore, the inclusion of the MeanRank test now allows for a
comparison between two groups (2-sample test), which is useful when a SuperSILAC or
label-free approach is used for quantification of phosphosite abundances.The repertoire of
interaction databases has been expanded from the protein-protein interaction database
STRING to more specific kinase-substrate interaction databases like PhosphoSitePlus
[116], PhosphELM [155] and NetPhos [156].
The MeanRank test (Chapter 3) focuses on detecting significantly regulated feature
from noisy and sparse high-throughput data with only few replicates. Its big advantages
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are the rank-based nature that does not require any a priori distribution assumptions, its
tolerance regarding missing values, and its high statistical power that scales well with the
number of available replicates. The test is especially valuable when only few replicates
are available and the fraction of truly regulated features is around or below 10%, which is
usually the case, when samples are treated with a kinase inhibitor. In such scenarios, the
MeanRank test outperforms well-established methods such as SAM and LIMMA. The
test has been incorporated into the standard proteome and phosphoproteome analysis
workflow at Evotec Munich, where it is now routinely applied to analyze customer projects
as well as research projects (e.g. [21]).
The latter two chapters of this thesis (NSCLC biomarker and Pareto biomarker) aim
at finding multivariate phosphorylation signatures for predicting the response of non-
small cell lung cancer (NSCLC) cell lines to the kinase inhibitor dasatinib. The earlier
method described in Chapter 4 (NSCLC biomarker) was the first published global and
unbiased approach to develop a biomarker based on the differences in the basal phos-
phorylation levels of cancer cell lines. The presented algorithm employs a robust feature
selection method in combination with support vector machine (SVM) classification in or-
der to identify a predictive set of phosphorylation sites. Applying the fully cross-validated
workflow led to a correct prediction of 18 out of 19 samples. The final signature consists
of 12 phosphorylation sites, and was able to correctly predict dasatinib sensitivity of 5
out of 6 samples from an independent breast cancer validation set. In a later study, a
similar workflow was applied to uncover a phosphorylation signature for predicting the
response of acute myeloid leukemia (AML) patient samples to the FLT3 inhibitor quizar-
tinib (AC220) [133]. Here, 11 out of 12 bone marrow samples could be correctly predicted
in the cross-validation procedure. By applying the final signature of 5 phosphorylation
sites to an independent validation set, 7 out of 9 predictions were correct.
The biomarker workflow described in Chapter 4 focuses on the identification of a sig-
nature that separates the two groups (responders and non-responders) well. While this
was the only objective in this study, the Pareto marker workflow presented in Chapter 5
adds additional objectives to the feature selection process, i.e. feature relevance and sig-
nature size. To this end, the multiobjective Pareto optimization algorithm NSGA-II was
incorporated into the biomarker workflow, resulting in a set of four Pareto signatures after
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filtering and clustering of the Pareto-optimal solutions. All of these four signatures were
smaller than the original signature reported in Chapter 4 (ranging from 3 to 7; originally
12) and three of them were on average closer related to the main target of dasatinib, the
SRC kinase. At the same time, the prediction performances of all Pareto signatures on
the validation set were as good before, and the key protein of the original signature –
integrin beta 4 (ITGB4) – was also present in all of them.
Concluding, the novel methods described in this thesis help to better understand the
processes underlying drug treatment and support the development of response prediction
biomarkers in the field of large-scale omics in general and phosphoproteomics in particular.
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A.1 Introduction to Genetic Algorithms (GAs)
GAs mimic the process of biological evolution. The primary component of the GA is the
individual, which contains exactly one chromosome and one fitness value. A chromosome
in GA language is a vector of values (in the simplest way in binary form) representing one
distinct solution for the optimization problem. The fitness value determines the quality
of the corresponding solution encoded by the chromosome. Depending on the underlying
fitness function it is desirable to either maximize or minimize the fitness value.
A typical GA has at least tens or hundreds of different individuals with different
chromosomes. As the algorithm evolves, individuals are selected according to their fitness
value and bred using crossover and mutation operators to create new offspring and thus
new solutions to the problem. Subsequently, some weak individuals (i.e. individuals with
low fitness value) from the parental generation are replaced by strong offspring individuals
and the process starts over again. According to the building block hypothesis, small areas
with superior fitness on different chromosomes are thus iteratively combined into longer
ones, leading to a steady increase in fitness (not necessarily for each individual but at the
level of the entire population). Random mutations reduce the risk of getting trapped in a
local optimum. The general workflow for a GA is depicted in Supplementary Figure A.1.
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Figure A.1: Schematic GA workflow. First, the individuals’ chromosomes are initialized.
Then, their fitnesses are evaluated and parents for the first reproduction are selected.
Subsequently, variation, i.e. recombination of the parents’ chromosomes and mutation,
takes place. This is followed by the fitness evaluation of the newly created individuals
and subsequent survival selection. In this step low-performing individuals of the parental
generation are replaced by high-performing offspring. Steps 3 to 6 are repeated until a
certain termination condition (e.g. number of generations or satisfying solution) is fulfilled.
A.2 Lower bound for parameter 𝛼
As described in the Artificial data subsection of the main article, a too small value for 𝛼 will
lead to incorporation of unregulated nodes if their only connection is to a well-regulated
one. To avoid this, the 𝛼 value should be chosen such that an unregulated node with only
one well-regulated neighbour always gets a higher score when it is flagged as inactive, i.e.
not part of an differentially regulated subnetwork. More formally, this requirement can
be expressed based on Equation 2.8 in the main article with the equation
ln (𝒩 (0|0, 1)) + ln (𝛼 + 0) > ln (︀𝒩 (0|0, 𝜎2𝑧))︀+ ln (𝛼 + 1). (A.1)
Solving for 𝛼 leads to
𝛼 > 𝛼𝑐 =
1
𝒩 (0|0,1)
𝒩 (0|0,𝜎2𝑧) − 1
, (A.2)
or equivalently
𝛼𝑐 =
𝒩 (0|0, 𝜎2𝑧)
𝒩 (0|0, 1)−𝒩 (0|0, 𝜎2𝑧)
. (A.3)
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Equation A.3 is then used to calculate the lower bound of reasonable values for 𝛼. Some
examples for varying 𝜎𝑧 values are:
𝜎𝑧 = 3: 𝛼𝑐 = 0.5
𝜎𝑧 = 5: 𝛼𝑐 = 0.25
𝜎𝑧 = 10: 𝛼𝑐 = 0.11
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A.3 Supplementary Figures
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Figure A.2: Different distributions and their fit to the sorafenib data. Normal-mixed is a
mixture model of two normal distributions; t-mixed is a mixture of a normal and t location
scale distribution.
A.4 Additional Files
Additional Files 2-5 can be found at:
http://www.biomedcentral.com/1471-2105/11/351/additional
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B.1 Pseudocode of one-sample MeanRank algorithm
Algorithm B.1 Calculation of 𝛼0, the expected number of false discoveries.
𝑀 = matrix holding features and replicates
𝑟𝑠𝑜𝑟𝑡𝑒𝑑 = vector of sorted mean ranks
𝛼0𝑠𝑢𝑚 = vector of length 𝑁
for all 𝑠 ∈ Cartesian product {−1,+1}𝑅 without{(−1, . . . ,−1), (+1, . . . ,+1)} do
𝑀𝑓𝑙𝑖𝑝𝑝𝑒𝑑 = multiply values in columns (𝑖 = 1, . . . , 𝑅) of 𝑀 with values of 𝑠𝑖
𝑟 = mean ranks of𝑀𝑓𝑙𝑖𝑝𝑝𝑒𝑑
for 𝑖 = 1, . . . , 𝑁 do
𝛼0𝑠𝑢𝑚(𝑖)+ = count 𝑟𝑓𝑙𝑖𝑝𝑝𝑒𝑑 < 𝑟𝑖,𝑠𝑜𝑟𝑡𝑒𝑑
end for
end for
𝛼0 = 𝛼0𝑠𝑢𝑚 / number of flips
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B.2 Two-sample Mean Rank test
The two-sample version of the proposed test is similar to the one-sample case, with only
a few modifications. For the two-sample case, the two input matrices, 𝑀1 and 𝑀2, hold
the data from two different groups, e.g. treated and untreated. Both must have the same
number of features 𝑁 , but the number of replicates may be different (𝑅1 and 𝑅2, respec-
tively). As the aim of two-sample tests is to find differentially regulated features between
two groups, we create a difference matrix prior to step 1. in Equation 3.1 in the main ar-
ticle. This difference matrix contains all possible 𝑅1 ·𝑅2 pair-wise differences between the
two data matrices. Note, that often values should be log-transformed to achieve a sym-
metric distribution of differences. The ranks are then calculated on the difference matrix
and steps 2. and 3. of Equation 3.1 are performed using this 𝑅1 · 𝑅2 matrix of difference
ranks.
The Bates distribution cannot be used for the parametric estimation of 𝛼0, as the𝑅1·𝑅2
columns of the difference rank matrix are not independent. Thus, the null distribution
has to be determined numerically. This is done by generating two random data matrices
(sampled from a standard normal distribution) with 𝑅1 and 𝑅2 columns, respectively,
and very large 𝑁 (≥ 100, 000). The difference rank matrix is then calculated as described
above, and the empirical distribution of the resulting mean rank values is determined,
which can then be used instead of FBates function to estimate 𝛼0.
The non-parametric estimation of 𝛼0 has to be modified for the two-sample test, as
well. Instead of performing sign flipping to estimate false positives, we now randomize the
group association and calculate 𝛼0 accordingly.
Additional simulations were carried out to assess the performance of the two-sample
MeanRank, and compare it to the two-sample versions of SAM, LIMMA, RankProducts
and the 𝑡-test. A two-sample version of GlobalRank does not exist. In line with the
results of the previous one-sample simulations, MeanRank and SAM performed better
than RankProducts and the 𝑡-test. In simulations with normally distributed data and no
missing values MeanRank and SAM showed comparable power and met the FDR level;
however, both were outperformed by LIMMA (see Supplementary Figure B.1A-C). In
the case of simulation data sampled from a non-normal (Student’s-𝑡) distribution, the
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Figure B.1: Performance of two-sample tests on simulated data. Performance plot of two-
sample significance tests under different simulation settings. Traces show the true positive
rate (TPR) of the respective tests for a given number of replicates. Bars denote the false
discovery rate (FDR). TPR and FDR are averaged over ten independent simulations. All
tests were set to control the FDR at 0.05.
TPR of the parametric MeanRank test drops below the non-parametric version, as the
parametric FDR estimation involves the assumption of normal distributions. Both MRs
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performed better than RankProducts and the 𝑡-test, but worse than SAM and LIMMA.
The introduction of missing values also led to a drop in power for MeanRank. This can
be explained by the way the difference-rank matrix is calculated. Since each subtraction
involving a missing value again produces a missing value, the proportion of missings in
the difference-rank matrix is larger than in the initial data matrices 𝑀1 and 𝑀2.
B.3 Supplementary Figures
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Figure B.2: Performance on simulated data using imputation. Performance plot of tests
for one-sample simulation data with missing data imputed by k-nearest-neighbor (k-NN)
with 𝑘 = 10.
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Figure B.3: Performance for different fractions of regulated and unregulated features.
Performance with fixed number of replicates (𝑅 = 6), over a varying fraction of regulated
features to background features.
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Figure B.4: Volcano plot highlighting spike-in concentrations. Volcano plot of the ’Ag-
Spike’ data, colored by fold-change of spike-in.
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B.4 Supplementary Tables
R replicates
R=5 R=30
N features Parametric Non-parametric Parametric Non-parametric
𝑁 = 1.000 < 1s / < 1MB < 1s / < 1MB 3s / < 1MB 2s / < 1MB
𝑁 = 10.000 8s / < 1MB 20s / 1MB 45s / 2MB 184s / 18MB
Table B.1: Computational performance of the MeanRank test. Computation time and
memory usage shown in seconds and megabytes, respectively. Measurements were per-
formed on a single core of an Intel i5 2400, with 3.1 GHz.
B.5 Additional Files
Additional Files 2-3 can be found at:
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0104504
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C.1 Cost matrix example
The example in Figure C.1A shows how the introduction of cost matrices influences the
support vector classification. The figure shows a classification example that aims at sepa-
rating red stars from blue crosses. Each class contains 10 samples with two features. The
values of both features were sampled from normal distributions (N(1,1) and N(-1,1) for
crosses and stars, respectively). The black line represents the separating hyperplane of
the SVM classification with linear kernel (parameter C=1), when no explicit cost matrix
is applied (i.e. the cost of misclassifying a star is the same as the cost for misclassifying
a cross). One can clearly see that the data is not linearly separable, which leads to one
misclassified cross and one misclassified star. The red line shows the hyperplane when the
cost for the false classification of stars is twice as high as the cost for star misclassification.
As a result, the separating hyperplane is shifted towards the cloud of red stars, but the
classification result is still the same. By increasing the cost factor of cross misclassification
to ten times the cost of star misclassification, the hyperplane (blue line) is shifted further
and all crosses are classified correctly. However, instead of one falsely predicted star there
are now four. Finally, when using a cost factor of 200 (see purple line), all samples would
be classified as crosses leading to ten wrongly predicted stars.
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This shifting of the hyperplane can be used to calculate the receiver operating charac-
teristic (ROC) curve and the area under it. A ROC curve based on the four different cost
matrices above would look like Figure C.1B (assuming that the crosses are the positives
and the stars the negatives in the ROC statistics). The point at (1.0|1.0) corresponds to
the purple hyperplane, where all crosses are classified correctly and all stars wrongly; the
point at (0.4|1.0) to the blue discrimination line, where all crosses are classified correctly
and 4 stars are falsely predicted as positives; the point at (0.1|0.9) to both the red and
black hyperplane, where 9 crosses are classified correctly and one star wrongly as positive;
and finally one more point at (0|0) that is not depicted in Figure C.1A but represents the
extreme when all samples are assumed to be negatives (stars), which can be considered
the opposite of the purple discrimination line. Finally, the area under the curve can be
computed, which is 0.93 in this example.
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Figure C.1: Classification example using a linear SVM with different cost matrices (A),
and the corresponding ROC curve (B).
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C.2 Details on SVM prediction
The decision function of the SVM classification is given by
𝑓(?⃗?) = sgn
(︃
𝑚∑︁
𝑖=1
𝑦𝑖𝛼𝑖𝑘 (𝑥𝑖, ?⃗?) + 𝑏
)︃
, (C.1)
where 𝑚 is the number of training samples (cell lines), 𝑦𝑖 the class label of the 𝑖th train-
ing sample (-1 or 1 for sensitive and resistant cell lines, respectively), 𝛼𝑖 the respective
Lagrange multiplier, ?⃗?𝑖 a vector of length 𝑓 (𝑓 being the number of selected features)
holding the ratios of the 𝑖th training sample, ?⃗? a vector of length 𝑓 holding the ratios of
the test sample, and 𝑏 the bias (i.e. the translation of the hyperplane with respect to the
origin). 𝑘(?⃗?𝑖, ?⃗?) is called a kernel, i.e. a function that characterizes the similarity of two
vectors. Equation C.1 can be rewritten as
𝑓(?⃗?) = sgn
(︁
𝑘 (?⃗?, ?⃗?) + 𝑏
)︁
, (C.2)
with the weight vector ?⃗?, whose elements represent the importance (influence) of the
corresponding features, defined as ?⃗? =
∑︀𝑚
𝑖=1 𝛼𝑖𝑦𝑖?⃗?𝑖. In the case of the linear SVM, the
kernel function is defined as the dot product of the two vectors, which leads to the linear
decision function
𝑓(?⃗?) = sgn
(︃
𝑓∑︁
𝑗=1
𝑤𝑗𝑥𝑗 + 𝑏
)︃
. (C.3)
So far, changes in the phosphorylation level were represented by ratios, which can be
expressed as 𝑥 = 𝑆 − 𝑆ref , where 𝑆 is the signal of the phosphosite in the corresponding
cell line and 𝑆ref the signal of the site in the reference cell line pool. Here, the signal is
defined as log intensity of the corresponding phosphosite. For data produced by other
methods such as multiple reaction monitoring or ELISA, where the quantitative data
are represented by intensities, one can still make predictions with the proposed phospho-
signature, but the decision function (Equation C.2) has to be modified to
𝑓(?⃗?) = sgn
(︁
𝑘
(︀
?⃗?, ?⃗?
)︀
+ 𝑏− 𝑘(︀?⃗?, ?⃗?ref )︀⏟  ⏞  
?˜?
)︁
. (C.4)
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Note, that only the bias term has to be modified while the weight vector ?⃗? stays the same.
In geometrical terms, the orientation of the hyperplane does not change, but is translated
to the new position. In the case of the linear SVM the decision function thus changes to
𝑓(?⃗?) = sgn
(︃
𝑓∑︁
𝑗=1
𝑤𝑗𝑆𝑗 + ?˜?
)︃
. (C.5)
C.3 Supplementary Figures
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Figure C.2: SILAC labelling diagram. The scheme illustrates how isotopic labelling en-
ables relative quantification of phosphorylation amounts via a spike-in reference (Super-
SILAC).
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Figure C.3: Workflow diagram for prediction quality assessment, where two cross valida-
tion loops are applied. In the inner CV loop the optimal number of features is determined.
This number is then used in the feature selection process in the outer CV loop. Subse-
quently, an SVM is trained and tested with the respective data sets. The prediction results
in each outer CV loop are combined and the prediction accuracy is calculated.
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Figure C.4: Workflow diagram for finding the final phospho-signature. The workflow
corresponds to one inner CV loop in Figure C.3 resulting in the optimal set of features,
which is then used to train the final SVM predictor.
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Figure C.5: The prediction accuracy depending on the number of top-ranked features
incorporated into the phospho-signature. While the accuracy increased with the first few
features, it reached its maximum at 12 features (circle), where it saturated.
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Figure C.6: Bar charts of log10 ratios(cell line/Super-SILAC) of phosphorylation sites
on tyrosine kinases quantified in at least two thirds of experiments.
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Figure C.7: Immunohistochemical staining of ITGB4 in lung cancer tissue from the
Human Protein Atlas. A red border indicates heavy staining, orange moderate, yellow
weak and grey no staining.
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Figure C.8: Immunohistochemical staining of ITGB4 in breast cancer tissue from the
Human Protein Atlas. A yellow border indicates weak and grey no staining.
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Figure C.9: Effect of the imputation method for the final predictor when applied to the
breast cancer samples. Purple dots indicate the classification results with the predictor
trained on the mean-imputed NSCLC data, the box plots show the results for the impu-
tation based on 100 samplings from the respective normal distribution of each feature and
class.
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C.4 Supplementary Tables
Table C.1: Cell line information
GI50(µM) GI50(µM) GI50(µM)
Supplier dasatinib dasatinib TP53 Doubling sorafenib
Cell line Indication Origin number literature1 this paper Class Valid2 status3 time (h) 4literature
Calu6 NSCLC ATCC HTB-56 22.54 2.8 - YES MUT 25 30
H1395 NSCLC ATCC CRL-5868 31.12 4.7 - YES WT 50 7.24
H1568 NSCLC ATCC CRL-5876 0.8975 5.44 + no – 59 6.46
H157 NSCLC MPI5 – 10.54 2.63 - YES MUT 25 6.61
H1648 NSCLC ATCC CRL-5882 0.0593 0.079 + YES MUT 50 6.03
H1666 NSCLC ATCC CRL-5885 0.175 0.076 + YES WT 30 30
H2009 NSCLC ATCC CRL-5911 0.7465 0.085 + YES MUT 50 11.09
H2030 NSCLC ATCC CRL-5914 0.1183 0.022 + YES MUT 25 7.76
H2077 NSCLC MPI – 10.07 4.75 - YES – 50 5.37
H2172 NSCLC ATCC CRL-5930 16.71 5.85 - YES – 50 –
H2887 NSCLC MPI – 11.3 0.176 - no – 40 13.65
H322 NSCLC MPI – 0.2588 2.1 + no MUT – 5.43
H460 NSCLC ATCC HTB-177 24.16 3.9 - YES WT 25 30
HCC827 NSCLC ATCC CRL-2868 0.1456 0.033 + YES – 43 5.25
H520 NSCLC ATCC HTB-182 11.56 1.43 - YES MUT 42 4.84
H647 NSCLC ATCC CRL-5834 12.39 0.016 - no MUT – 12.45
HCC1359 NSCLC MPI – 11.3 0.52 - no MUT 30 11.89
LCLC103H NSCLC DSMZ ACC 384 13.9 0.08 - no MUT – 9.66
LouNH91 NSCLC DSMZ ACC 393 0.113 0.068 + YES – 55 4.68
HCC366 NSCLC DSMZ ACC 492 0.482 0.017 + YES – 53 6.03
HCC4006 NSCLC ATCC CRL-2871 0.8376 0.95 + YES – – 6.46
HCC78 NSCLC DSMZ ACC 563 13.9 17.05 - YES – – 11.09
H322M NSCLC MPI – 0.0819 0.311 + YES MUT – 14.13
HOP62 NSCLC MPI – 12.76 0.014 - no MUT – 9.44
HCC2279 NSCLC MPI – 0.139 0.045 + YES MUT – 12.45
PC9 NSCLC MPI – 0.4603 0.02 + YES MUT 25 15.85
BT-20 Breast c. ATCC HTB-19 0.1652 0.497 + YES MUT – –
BT-549 Breast c. ATCC HTB-122 9.0576 1.71 - YES MUT – –
MDA-MB-468 Breast c. ATCC HTB-132 7.1258 2.8 - YES MUT – –
MDA-MB-231 Breast c. ATCC HTB-26 0.0095 0.036 + YES MUT – –
MCF7 Breast c. ATCC HTB-22 >9.524 3.27 - YES WT – –
HCC1937 Breast c. ATCC CRL-2336 0.07 0.082 + YES MUT – –
1NSCLC data from Sos, et al. [94], breast cancer data from Huang, et al. [86]
2Whether the GI50 values from the literature and this paper agree
3According to the IARC TP53 database [123] version R15
4Data from Sos, et al. [94]
5Max Planck Institute for Neurological Research (Cologne, Germany)
131
C. Supplementary Information to Chapter 4
Table C.2: Mass spectrometric pairing scheme
Exp. Group Group Cell line Cell line Cell line
number medium heavy light medium heavy
1 + - CELLMIX LouNH91 H460
2 + - CELLMIX H1648 Calu6
3 + - CELLMIX HCC827 6LCLC103H
4 + - CELLMIX H322M H2077
5 + - CELLMIX H2030 H1395
6 + - CELLMIX HCC2279 H2172
7 + - CELLMIX H15686 6H647
8 + - CELLMIX H3226 6HOP62
9 + - CELLMIX HCC366 HCC78
10 + - CELLMIX HCC4006 6HCC1359
11 + - CELLMIX H1666 H157
12 + - CELLMIX PC9 H520
13 + - CELLMIX H2009 6H2887
147 - + CELLMIX H2077 H322M
158 - + CELLMIX H28876 H2009
16 + - CELLMIX BT-20 MDA-MB-468
17 - + CELLMIX BT-549 MDA-MB231
18 + - CELLMIX HCC1937 MCF7
Table C.3: Additional phosphorylation site information
Gene Canonical Canonical Known
Name Site9 Uniprot id10 site11 All Uniprot ids12 13site
ITGB4 S1448 P16144 S1518 A0AVL6;B7ZLD5;B7ZLD8;Q0VF97;Q59H46;P16144-2/-4;P16144 YES
BAIAP2 S509 Q9UQB8-5 S509 Q9UQB8-5;B3KPV9 no
ITGB4 S1387 P16144 S1457 A0AVL6;B7ZLD5;B7ZLD8;Q0VF97;Q59H46;P16144-2/-3/-4;P16144 YES
ITGB4 T1385 P16144 T1455 A0AVL6;B7ZLD5;B7ZLD8;Q0VF97;Q59H46;P16144-2/-3/-4;P16144 no
ITGB4 S1069 P16144 S1069 A0AVL6;B7ZLD5;B7ZLD8;Q0VF97;Q59H46;P16144-2/-3/-4;P16144 14YES
GPCR5A S345 Q8NFJ5 S345 A8K556;Q8NFJ5 YES
ITPR3 S916 Q14573 S916 Q14573;Q59ES2;A6H8K3 YES
TNKS1BP1 S429 Q9C0C2 S429 Q9C0C2;B3KXS7 YES
ARHGEF18 S1101 Q6ZSZ5 S1101 Q6ZSZ5;B5ME81;D6W646;Q6ZSZ5-2/-3;A8MV62 YES
IASPP S102 Q8WUF5 S102 Q8WUF5;Q6ZNZ8 YES
APG16L S269 Q676U5 S269 Q676U5;Q676U5-3/-4;Q17RG0;Q53SV2 YES
TPD52L2 S141 O43399 S161 O43399;Q6FGS1;Q53GA0;B4DDV4;O43399-2;Q68E05;B4DPJ6 YES
6GI50 value inconsistent with the one reported in Sos, et al. [94]; cell line was not used in analysis
7Label switch of experiment 4
8Label switch of experiment 13
9As reported throughout the paper
10The main Uniprot entry of the corresponding protein
11The position in the canonical Uniprot entry
12All Uniprot accession numbers from which the corresponding phosphopeptide could originate
13According to PhosphoSitePlus (www.phosphosite.org) accessed on 6thAugust 2011
14Detected in mouse only
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Table C.6: Significantly enriched GO terms
GO term GO id Category15 q-value16
cell communication GO:0007154 GOBP 2.5E-06
signal transduction GO:0007165 GOBP 2.5E-06
signal transducer activity GO:0004871 GOMF 5.1E-04
cytoskeletal protein binding GO:0008092 GOMF 5.1E-04
small GTPase regulator activity GO:0005083 GOMF 5.5E-04
regulation of cellular process GO:0050794 GOBP 7.2E-04
GTPase regulator activity GO:0030695 GOMF 1.1E-03
protein kinase activity GO:0004672 GOMF 2.0E-03
protein serine/threonine kinase activity GO:0004674 GOMF 2.9E-03
protein tyrosine kinase activity GO:0004713 GOMF 2.9E-03
receptor activity GO:0004872 GOMF 2.9E-03
phosphotransferase activity, alcohol group as acceptor GO:0016773 GOMF 3.6E-03
lipid binding GO:0008289 GOMF 3.6E-03
kinase activity GO:0016301 GOMF 3.7E-03
actin binding GO:0003779 GOMF 3.7E-03
zinc ion binding GO:0008270 GOMF 1.2E-02
Ras protein signal transduction GO:0007265 GOBP 1.2E-02
protein amino acid phosphorylation GO:0006468 GOBP 1.2E-02
regulation of cell communication GO:0010646 GOBP 1.3E-02
transferase activity, transferring phosphorus-containing groups GO:0016772 GOMF 1.3E-02
regulation of signal transduction GO:0009966 GOBP 1.7E-02
GTPase activator activity GO:0005096 GOMF 2.0E-02
cell surface receptor linked signal transduction GO:0007166 GOBP 2.1E-02
intracellular signaling cascade GO:0007242 GOBP 2.2E-02
enzyme activator activity GO:0008047 GOMF 2.2E-02
vesicle-mediated transport GO:0016192 GOBP 2.4E-02
Rho protein signal transduction GO:0007266 GOBP 2.5E-02
transport GO:0006810 GOBP 2.5E-02
establishment of localization GO:0051234 GOBP 2.5E-02
amine binding GO:0043176 GOMF 2.7E-02
epidermal cell differentiation GO:0009913 GOBP 2.9E-02
phosphorylation GO:0016310 GOBP 2.9E-02
transmembrane receptor activity GO:0004888 GOMF 3.1E-02
cytoskeleton organization GO:0007010 GOBP 3.5E-02
locomotory behavior GO:0007626 GOBP 3.5E-02
transition metal ion binding GO:0046914 GOMF 3.8E-02
phosphate metabolic process GO:0006796 GOBP 4.0E-02
Rho guanyl-nucleotide exchange factor activity GO:0005089 GOMF 4.3E-02
actin filament binding GO:0051015 GOMF 4.6E-02
post-translational protein modification GO:0043687 GOBP 4.7E-02
C.5 Additional Files
Additional Files 2-5 can be found at:
http://www.mcponline.org/content/11/9/651/suppl/DC1
15GOBP: biological process, GOMF: melecular function
16Adjusted p-value
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D.1 Supplementary Figures
Pareto point
Feasible point
Infeasible point
Utopia point
Objective 1
O
bj
ec
tiv
e 
2
Pareto front
Figure D.1: Example of a Pareto front in a minimization problem. The plot shows
different solutions of a toy example. Blue points are feasible solutions, where those that
are not dominated by any other solution are referred to as Pareto points (dark-blue).
Together they form the Pareto front. The points in the lower left area represent solutions
that are desired but not feasible (yellow/red).
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